[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fuYujboBxxLyos8HyIrB_kJFYOLKx7EtWqg4cHYNJqug":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":36,"phaseBuckets":84,"rows":91},"Biogen",[4],506,false,39,95,290141,33,52,[14,17,20,23,26,29,31,34],{"name":15,"count":16},"Multiple Sclerosis",83,{"name":18,"count":19},"Healthy",43,{"name":21,"count":22},"Relapsing-Remitting Multiple Sclerosis",40,{"name":24,"count":25},"Healthy Volunteer",25,{"name":27,"count":28},"Multiple Sclerosis, Relapsing-Remitting",22,{"name":30,"count":28},"Healthy Volunteers",{"name":32,"count":33},"Rheumatoid Arthritis",13,{"name":35,"count":33},"Spinal Muscular Atrophy",[37,42,47,52,57,62,67,70,74,79],{"nctId":38,"briefTitle":39,"date":40,"intervention":41},"NCT06054893","A Study to Find Out How BIIB141 (Omaveloxolone) is Processed in the Body and to Learn More About Its Safety in Participants With Friedreich's Ataxia Aged 2 to 15 Years Old","2025-09-30","Omaveloxolone",{"nctId":43,"briefTitle":44,"date":45,"intervention":46},"NCT05399888","A Study to Learn About the Safety of BIIB080 Injections and Whether They Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age","2026-05-14","BIIB080",{"nctId":48,"briefTitle":49,"date":50,"intervention":51},"NCT04729907","A Study to Learn About the Long-Term Safety of Higher Doses of Nusinersen (BIIB058) Given as Injections to Participants With Spinal Muscular Atrophy (SMA) Who Took Part in an Earlier Nusinersen Trial (ONWARD)","2026-07-31","Nusinersen",{"nctId":53,"briefTitle":54,"date":55,"intervention":56},"NCT07133828","A Study to Learn About the Safety of BIIB142 and How it is Processed in the Body of Healthy Adult Participants Aged 18 to 55 Years Old","2026-08-06","BIIB142",{"nctId":58,"briefTitle":59,"date":60,"intervention":61},"NCT07047820","A Study to Learn More About How Zuranolone Affects Postpartum Depression Symptoms in Participants Who Took it Within 1 Year After The End of Their Pregnancy","2026-08-24","Zuranolone",{"nctId":63,"briefTitle":64,"date":65,"intervention":66},"NCT04961567","A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus","2026-09-27","Litifilimab",{"nctId":68,"briefTitle":64,"date":69,"intervention":66},"NCT04895241","2026-09-30",{"nctId":71,"briefTitle":72,"date":73,"intervention":66},"NCT05531565","A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus","2026-10-20",{"nctId":75,"briefTitle":76,"date":77,"intervention":78},"NCT05925049","A Study Utilising Data From European Union (EU) National Multiple Sclerosis (MS) Registries to Assess the Incidence of Anti-Natalizumab Antibody Among Participants Who Receive Subcutaneous Administration of Natalizumab for Treatment of Relapsing-remitting Multiple Sclerosis (RRMS)","2026-10-31","Natalizumab",{"nctId":80,"briefTitle":81,"date":82,"intervention":83},"NCT06685757","A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR)","2026-12-01","Felzartamab",[85,86,87,88,89,90],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[92,181,248,303,471,578,623,977,1128,1160,1236,1289,1307,1325,1343,1375,1398,1418,1442,1817,1856,1945,1993,2043,2080,2112,2134,2152,2170,2188,2206,2224,2242,2260,2339,2402,2462,2493,2526,2554,2572,2590,2608,2626,2644,2668,2686,2711,2729,2747,2765,2783,2801,2819,2843,2865,2886,3086,3209,3339,3439,3508,3566,3612,3640,3662,3696,3729,3761,3779,3797,3815,3833,3855,3881,3899,3921,3939,3963,3981,3999,4017,4035,4053,4071,4089,4107,4125,4149,4167,4185,4203,4315,4378,4437,4487,4537,4576,4619,4664,4714,4753,4788,4826,4865,4914,4936,4958,4980,5002,5024,5046,5078,5109,5131,5153,5182,5214,5232,5250,5268,5286,5313,5331,5349,5367,5385,5410,5428,5446,5468,5491,5509,5527,5545,5568,5586,5608,5632,5650,5673,5701,5719,5737,5760,5778,5796,5820,5841,5864,5882,5900,5918,5936,5960,5981,6004,6027,6048,6073,6091,6109,6127,6145,6163,6181,6199,6217,6235,6253,6276,6297,6315,6345,6383,6407,6429,6460,6492,6525,6547,6569,6595,6623,6656,6686,6712,6738,6756,6774,6797,6815,6841,6859,6877,6895,6913,6931,6955,6973,6997,7018,7041,7062,7080,7101,7119,7137,7159,7177,7195,7213,7236,7260,7278,7300,7324,7342,7360,7383,7401,7423,7441,7459,7481,7499,7517,7539,7564,7582,7604,7622,7640,7658,7676,7694,7719,7737,7759,7781,7799,7820,7844,7868,7886,7904,7931,7949,7967,7985,8003,8025,8048,8071,8093,8111,8136,8154,8172,8190,8212,8230,8252,8279,8303,8326,8349,8372,8390,8412,8433,8455,8478,8496,8520,8538,8556,8579,8597,8620,8641,8741,8787,8829,8875,8909,8931,8955,8973,8998,9016,9034,9056],{"intervention":93,"totalTrials":94,"cells":95},"Tofersen",7,{"EARLY_PHASE1":96,"PHASE1":99,"PHASE2":113,"PHASE3":115,"PHASE4":150,"NA":162},{"trials":97,"activeCount":98},[],0,{"trials":100,"activeCount":98},[101],{"nctId":102,"briefTitle":103,"status":104,"phases":105,"primaryCompletion":106,"completion":107,"start":108,"enrollment":109,"conditions":110,"interventions":111},"NCT03764488","A Study to Evaluate Safety, Tolerability, and Distribution of a Microdose of Radiolabeled BIIB067 (99mTc-MAG3-BIIB067) Co-administered With BIIB067 (Tofersen) to Healthy Adults","COMPLETED",[86],"2021-06-10","2021-07-10","2018-12-20",8,[30],[93,112],"99mTc-MAG3-BIIB067",{"trials":114,"activeCount":98},[],{"trials":116,"activeCount":149,"soonestReadout":122},[117,129,139],{"nctId":118,"briefTitle":119,"status":120,"phases":121,"primaryCompletion":122,"completion":123,"start":124,"enrollment":125,"conditions":126,"interventions":128},"NCT04856982","A Study of BIIB067 (Tofersen) Initiated in Clinically Presymptomatic Adults With a Confirmed Superoxide Dismutase 1 Mutation","ACTIVE_NOT_RECRUITING",[88],"2027-08-07","2028-04-30","2021-05-17",158,[127],"Amyotrophic Lateral Sclerosis Associated With a SOD1 Gene Mutation",[93],{"nctId":130,"briefTitle":131,"status":104,"phases":132,"primaryCompletion":133,"completion":133,"start":134,"enrollment":135,"conditions":136,"interventions":138},"NCT02623699","An Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of BIIB067 (Tofersen) in Adults With Inherited Amyotrophic Lateral Sclerosis (ALS)",[88],"2021-07-16","2016-01-20",176,[137],"Amyotrophic Lateral Sclerosis",[93],{"nctId":140,"briefTitle":141,"status":104,"phases":142,"primaryCompletion":143,"completion":143,"start":144,"enrollment":145,"conditions":146,"interventions":148},"NCT03070119","Long-Term Evaluation of BIIB067 (Tofersen)",[88],"2024-08-12","2017-03-08",139,[147],"ALS Caused by Superoxide Dismutase 1 (SOD1) Mutation",[93],1,{"trials":151,"activeCount":149,"soonestReadout":157},[152],{"nctId":153,"briefTitle":154,"status":155,"phases":156,"primaryCompletion":157,"completion":157,"start":158,"enrollment":159,"conditions":160,"interventions":161},"NCT07223723","A Study to Learn More About the Long-Term Safety of Tofersen (Qalsody) in Chinese Participants With SOD-1 Amyotrophic Lateral Sclerosis (ALS)","RECRUITING",[89],"2027-12-16","2025-12-11",12,[137],[93],{"trials":163,"activeCount":149,"soonestReadout":168},[164,173],{"nctId":165,"briefTitle":166,"status":155,"phases":167,"primaryCompletion":168,"completion":168,"start":169,"enrollment":170,"conditions":171,"interventions":172},"NCT07259980","A Study to Learn More About the Long-Term Safety of Tofersen (Qalsody) in Participants With Superoxide Dismutase 1 (SOD-1) Amyotrophic Lateral Sclerosis (ALS)",[],"2033-12-30","2026-01-02",125,[137],[93],{"nctId":174,"briefTitle":175,"status":176,"phases":177,"conditions":178,"interventions":180},"NCT04972487","Expanded Access Program for Tofersen in Participants With Superoxide Dismutase 1-Amyotropic Lateral Sclerosis","APPROVED_FOR_MARKETING",[],[179],"Superoxide Dismutase 1-Amyotropic Lateral Sclerosis",[93],{"intervention":83,"totalTrials":182,"cells":183},5,{"EARLY_PHASE1":184,"PHASE1":186,"PHASE2":188,"PHASE3":200,"PHASE4":244,"NA":246},{"trials":185,"activeCount":98},[],{"trials":187,"activeCount":98},[],{"trials":189,"activeCount":149,"soonestReadout":194},[190],{"nctId":191,"briefTitle":192,"status":155,"phases":193,"primaryCompletion":194,"completion":194,"start":195,"enrollment":196,"conditions":197,"interventions":199},"NCT07219043","A Study to Learn About the Effects of Felzartamab Infusions in Adults With Kidney Transplants Who Have Late Isolated Microvascular Inflammation",[87],"2028-02-10","2026-01-05",81,[198],"Microvascular Inflammation",[83],{"trials":201,"activeCount":243,"soonestReadout":82},[202,213,224,237],{"nctId":203,"briefTitle":204,"status":155,"phases":205,"primaryCompletion":206,"completion":207,"start":208,"enrollment":209,"conditions":210,"interventions":212},"NCT06935357","A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)",[88],"2027-05-31","2029-06-05","2025-05-08",454,[211],"Immunoglobulin A Nephropathy (IgAN)",[83],{"nctId":214,"briefTitle":215,"status":216,"phases":217,"primaryCompletion":218,"completion":218,"start":219,"enrollment":220,"conditions":221,"interventions":223},"NCT07444489","A Study to Learn More About the Long-Term Safety and Effects of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR)","ENROLLING_BY_INVITATION",[88],"2031-05-28","2026-04-16",120,[222],"Antibody-mediated Rejection",[83],{"nctId":225,"briefTitle":226,"status":155,"phases":227,"primaryCompletion":228,"completion":229,"start":230,"enrollment":231,"conditions":232,"interventions":234},"NCT06962800","A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN)",[88],"2028-12-29","2029-03-29","2025-05-22",180,[233],"Primary Membranous Nephropathy",[83,235,236],"Tacrolimus","Standard of Care IST",{"nctId":80,"briefTitle":81,"status":155,"phases":238,"primaryCompletion":82,"completion":239,"start":240,"enrollment":220,"conditions":241,"interventions":242},[88],"2027-06-01","2024-12-03",[222],[83],4,{"trials":245,"activeCount":98},[],{"trials":247,"activeCount":98},[],{"intervention":66,"totalTrials":182,"cells":249},{"EARLY_PHASE1":250,"PHASE1":252,"PHASE2":263,"PHASE3":265,"PHASE4":299,"NA":301},{"trials":251,"activeCount":98},[],{"trials":253,"activeCount":98},[254],{"nctId":255,"briefTitle":256,"status":104,"phases":257,"primaryCompletion":258,"completion":258,"start":259,"enrollment":260,"conditions":261,"interventions":262},"NCT06741657","A Study to Find Out How Litifilimab is Processed in the Body in Healthy Participants When Given Under the Skin in 3 Different Ways",[86],"2026-03-10","2025-01-02",404,[24],[66],{"trials":264,"activeCount":98},[],{"trials":266,"activeCount":243,"soonestReadout":65},[267,277,286,293],{"nctId":268,"briefTitle":269,"status":216,"phases":270,"primaryCompletion":271,"completion":271,"start":272,"enrollment":273,"conditions":274,"interventions":276},"NCT05352919","An Extension Study to Learn More About the Long-Term Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus",[88],"2030-03-29","2022-06-10",864,[275],"Systemic Lupus Erythematosus (SLE)",[66],{"nctId":71,"briefTitle":72,"status":155,"phases":278,"primaryCompletion":73,"completion":279,"start":280,"enrollment":281,"conditions":282,"interventions":285},[87,88],"2027-12-14","2022-09-13",450,[283,284],"Subacute Cutaneous Lupus Erythematosus","Chronic Cutaneous Lupus Erythematosus",[66],{"nctId":63,"briefTitle":64,"status":120,"phases":287,"primaryCompletion":65,"completion":288,"start":133,"enrollment":289,"conditions":290,"interventions":292},[88],"2027-03-16",562,[291],"Lupus Erythematosus, Systemic",[66],{"nctId":68,"briefTitle":64,"status":120,"phases":294,"primaryCompletion":69,"completion":288,"start":295,"enrollment":296,"conditions":297,"interventions":298},[88],"2021-05-25",548,[291],[66],{"trials":300,"activeCount":98},[],{"trials":302,"activeCount":98},[],{"intervention":41,"totalTrials":304,"cells":305},15,{"EARLY_PHASE1":306,"PHASE1":308,"PHASE2":413,"PHASE3":430,"PHASE4":442,"NA":444},{"trials":307,"activeCount":98},[],{"trials":309,"activeCount":149,"soonestReadout":40},[310,319,330,340,349,356,374,383,394,405],{"nctId":311,"briefTitle":312,"status":104,"phases":313,"primaryCompletion":314,"completion":314,"start":315,"enrollment":316,"conditions":317,"interventions":318},"NCT07297199","A Study to Learn How the Body Processes BIIB141 (Omaveloxolone) When Taken as a Capsule or as a Tablet Dissolved in Liquid, and to Learn About Its Safety in Healthy Adults Ages 18 to 55",[86],"2026-05-01","2025-12-12",70,[24],[41],{"nctId":320,"briefTitle":321,"status":104,"phases":322,"primaryCompletion":323,"completion":323,"start":324,"enrollment":325,"conditions":326,"interventions":328},"NCT05909644","An Open-label DDI Study of Omaveloxolone in Healthy Subjects",[86],"2023-08-30","2023-07-05",20,[327],"Healthy Adult Subjects",[41,329],"Efavirenz",{"nctId":331,"briefTitle":332,"status":104,"phases":333,"primaryCompletion":334,"completion":334,"start":335,"enrollment":336,"conditions":337,"interventions":338},"NCT03664453","A Pharmacokinetic Study of Omaveloxolone in Healthy Volunteers",[86],"2018-11-20","2018-10-29",32,[18],[339],"omaveloxolone",{"nctId":341,"briefTitle":342,"status":104,"phases":343,"primaryCompletion":344,"completion":344,"start":345,"enrollment":28,"conditions":346,"interventions":347},"NCT07149415","A Study to Learn if Taking BIIB141 (Omaveloxolone) Affects How Omeprazole is Processed in the Body and About BIIB141's Safety in Healthy Adults Aged 18 to 55",[86],"2025-10-16","2025-09-02",[24],[41,348],"Omeprazole",{"nctId":38,"briefTitle":39,"status":120,"phases":350,"primaryCompletion":40,"completion":351,"start":352,"enrollment":11,"conditions":353,"interventions":355},[86],"2030-11-22","2024-07-01",[354],"Friedreich Ataxia",[41],{"nctId":357,"briefTitle":358,"status":104,"phases":359,"primaryCompletion":360,"completion":361,"start":362,"enrollment":363,"conditions":364,"interventions":365},"NCT04008186","A Clinical Drug-Drug Interaction (DDI) Study With Omaveloxolone",[86],"2019-08-18","2019-08-28","2019-06-14",61,[327],[41,366,367,368,369,370,371,372,373],"Midazolam oral solution","Repaglinide 1 MG","MetFORMIN 500 Mg Oral","Rosuvastatin","Digoxin","Gemfibrozil","Itraconazole","Verapamil Pill",{"nctId":375,"briefTitle":376,"status":104,"phases":377,"primaryCompletion":378,"completion":379,"start":380,"enrollment":159,"conditions":381,"interventions":382},"NCT06612879","A Study to Find Out How BIIB141 (Omaveloxolone) Moves From the Blood Into the Breastmilk of Healthy Women Who Are Breastfeeding or Pumping Milk",[86],"2025-03-11","2025-04-08","2024-10-18",[24],[41],{"nctId":384,"briefTitle":385,"status":104,"phases":386,"primaryCompletion":387,"completion":387,"start":388,"enrollment":389,"conditions":390,"interventions":392},"NCT05927649","A TQTc Study for Omaveloxolone",[86],"2023-09-01","2023-07-11",30,[391],"Health Adult Subjects",[41,393],"Moxifloxacin",{"nctId":395,"briefTitle":396,"status":104,"phases":397,"primaryCompletion":398,"completion":398,"start":399,"enrollment":400,"conditions":401,"interventions":404},"NCT02029729","RTA 408 in the Treatment of Advanced Solid Tumors (NSCLC & Melanoma) - DISCOVER",[86],"2015-10-01","2013-12-31",11,[402,403],"Metastatic or Incurable Non-small Cell Lung Cancer","Relapsed, Refractory Melanoma",[339],{"nctId":406,"briefTitle":407,"status":104,"phases":408,"primaryCompletion":409,"completion":409,"start":410,"enrollment":12,"conditions":411,"interventions":412},"NCT07019064","A Study to Learn How BIIB141 (Omaveloxolone) is Processed in the Body When Taken as Capsules Compared to Sprinkled on Yogurt in Healthy Adults Aged 18 to 55",[86],"2025-08-19","2025-06-11",[24],[41],{"trials":414,"activeCount":98},[415],{"nctId":416,"briefTitle":417,"status":104,"phases":418,"primaryCompletion":419,"completion":420,"start":421,"enrollment":422,"conditions":423,"interventions":427},"NCT02259231","RTA 408 Capsules in Patients With Melanoma - REVEAL",[86,87],"2018-05-09","2018-07-23","2014-10-31",41,[424,425,426],"Melanoma","Unresectable (Stage III) Melanoma","Metastatic (Stage IV) Melanoma",[41,428,429,41,41],"Ipilimumab","Nivolumab",{"trials":431,"activeCount":149,"soonestReadout":436},[432],{"nctId":433,"briefTitle":434,"status":155,"phases":435,"primaryCompletion":436,"completion":437,"start":438,"enrollment":439,"conditions":440,"interventions":441},"NCT06953583","A Study to Learn More About the Effects and Long-Term Safety of Omaveloxolone (BIIB141) in Children and Teens With Friedreich's Ataxia",[88],"2027-11-16","2029-11-22","2025-06-09",255,[354],[41],{"trials":443,"activeCount":98},[],{"trials":445,"activeCount":470,"soonestReadout":450},[446,455,462],{"nctId":447,"briefTitle":448,"status":155,"phases":449,"primaryCompletion":450,"completion":450,"start":451,"enrollment":452,"conditions":453,"interventions":454},"NCT06623890","A Study to Learn More About the Long-Term Safety of BIIB141 (Omaveloxolone) in Participants With Friedreich's Ataxia Who Are Prescribed it by Their Own Doctors",[],"2029-10-01","2024-12-12",300,[354],[41],{"nctId":456,"briefTitle":457,"status":458,"phases":459,"conditions":460,"interventions":461},"NCT03593499","Expanded Access to Omaveloxolone for Melanoma for Patients Previously Enrolled in 408-C-1401","NO_LONGER_AVAILABLE",[],[424],[339],{"nctId":463,"briefTitle":464,"status":155,"phases":465,"primaryCompletion":466,"completion":466,"start":467,"enrollment":325,"conditions":468,"interventions":469},"NCT06628687","A Study to Learn How BIIB141 (Omaveloxolone) Affects the Health of Participants With Friedrich's Ataxia Who Took it During Pregnancy and\u002For During Breastfeeding and About the Health of Their Babies",[],"2035-04-30","2026-10-26",[354],[41],2,{"intervention":472,"totalTrials":109,"cells":473},"Diroximel Fumarate",{"EARLY_PHASE1":474,"PHASE1":476,"PHASE2":488,"PHASE3":490,"PHASE4":515,"NA":517},{"trials":475,"activeCount":98},[],{"trials":477,"activeCount":98},[478],{"nctId":479,"briefTitle":480,"status":104,"phases":481,"primaryCompletion":482,"completion":483,"start":484,"enrollment":336,"conditions":485,"interventions":486},"NCT05127564","A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Diroximel Fumarate (DRF) in Chinese and Caucasian Adult Healthy Participants",[86],"2022-06-09","2022-06-29","2021-12-03",[30],[487],"Diroximel fumarate",{"trials":489,"activeCount":98},[],{"trials":491,"activeCount":149,"soonestReadout":507},[492,502],{"nctId":493,"briefTitle":494,"status":104,"phases":495,"primaryCompletion":496,"completion":496,"start":497,"enrollment":498,"conditions":499,"interventions":501},"NCT05083923","A Study of Diroximel Fumarate (DRF) in Adult Participants From the Asia-Pacific Region With Relapsing Forms of Multiple Sclerosis (RMS)",[88],"2024-09-11","2021-11-18",136,[500],"Relapsing Forms of Multiple Sclerosis",[487],{"nctId":503,"briefTitle":504,"status":505,"phases":506,"primaryCompletion":507,"completion":508,"start":509,"enrollment":510,"conditions":511,"interventions":512},"NCT07483632","A Study to Learn About the Safety of Diroximel Fumarate (DRF) and Dimethyl Fumarate (DMF) and Their Effects on Relapses in Pediatric Participants With Relapsing Forms of Multiple Sclerosis (RMS)","NOT_YET_RECRUITING",[88],"2034-07-28","2035-06-19","2026-11-16",185,[500],[472,513,514],"Dimethyl Fumarate","Fingolimod",{"trials":516,"activeCount":98},[],{"trials":518,"activeCount":577,"soonestReadout":545},[519,530,541,559,567],{"nctId":520,"briefTitle":521,"status":522,"phases":523,"primaryCompletion":524,"completion":524,"start":525,"enrollment":526,"conditions":527,"interventions":529},"NCT04948606","Exploring Diroximel Fumarate Real-world Experience in Canada and Israel","TERMINATED",[],"2023-04-14","2021-12-09",64,[528],"Relapsing Forms of MS",[472],{"nctId":531,"briefTitle":532,"status":155,"phases":533,"primaryCompletion":534,"completion":534,"start":535,"enrollment":536,"conditions":537,"interventions":538},"NCT05658497","Pregnancy Exposure Registry for Vumerity (Diroximel Fumarate)",[],"2032-07-06","2023-10-27",908,[15],[472,539,540,513],"Avonex","Tysabri",{"nctId":542,"briefTitle":543,"status":120,"phases":544,"primaryCompletion":545,"completion":545,"start":546,"enrollment":547,"conditions":548,"interventions":549},"NCT05688436","A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY®) in Participants Who Took it During Pregnancy And About the Health of Their Babies",[],"2031-01-17","2021-09-24",1178,[15],[472,550,514,551,552,78,553,554,555,556,557,558],"Alemtuzumab","Glatiramer acetate","Interferon beta","Ocrelizumab","Ofatumumab","Ozanimod","Peginterferon beta-1a","Ponesimod","Siponimod",{"nctId":560,"briefTitle":561,"status":522,"phases":562,"primaryCompletion":524,"completion":524,"start":563,"enrollment":564,"conditions":565,"interventions":566},"NCT04746976","Study of Diroximel Fumarate in the Real-World Setting",[],"2021-03-01",75,[528],[472],{"nctId":568,"briefTitle":569,"status":120,"phases":570,"primaryCompletion":571,"completion":571,"start":572,"enrollment":573,"conditions":574,"interventions":575},"NCT05767736","A Study to Evaluate Long-Term Safety of Vumerity and Tecfidera in Participants With Multiple Sclerosis (MS)",[],"2032-12-01","2024-06-08",10500,[15],[472,513,576],"Disease-Modifying Therapies",3,{"intervention":579,"totalTrials":577,"cells":580},"Salanersen",{"EARLY_PHASE1":581,"PHASE1":583,"PHASE2":585,"PHASE3":587,"PHASE4":619,"NA":621},{"trials":582,"activeCount":98},[],{"trials":584,"activeCount":98},[],{"trials":586,"activeCount":98},[],{"trials":588,"activeCount":577,"soonestReadout":603},[589,599,609],{"nctId":590,"briefTitle":591,"status":155,"phases":592,"primaryCompletion":593,"completion":594,"start":595,"enrollment":389,"conditions":596,"interventions":598},"NCT07221669","A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety When Given Before Symptoms Appear in Babies With Genetically Diagnosed Spinal Muscular Atrophy (SMA)",[88],"2028-11-28","2032-05-29","2026-04-28",[597],"Muscular Atrophy, Spinal",[579],{"nctId":600,"briefTitle":601,"status":155,"phases":602,"primaryCompletion":603,"completion":604,"start":605,"enrollment":606,"conditions":607,"interventions":608},"NCT07444476","A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety in Participants Aged 15 to 60 Years With Spinal Muscular Atrophy (SMA) Who Are Either New to SMA Treatment or Were Previously Treated With Risdiplam",[88],"2028-06-23","2032-06-22","2026-04-03",90,[35],[579],{"nctId":610,"briefTitle":611,"status":505,"phases":612,"primaryCompletion":613,"completion":614,"start":615,"enrollment":616,"conditions":617,"interventions":618},"NCT07444450","A Study to Learn About the Safety and Effects of Salanersen (BIIB115) When Given to Babies With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Onasemnogene Abeparvovec",[88],"2029-07-27","2033-07-26","2026-09-04",42,[597],[579],{"trials":620,"activeCount":98},[],{"trials":622,"activeCount":98},[],{"intervention":624,"totalTrials":625,"cells":626},"dimethyl fumarate",38,{"EARLY_PHASE1":627,"PHASE1":629,"PHASE2":658,"PHASE3":690,"PHASE4":799,"NA":890},{"trials":628,"activeCount":98},[],{"trials":630,"activeCount":98},[631,641,649],{"nctId":632,"briefTitle":633,"status":104,"phases":634,"primaryCompletion":635,"completion":635,"start":636,"enrollment":637,"conditions":638,"interventions":639},"NCT01281111","Alternate Dosing Regimens of BG00012 in Healthy Volunteers",[86],"2011-03-18","2011-02-01",56,[18],[513,640],"Aspirin",{"nctId":642,"briefTitle":643,"status":104,"phases":644,"primaryCompletion":645,"completion":645,"start":646,"enrollment":336,"conditions":647,"interventions":648},"NCT01924832","BG00012 Regional Absorption Study",[86],"2014-04","2013-08",[18],[624],{"nctId":650,"briefTitle":651,"status":104,"phases":652,"primaryCompletion":653,"completion":653,"start":646,"enrollment":654,"conditions":655,"interventions":656},"NCT01915901","PeptoBismol® Use to Reduce Gastrointestinal Events in Healthy Volunteers Receiving DMF [Tecfidera®] Twice Daily",[86],"2013-12",175,[18],[657,624],"bismuth subsalicylate",{"trials":659,"activeCount":98},[660,668,677],{"nctId":661,"briefTitle":662,"status":104,"phases":663,"primaryCompletion":664,"completion":664,"start":665,"enrollment":28,"conditions":666,"interventions":667},"NCT02410200","Study of the Effect of BG00012 on MRI Lesions and Pharmacokinetics in Pediatric Subjects With RRMS",[87],"2016-09-23","2015-09-30",[27],[624],{"nctId":669,"briefTitle":670,"status":104,"phases":671,"primaryCompletion":672,"completion":672,"start":673,"enrollment":674,"conditions":675,"interventions":676},"NCT01156311","BG00012 Phase 2 Combination Study in Participants With Multiple Sclerosis",[87],"2012-03","2010-06",108,[21,15],[624],{"nctId":678,"briefTitle":679,"status":104,"phases":680,"primaryCompletion":681,"completion":681,"start":682,"enrollment":683,"conditions":684,"interventions":685},"NCT02097849","Vaccination Response in Tecfidera-Treated Versus Interferon-Treated Participants With Relapsing Forms of Multiple Sclerosis.",[87],"2016-05-02","2015-02-28",71,[500],[624,686,687,688,689],"tetanus diphtheria toxoids vaccine","23-valent pneumococcal polysaccharide vaccine","meningococcal polysaccharide diphtheria conjugate vaccine","non-pegylated interferon",{"trials":691,"activeCount":149,"soonestReadout":507},[692,702,711,721,729,739,749,758,767,776,780,789],{"nctId":693,"briefTitle":694,"status":104,"phases":695,"primaryCompletion":696,"completion":696,"start":697,"enrollment":6,"conditions":698,"interventions":700},"NCT03093324","A Tolerability Study of ALKS 8700 in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) EVOLVE-MS-2",[88],"2019-06-27","2017-03-15",[699],"Relapsing Remitting Multiple Sclerosis",[701,513],"ALKS 8700",{"nctId":703,"briefTitle":704,"status":705,"phases":706,"primaryCompletion":707,"completion":707,"start":708,"enrollment":98,"conditions":709,"interventions":710},"NCT02428218","Placebo-Controlled Study of the Efficacy and Safety of BG00012 in Pediatric Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)","WITHDRAWN",[88],"2027-01","2016-05",[21,500],[624],{"nctId":712,"briefTitle":713,"status":522,"phases":714,"primaryCompletion":715,"completion":715,"start":716,"enrollment":717,"conditions":718,"interventions":720},"NCT02430532","BG00012 and Delay of Disability Progression in Secondary Progressive Multiple Sclerosis",[88],"2016-01","2015-05",58,[719],"Multiple Sclerosis, Secondary Progressive",[624],{"nctId":722,"briefTitle":723,"status":104,"phases":724,"primaryCompletion":725,"completion":725,"start":726,"enrollment":325,"conditions":727,"interventions":728},"NCT02555215","Extension Study of BG00012 in Pediatric Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)",[88],"2018-09-24","2016-02-22",[27],[624],{"nctId":730,"briefTitle":731,"status":104,"phases":732,"primaryCompletion":733,"completion":734,"start":735,"enrollment":736,"conditions":737,"interventions":738},"NCT02525874","Effect of BG00012 on Lymphocyte Subsets and Immunoglobulins in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS).",[88],"2017-04-24","2018-04-23","2015-08-11",218,[27,15],[624],{"nctId":740,"briefTitle":741,"status":104,"phases":742,"primaryCompletion":743,"completion":744,"start":745,"enrollment":746,"conditions":747,"interventions":748},"NCT01838668","An Efficacy and Safety Study of BG00012 (Dimethyl Fumarate) in Asian Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)",[88],"2015-06-16","2018-09-04","2013-03-28",225,[21,15],[624],{"nctId":750,"briefTitle":751,"status":522,"phases":752,"primaryCompletion":753,"completion":753,"start":754,"enrollment":400,"conditions":755,"interventions":756},"NCT03870763","Study to Evaluate the Efficacy and Safety of Dimethyl Fumarate (Tecfidera) and Peginterferon Beta-1a (Plegridy) for the Treatment of Relapsing-Remitting Multiple Sclerosis in Pediatric Participants",[88],"2022-07-21","2019-03-19",[27],[513,757],"Peginterferon Beta-1a",{"nctId":759,"briefTitle":760,"status":104,"phases":761,"primaryCompletion":762,"completion":762,"start":763,"enrollment":764,"conditions":765,"interventions":766},"NCT02579681","Study Assessing Cognition in Relapsing Remitting Multiple Sclerosis (RRMS) Patients Treated With BG00012",[88],"2016-12-21","2014-04-30",221,[27],[624],{"nctId":768,"briefTitle":769,"status":522,"phases":770,"primaryCompletion":771,"completion":715,"start":772,"enrollment":773,"conditions":774,"interventions":775},"NCT02428231","Tecfidera Slow-Titration Study",[88],"2015-12","2015-04",62,[15],[624],{"nctId":503,"briefTitle":504,"status":505,"phases":777,"primaryCompletion":507,"completion":508,"start":509,"enrollment":510,"conditions":778,"interventions":779},[88],[500],[472,513,514],{"nctId":781,"briefTitle":782,"status":104,"phases":783,"primaryCompletion":784,"completion":784,"start":785,"enrollment":786,"conditions":787,"interventions":788},"NCT00835770","BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS)",[88],"2019-11-08","2009-02-03",1736,[21],[624],{"nctId":790,"briefTitle":791,"status":104,"phases":792,"primaryCompletion":793,"completion":793,"start":794,"enrollment":795,"conditions":796,"interventions":797},"NCT02283853","Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)",[88],"2025-07-08","2014-08-28",156,[21],[624,798],"Interferon β-1a",{"trials":800,"activeCount":98},[801,812,823,833,841,853,862,870,880],{"nctId":802,"briefTitle":803,"status":104,"phases":804,"primaryCompletion":805,"completion":806,"start":807,"enrollment":808,"conditions":809,"interventions":810},"NCT05658484","A Study of Dimethyl Fumarate (DMF) in Relapsing Forms of Multiple Sclerosis (RMS) Participants in China",[89],"2025-03-27","2025-04-12","2023-06-09",60,[15],[811],"Dimethyl fumarate",{"nctId":813,"briefTitle":814,"status":104,"phases":815,"primaryCompletion":816,"completion":817,"start":818,"enrollment":819,"conditions":820,"interventions":821},"NCT02410278","Study of Montelukast on Gastrointestinal Tolerability in Patients With Relapsing Forms of Multiple Sclerosis Receiving Tecfidera",[89],"2017-02-16","2017-04-27","2015-03-12",102,[15],[624,822],"montelukast",{"nctId":824,"briefTitle":825,"status":104,"phases":826,"primaryCompletion":827,"completion":828,"start":829,"enrollment":830,"conditions":831,"interventions":832},"NCT01930708","A Study Evaluating the Effectiveness of Tecfidera (Dimethyl Fumarate) on Multiple Sclerosis (MS) Disease Activity and Patient-Reported Outcomes",[89],"2016-03-31","2020-01-09","2013-10-31",1114,[21,15],[624],{"nctId":834,"briefTitle":835,"status":522,"phases":836,"primaryCompletion":837,"completion":837,"start":682,"enrollment":838,"conditions":839,"interventions":840},"NCT02343159","Study to Evaluate Whether a Medication Event Monitoring System (MEMS) Can Improve Adherence to Tecfidera Treatment in Multiple Sclerosis Patients.",[89],"2016-04-15",84,[15],[624],{"nctId":842,"briefTitle":843,"status":104,"phases":844,"primaryCompletion":845,"completion":846,"start":847,"enrollment":848,"conditions":849,"interventions":850},"NCT02090413","Phase 4 Study of Effect of Aspirin on Flushing in Dimethyl Fumarate-Treated Participants With Relapsing-Remitting Multiple Sclerosis",[89],"2015-02","2015-11","2014-05",241,[21],[624,851,852],"acetylsalicylic acid","ASA-Placebo",{"nctId":854,"briefTitle":855,"status":705,"phases":856,"primaryCompletion":857,"completion":858,"start":859,"enrollment":98,"conditions":860,"interventions":861},"NCT02472938","Study to Explore the Onset of Efficacy on Magnetic Resonance Disease Activity of BG00012 (Dimethyl Fumarate) in Patients With Relapsing remitTing Multiple Sclerosis",[89],"2019-07","2020-07","2015-07",[699],[624],{"nctId":863,"briefTitle":864,"status":705,"phases":865,"primaryCompletion":866,"completion":866,"start":867,"enrollment":98,"conditions":868,"interventions":869},"NCT02090348","Study to Evaluate Fatigue in Participants With Relapsing Remitting Multiple Sclerosis When Treated With Dimethyl Fumarate",[89],"2017-10","2015-06",[21,15],[624],{"nctId":871,"briefTitle":872,"status":104,"phases":873,"primaryCompletion":874,"completion":874,"start":875,"enrollment":876,"conditions":877,"interventions":878},"NCT02471560","Tecfidera and the Gut Microbiota",[89],"2017-06-12","2015-11-06",36,[27],[624,879],"injectable MS DMT",{"nctId":881,"briefTitle":882,"status":104,"phases":883,"primaryCompletion":884,"completion":885,"start":886,"enrollment":887,"conditions":888,"interventions":889},"NCT02125604","Gastrointestinal Tolerability Study Of Dimethyl Fumarate In Participants With Relapsing-Remitting Multiple Sclerosis In Germany",[89],"2016-02","2016-03","2014-06",214,[21],[624],{"trials":891,"activeCount":470,"soonestReadout":534},[892,902,909,918,927,936,943,950,960,964,973],{"nctId":893,"briefTitle":894,"status":104,"phases":895,"primaryCompletion":896,"completion":896,"start":897,"enrollment":898,"conditions":899,"interventions":901},"NCT01911767","Biogen Multiple Sclerosis Pregnancy Exposure Registry",[],"2022-02-10","2013-10-30",408,[15,900],"Exposure During Pregnancy",[811,556],{"nctId":903,"briefTitle":904,"status":104,"phases":905,"primaryCompletion":884,"completion":884,"start":646,"enrollment":906,"conditions":907,"interventions":908},"NCT01903291","Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS",[],333,[500],[624],{"nctId":910,"briefTitle":911,"status":104,"phases":912,"primaryCompletion":913,"completion":913,"start":914,"enrollment":915,"conditions":916,"interventions":917},"NCT04221191","Dimethyl Fumarate (DMF, Tecfidera®) Persistence in RR-MS Patients Included in the French Patient Support Program OroSEP",[],"2022-09-14","2019-08-19",353,[27],[513],{"nctId":919,"briefTitle":920,"status":104,"phases":921,"primaryCompletion":922,"completion":922,"start":923,"enrollment":924,"conditions":925,"interventions":926},"NCT02969304","Study of Utilization Patterns of Dimethyl Fumarate in Germany",[],"2017-03-02","2016-12-30",930,[15],[624],{"nctId":928,"briefTitle":929,"status":104,"phases":930,"primaryCompletion":931,"completion":931,"start":932,"enrollment":933,"conditions":934,"interventions":935},"NCT02047097","Dimethyl Fumarate (DMF) Observational Study",[],"2022-10-31","2013-11-19",5487,[15],[624],{"nctId":937,"briefTitle":938,"status":104,"phases":939,"primaryCompletion":884,"completion":884,"start":859,"enrollment":940,"conditions":941,"interventions":942},"NCT02519413","Tecfidera Lymphocyte Chart Review",[],483,[15],[624],{"nctId":944,"briefTitle":945,"status":522,"phases":946,"primaryCompletion":885,"completion":885,"start":716,"enrollment":947,"conditions":948,"interventions":949},"NCT02323269","Effectiveness of DMF (Dimethyl Fumarate) and Its Impact on PROs (Patient Reported Outcomes) in Treatment-Naive or Suboptimal IFN (Interferon) or GA (Glatiramer Acetate) Responders With RRMS (ImPROve)",[],24,[27,21],[624],{"nctId":951,"briefTitle":952,"status":104,"phases":953,"primaryCompletion":954,"completion":954,"start":955,"enrollment":956,"conditions":957,"interventions":958},"NCT02159573","Real-world Outcomes on Tecfidera (BG00012, Dimethyl Fumarate) Post-Tysabri (BG00002, Natalizumab)",[],"2015-01","2014-07",530,[21],[959,624],"natalizumab",{"nctId":531,"briefTitle":532,"status":155,"phases":961,"primaryCompletion":534,"completion":534,"start":535,"enrollment":536,"conditions":962,"interventions":963},[],[15],[472,539,540,513],{"nctId":965,"briefTitle":966,"status":104,"phases":967,"primaryCompletion":968,"completion":968,"start":969,"enrollment":970,"conditions":971,"interventions":972},"NCT04756687","Real World Analysis on Lymphocyte Reconstitution After Lymphopenia in Participants Treated by Tecfidera",[],"2021-06-15","2021-03-10",1507,[15,27],[811],{"nctId":568,"briefTitle":569,"status":120,"phases":974,"primaryCompletion":571,"completion":571,"start":572,"enrollment":573,"conditions":975,"interventions":976},[],[15],[472,513,576],{"intervention":51,"totalTrials":978,"cells":979},16,{"EARLY_PHASE1":980,"PHASE1":982,"PHASE2":1019,"PHASE3":1054,"PHASE4":1108,"NA":1119},{"trials":981,"activeCount":98},[],{"trials":983,"activeCount":149,"soonestReadout":1007},[984,994,1003,1011],{"nctId":985,"briefTitle":986,"status":104,"phases":987,"primaryCompletion":988,"completion":988,"start":989,"enrollment":990,"conditions":991,"interventions":992},"NCT02052791","An Open-label Safety and Tolerability Study of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy (SMA) Who Previously Participated in ISIS 396443-CS2 (NCT01703988) or ISIS 396443-CS10 (NCT01780246)",[86],"2017-01-31","2014-01-31",47,[35],[993],"nusinersen",{"nctId":995,"briefTitle":996,"status":104,"phases":997,"primaryCompletion":998,"completion":998,"start":999,"enrollment":1000,"conditions":1001,"interventions":1002},"NCT01780246","An Open-label Safety and Tolerability Study of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy Who Previously Participated in ISIS 396443-CS1 (NCT01494701)",[86],"2014-02-28","2013-01-31",18,[35],[993],{"nctId":1004,"briefTitle":1005,"status":155,"phases":1006,"primaryCompletion":1007,"completion":1007,"start":1008,"enrollment":717,"conditions":1009,"interventions":1010},"NCT06555419","A Study to Find Out How Nusinersen is Processed in the Body When Given Through the ThecaFlex DRx™ System in Adult and Pediatric Participants With Spinal Muscular Atrophy (PIERRE-PK)",[86],"2027-06-25","2025-01-16",[597],[51],{"nctId":1012,"briefTitle":1013,"status":104,"phases":1014,"primaryCompletion":999,"completion":999,"start":1015,"enrollment":1016,"conditions":1017,"interventions":1018},"NCT01494701","An Open-label Safety, Tolerability, and Dose-range Finding Study of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy (SMA)",[86],"2011-11-30",28,[35],[993],{"trials":1020,"activeCount":98},[1021,1030,1039,1047],{"nctId":1022,"briefTitle":1023,"status":104,"phases":1024,"primaryCompletion":1025,"completion":1025,"start":1026,"enrollment":1027,"conditions":1028,"interventions":1029},"NCT01703988","An Open-label Safety, Tolerability and Dose-Range Finding Study of Multiple Doses of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy",[86,87],"2015-01-31","2012-10-31",34,[35],[51],{"nctId":1031,"briefTitle":1032,"status":104,"phases":1033,"primaryCompletion":1034,"completion":1034,"start":1035,"enrollment":1036,"conditions":1037,"interventions":1038},"NCT01839656","A Study to Assess the Efficacy, Safety and Pharmacokinetics of Nusinersen (ISIS 396443) in Infants With Spinal Muscular Atrophy (SMA)",[87],"2017-08-21","2013-05-08",21,[35],[993],{"nctId":1040,"briefTitle":1041,"status":104,"phases":1042,"primaryCompletion":1043,"completion":1043,"start":1044,"enrollment":25,"conditions":1045,"interventions":1046},"NCT02386553","A Study of Multiple Doses of Nusinersen (ISIS 396443) Delivered to Infants With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy",[87],"2024-12-17","2015-05-18",[35],[51],{"nctId":1048,"briefTitle":1049,"status":522,"phases":1050,"primaryCompletion":725,"completion":725,"start":1051,"enrollment":1036,"conditions":1052,"interventions":1053},"NCT02462759","A Study to Assess the Safety and Tolerability of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy (SMA).",[87],"2015-08-19",[35],[51],{"trials":1055,"activeCount":470,"soonestReadout":50},[1056,1065,1075,1084,1093,1099],{"nctId":1057,"briefTitle":1058,"status":104,"phases":1059,"primaryCompletion":1060,"completion":1060,"start":1061,"enrollment":1062,"conditions":1063,"interventions":1064},"NCT02594124","A Study for Participants With Spinal Muscular Atrophy (SMA) Who Previously Participated in Nusinersen (ISIS 396443) Investigational Studies",[88],"2023-08-21","2015-11-04",292,[35],[993],{"nctId":1066,"briefTitle":1067,"status":104,"phases":1068,"primaryCompletion":1069,"completion":1070,"start":1071,"enrollment":1072,"conditions":1073,"interventions":1074},"NCT04089566","Study of Nusinersen (BIIB058) in Participants With Spinal Muscular Atrophy",[88],"2024-02-21","2024-05-30","2020-03-26",145,[597],[51],{"nctId":1076,"briefTitle":1077,"status":522,"phases":1078,"primaryCompletion":1079,"completion":1079,"start":1080,"enrollment":1081,"conditions":1082,"interventions":1083},"NCT02193074","A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Infants With Spinal Muscular Atrophy",[88],"2016-11-21","2014-08-19",122,[35],[993],{"nctId":1085,"briefTitle":1086,"status":120,"phases":1087,"primaryCompletion":1088,"completion":1088,"start":1089,"enrollment":1090,"conditions":1091,"interventions":1092},"NCT05067790","A Study to Learn About the Effect of Higher Doses of Nusinersen (BIIB058) Given as Injections to Participants With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Risdiplam (ASCEND)",[88],"2027-09-24","2022-01-21",45,[35],[51],{"nctId":48,"briefTitle":49,"status":120,"phases":1094,"primaryCompletion":50,"completion":50,"start":1095,"enrollment":1096,"conditions":1097,"interventions":1098},[88],"2021-04-19",115,[597],[51],{"nctId":1100,"briefTitle":1101,"status":104,"phases":1102,"primaryCompletion":1103,"completion":1103,"start":1104,"enrollment":1105,"conditions":1106,"interventions":1107},"NCT02292537","A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Participants With Later-onset Spinal Muscular Atrophy (SMA)",[88],"2017-02-20","2014-11-24",126,[35],[51],{"trials":1109,"activeCount":98},[1110],{"nctId":1111,"briefTitle":1112,"status":104,"phases":1113,"primaryCompletion":1114,"completion":1114,"start":1115,"enrollment":1116,"conditions":1117,"interventions":1118},"NCT04488133","A Study to Learn About the Effect of Nusinersen (BIIB058) Given as Injections to Children With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Onasemnogene Abeparvovec (RESPOND)",[89],"2025-10-09","2021-01-04",46,[597],[51],{"trials":1120,"activeCount":98},[1121],{"nctId":1122,"briefTitle":1123,"status":458,"phases":1124,"conditions":1125,"interventions":1127},"NCT02865109","Expanded Access Program (EAP) for Nusinersen in Participants With Infantile-onset (Consistent With Type 1) Spinal Muscular Atrophy (SMA)",[],[1126],"Infantile-onset Spinal Muscular Atrophy",[51],{"intervention":514,"totalTrials":577,"cells":1129},{"EARLY_PHASE1":1130,"PHASE1":1132,"PHASE2":1134,"PHASE3":1136,"PHASE4":1142,"NA":1154},{"trials":1131,"activeCount":98},[],{"trials":1133,"activeCount":98},[],{"trials":1135,"activeCount":98},[],{"trials":1137,"activeCount":149,"soonestReadout":507},[1138],{"nctId":503,"briefTitle":504,"status":505,"phases":1139,"primaryCompletion":507,"completion":508,"start":509,"enrollment":510,"conditions":1140,"interventions":1141},[88],[500],[472,513,514],{"trials":1143,"activeCount":98},[1144],{"nctId":1145,"briefTitle":1146,"status":522,"phases":1147,"primaryCompletion":1148,"completion":1148,"start":1149,"enrollment":1150,"conditions":1151,"interventions":1152},"NCT02342704","Impact of Natalizumab Versus Fingolimod in Relapsing-Remitting Multiple Sclerosis (RRMS) Participants",[89],"2016-05-18","2014-11-30",111,[21],[959,1153],"fingolimod",{"trials":1155,"activeCount":149,"soonestReadout":545},[1156],{"nctId":542,"briefTitle":543,"status":120,"phases":1157,"primaryCompletion":545,"completion":545,"start":546,"enrollment":547,"conditions":1158,"interventions":1159},[],[15],[472,550,514,551,552,78,553,554,555,556,557,558],{"intervention":1161,"totalTrials":1162,"cells":1163},"BIIB017",6,{"EARLY_PHASE1":1164,"PHASE1":1166,"PHASE2":1187,"PHASE3":1189,"PHASE4":1222,"NA":1234},{"trials":1165,"activeCount":98},[],{"trials":1167,"activeCount":98},[1168,1178],{"nctId":1169,"briefTitle":1170,"status":104,"phases":1171,"primaryCompletion":1172,"completion":1172,"start":1173,"enrollment":1174,"conditions":1175,"interventions":1177},"NCT01119781","A Single-Dose, Pharmacokinetic\u002FPharmacodynamic (PK\u002FPD), & Safety Study of BIIB017 in Participants With Renal Impairment & Healthy Volunteers",[86],"2011-08","2010-05",35,[18,1176],"Renal Insufficiency",[1161],{"nctId":1179,"briefTitle":1180,"status":104,"phases":1181,"primaryCompletion":1182,"completion":1182,"start":1183,"enrollment":1184,"conditions":1185,"interventions":1186},"NCT02125578","A Multiple Dose Safety Study of PEG-IFN in Healthy Volunteers",[86],"2008-05","2008-03",69,[18],[1161],{"trials":1188,"activeCount":98},[],{"trials":1190,"activeCount":149,"soonestReadout":1195},[1191,1201,1212],{"nctId":1192,"briefTitle":1193,"status":120,"phases":1194,"primaryCompletion":1195,"completion":1195,"start":1196,"enrollment":1197,"conditions":1198,"interventions":1199},"NCT03958877","A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis",[88],"2027-05-20","2019-10-18",152,[27],[1161,1200],"Interferon beta type 1a",{"nctId":1202,"briefTitle":1203,"status":104,"phases":1204,"primaryCompletion":1205,"completion":846,"start":1206,"enrollment":1207,"conditions":1208,"interventions":1210},"NCT01939002","Characterize Flu-like Symptoms in Relapsing Multiple Sclerosis Patients Transitioning From Non-Pegylated Interferon Beta (IFN-β) Therapies to Peginterferon Beta-1a (BIIB017)",[88],"2015-10","2013-11",251,[1209],"Relapsing Multiple Sclerosis",[1161,1211],"naproxen",{"nctId":1213,"briefTitle":1214,"status":104,"phases":1215,"primaryCompletion":1216,"completion":1217,"start":1218,"enrollment":1219,"conditions":1220,"interventions":1221},"NCT00906399","Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple Sclerosis",[88],"2012-10","2013-10","2009-06",1516,[1209],[1161],{"trials":1223,"activeCount":98},[1224],{"nctId":1225,"briefTitle":1226,"status":705,"phases":1227,"primaryCompletion":1228,"completion":1229,"start":1230,"enrollment":98,"conditions":1231,"interventions":1232},"NCT02234869","Transition to Peginterferon Beta-1a (BIIB017) From Subcutaneous Interferon Therapy",[89],"2017-02","2018-03","2014-10",[1209],[1233,1161],"Interferon Beta",{"trials":1235,"activeCount":98},[],{"intervention":1237,"totalTrials":243,"cells":1238},"BIIB059",{"EARLY_PHASE1":1239,"PHASE1":1241,"PHASE2":1261,"PHASE3":1273,"PHASE4":1285,"NA":1287},{"trials":1240,"activeCount":98},[],{"trials":1242,"activeCount":98},[1243,1252],{"nctId":1244,"briefTitle":1245,"status":104,"phases":1246,"primaryCompletion":1247,"completion":1247,"start":763,"enrollment":1248,"conditions":1249,"interventions":1251},"NCT02106897","Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Single Doses and Multiple Doses of BIIB059 (Litifilimab) in Healthy Volunteers and Participants With Systemic Lupus Erythematosus",[86],"2016-05-24",109,[1250,30],"Systemic Lupus Erythematosus",[1237],{"nctId":1253,"briefTitle":1254,"status":104,"phases":1255,"primaryCompletion":1256,"completion":1256,"start":1257,"enrollment":336,"conditions":1258,"interventions":1260},"NCT03224793","Safety, Tolerability, and Pharmacokinetics of Single Doses of BIIB059 in Healthy Japanese Subjects.",[86],"2018-06-12","2017-10-04",[1259],"Healthy Subjects",[1237],{"trials":1262,"activeCount":98},[1263],{"nctId":1264,"briefTitle":1265,"status":104,"phases":1266,"primaryCompletion":361,"completion":1267,"start":1268,"enrollment":1269,"conditions":1270,"interventions":1272},"NCT02847598","Study to Evaluate BIIB059 (Litifilimab) in Cutaneous Lupus Erythematosus (CLE) With or Without Systemic Lupus Erythematosus (SLE)",[87],"2019-11-18","2016-10-20",264,[1250,1271],"Active Cutaneous Lupus Erythematosus",[1237],{"trials":1274,"activeCount":149,"soonestReadout":1279},[1275],{"nctId":1276,"briefTitle":1277,"status":216,"phases":1278,"primaryCompletion":1279,"completion":1280,"start":1281,"enrollment":1282,"conditions":1283,"interventions":1284},"NCT06044337","A Long-Term Extension Study to Learn More About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus",[88],"2029-06-26","2029-12-11","2023-10-03",322,[283,284],[1237],{"trials":1286,"activeCount":98},[],{"trials":1288,"activeCount":98},[],{"intervention":1200,"totalTrials":149,"cells":1290},{"EARLY_PHASE1":1291,"PHASE1":1293,"PHASE2":1295,"PHASE3":1297,"PHASE4":1303,"NA":1305},{"trials":1292,"activeCount":98},[],{"trials":1294,"activeCount":98},[],{"trials":1296,"activeCount":98},[],{"trials":1298,"activeCount":149,"soonestReadout":1195},[1299],{"nctId":1192,"briefTitle":1193,"status":120,"phases":1300,"primaryCompletion":1195,"completion":1195,"start":1196,"enrollment":1197,"conditions":1301,"interventions":1302},[88],[27],[1161,1200],{"trials":1304,"activeCount":98},[],{"trials":1306,"activeCount":98},[],{"intervention":235,"totalTrials":149,"cells":1308},{"EARLY_PHASE1":1309,"PHASE1":1311,"PHASE2":1313,"PHASE3":1315,"PHASE4":1321,"NA":1323},{"trials":1310,"activeCount":98},[],{"trials":1312,"activeCount":98},[],{"trials":1314,"activeCount":98},[],{"trials":1316,"activeCount":149,"soonestReadout":228},[1317],{"nctId":225,"briefTitle":226,"status":155,"phases":1318,"primaryCompletion":228,"completion":229,"start":230,"enrollment":231,"conditions":1319,"interventions":1320},[88],[233],[83,235,236],{"trials":1322,"activeCount":98},[],{"trials":1324,"activeCount":98},[],{"intervention":236,"totalTrials":149,"cells":1326},{"EARLY_PHASE1":1327,"PHASE1":1329,"PHASE2":1331,"PHASE3":1333,"PHASE4":1339,"NA":1341},{"trials":1328,"activeCount":98},[],{"trials":1330,"activeCount":98},[],{"trials":1332,"activeCount":98},[],{"trials":1334,"activeCount":149,"soonestReadout":228},[1335],{"nctId":225,"briefTitle":226,"status":155,"phases":1336,"primaryCompletion":228,"completion":229,"start":230,"enrollment":231,"conditions":1337,"interventions":1338},[88],[233],[83,235,236],{"trials":1340,"activeCount":98},[],{"trials":1342,"activeCount":98},[],{"intervention":46,"totalTrials":470,"cells":1344},{"EARLY_PHASE1":1345,"PHASE1":1347,"PHASE2":1358,"PHASE3":1369,"PHASE4":1371,"NA":1373},{"trials":1346,"activeCount":98},[],{"trials":1348,"activeCount":98},[1349],{"nctId":1350,"briefTitle":1351,"status":104,"phases":1352,"primaryCompletion":1353,"completion":1353,"start":1354,"enrollment":182,"conditions":1355,"interventions":1356},"NCT06454721","A Study to Determine the Biodistribution, Safety, and Tolerability of a Microdose of Radiolabeled BIIB080 Co-administered With BIIB080 in Healthy Adults",[86],"2026-03-05","2025-01-30",[24],[1357,46],"[89Zr]Zr-DFO-BIIB080",{"trials":1359,"activeCount":149,"soonestReadout":45},[1360],{"nctId":43,"briefTitle":44,"status":120,"phases":1361,"primaryCompletion":45,"completion":1362,"start":1363,"enrollment":1364,"conditions":1365,"interventions":1368},[87],"2029-01-08","2022-08-24",416,[1366,1367],"Mild Cognitive Impairment Due to Alzheimer's Disease","Alzheimer's Disease Dementia",[46],{"trials":1370,"activeCount":98},[],{"trials":1372,"activeCount":98},[],{"trials":1374,"activeCount":98},[],{"intervention":1376,"totalTrials":149,"cells":1377},"BIIB115",{"EARLY_PHASE1":1378,"PHASE1":1380,"PHASE2":1390,"PHASE3":1392,"PHASE4":1394,"NA":1396},{"trials":1379,"activeCount":98},[],{"trials":1381,"activeCount":149,"soonestReadout":1386},[1382],{"nctId":1383,"briefTitle":1384,"status":120,"phases":1385,"primaryCompletion":1386,"completion":1386,"start":1387,"enrollment":773,"conditions":1388,"interventions":1389},"NCT05575011","A Study to Learn About the Safety of BIIB115 Injections and How BIIB115 is Processed in the Bodies of Healthy Adult Male Volunteers and of Pediatric Participants With Spinal Muscular Atrophy Who Previously Took Onasemnogene Abeparvovec",[86],"2031-11-14","2022-10-10",[24,597],[1376],{"trials":1391,"activeCount":98},[],{"trials":1393,"activeCount":98},[],{"trials":1395,"activeCount":98},[],{"trials":1397,"activeCount":98},[],{"intervention":56,"totalTrials":149,"cells":1399},{"EARLY_PHASE1":1400,"PHASE1":1402,"PHASE2":1410,"PHASE3":1412,"PHASE4":1414,"NA":1416},{"trials":1401,"activeCount":98},[],{"trials":1403,"activeCount":149,"soonestReadout":55},[1404],{"nctId":53,"briefTitle":54,"status":155,"phases":1405,"primaryCompletion":55,"completion":55,"start":1406,"enrollment":1407,"conditions":1408,"interventions":1409},[86],"2025-08-29",78,[24],[56],{"trials":1411,"activeCount":98},[],{"trials":1413,"activeCount":98},[],{"trials":1415,"activeCount":98},[],{"trials":1417,"activeCount":98},[],{"intervention":1419,"totalTrials":149,"cells":1420},"BIIB145",{"EARLY_PHASE1":1421,"PHASE1":1423,"PHASE2":1434,"PHASE3":1436,"PHASE4":1438,"NA":1440},{"trials":1422,"activeCount":98},[],{"trials":1424,"activeCount":149,"soonestReadout":1429},[1425],{"nctId":1426,"briefTitle":1427,"status":155,"phases":1428,"primaryCompletion":1429,"completion":1429,"start":1430,"enrollment":1431,"conditions":1432,"interventions":1433},"NCT07225517","A Study to Learn More About the Safety of BIIB145 and How it is Processed in the Body of Healthy Adult Participants",[86],"2027-02-02","2025-12-18",104,[24],[1419],{"trials":1435,"activeCount":98},[],{"trials":1437,"activeCount":98},[],{"trials":1439,"activeCount":98},[],{"trials":1441,"activeCount":98},[],{"intervention":959,"totalTrials":1443,"cells":1444},44,{"EARLY_PHASE1":1445,"PHASE1":1447,"PHASE2":1467,"PHASE3":1565,"PHASE4":1666,"NA":1709},{"trials":1446,"activeCount":98},[],{"trials":1448,"activeCount":98},[1449,1457],{"nctId":1450,"briefTitle":1451,"status":104,"phases":1452,"primaryCompletion":1453,"completion":1453,"start":1454,"enrollment":33,"conditions":1455,"interventions":1456},"NCT01884935","PK and PD Study of Natalizumab in Pediatric Subjects With RRMS",[86],"2014-09","2013-07",[21],[78],{"nctId":1458,"briefTitle":1459,"status":104,"phases":1460,"primaryCompletion":1461,"completion":1461,"start":1462,"enrollment":1463,"conditions":1464,"interventions":1466},"NCT00559702","Safety Study of Natalizumab to Treat Multiple Sclerosis (MS)",[86],"2011-11","2007-10",76,[21,1465],"Secondary Progressive Multiple Sclerosis",[959],{"trials":1468,"activeCount":98},[1469,1478,1486,1497,1505,1513,1523,1531,1541,1550,1557],{"nctId":1470,"briefTitle":1471,"status":104,"phases":1472,"primaryCompletion":1473,"completion":1473,"start":1474,"enrollment":1475,"conditions":1476,"interventions":1477},"NCT01416155","Extension Study to Evaluate Safety and Efficacy of Natalizumab in Japanese Participants With Relapsing-Remitting Multiple Sclerosis",[87],"2014-12","2010-10",97,[21,15],[959],{"nctId":1479,"briefTitle":1480,"status":522,"phases":1481,"primaryCompletion":1482,"start":1483,"conditions":1484,"interventions":1485},"NCT00831649","A Phase II, Multicenter, Open-Label, Long-Term Study of the Safety, Tolerability, and Efficacy of Intravenous Natalizumab in Subjects With Rheumatoid Arthritis Who Have Previously Participated in Study ELN100226-RA201",[87],"2005-02","2004-09",[32],[959],{"nctId":1487,"briefTitle":1488,"status":104,"phases":1489,"primaryCompletion":1490,"completion":1491,"start":1492,"enrollment":1493,"conditions":1494,"interventions":1496},"NCT03283371","Phase 2 Efficacy, Safety, and Tolerability Study of Natalizumab in Focal Epilepsy",[87],"2020-01-11","2020-11-18","2018-03-20",67,[1495],"Epilepsy, Focal Seizures, Partial Seizures",[78],{"nctId":1498,"briefTitle":1499,"status":522,"phases":1500,"primaryCompletion":1501,"completion":1501,"start":1502,"enrollment":470,"conditions":1503,"interventions":1504},"NCT02142192","Natalizumab Subcutaneous Immunogenicity and Safety Study",[87],"2015-06-04","2014-12-01",[1209],[959],{"nctId":1506,"briefTitle":1507,"status":522,"phases":1508,"primaryCompletion":1482,"start":1509,"enrollment":1510,"conditions":1511,"interventions":1512},"NCT00083759","Natalizumab in the Treatment of Rheumatoid Arthritis in Subjects Receiving Methotrexate",[87],"2004-05",299,[32],[959],{"nctId":1514,"briefTitle":1515,"status":104,"phases":1516,"primaryCompletion":1517,"completion":1517,"start":1518,"enrollment":1519,"conditions":1520,"interventions":1522},"NCT02730455","Safety and Efficacy of Intravenous Natalizumab in Acute Ischemic Stroke",[87],"2017-11-20","2016-07-18",277,[1521],"Acute Ischemic Stroke",[959],{"nctId":1524,"briefTitle":1525,"status":104,"phases":1526,"primaryCompletion":1509,"completion":1509,"start":1527,"enrollment":389,"conditions":1528,"interventions":1530},"NCT00055367","Safety, Tolerability and Effectiveness of Natalizumab in Adolescents With Active Crohn's Disease",[87],"2002-04",[1529],"Crohn's Disease",[959],{"nctId":1532,"briefTitle":1533,"status":104,"phases":1534,"primaryCompletion":1461,"completion":1461,"start":1535,"enrollment":654,"conditions":1536,"interventions":1537},"NCT01071083","Treatment Interruption of Natalizumab",[87],"2010-03",[699],[959,1538,1539,1540],"interferon beta 1-a","methylprednisolone","glatiramer acetate",{"nctId":1542,"briefTitle":1543,"status":104,"phases":1544,"primaryCompletion":1545,"completion":1545,"start":1546,"enrollment":1547,"conditions":1548,"interventions":1549},"NCT00097760","Natalizumab in Combination With Glatiramer Acetate (GA) in Patients With Relapsing-Remitting Multiple Sclerosis",[87],"2004-03","2003-06",110,[27],[78,78],{"nctId":1551,"briefTitle":1552,"status":104,"phases":1553,"primaryCompletion":1554,"completion":1554,"start":1527,"enrollment":808,"conditions":1555,"interventions":1556},"NCT00055536","Safety and Efficacy of Natalizumab in Combination With Remicade in the Treatment of Crohn's Disease",[87],"2003-07",[1529],[959],{"nctId":1558,"briefTitle":1559,"status":104,"phases":1560,"primaryCompletion":845,"completion":772,"start":1561,"enrollment":1562,"conditions":1563,"interventions":1564},"NCT01955707","Effect of Natalizumab on Infarct Volume in Acute Ischemic Stroke",[87],"2014-01",161,[1521],[959],{"trials":1566,"activeCount":98},[1567,1575,1584,1591,1600,1610,1618,1628,1638,1646,1656],{"nctId":1568,"briefTitle":1569,"status":104,"phases":1570,"primaryCompletion":1571,"completion":1571,"start":1545,"enrollment":1572,"conditions":1573,"interventions":1574},"NCT00078611","A Clinical Trial of Natalizumab in Individuals With Moderately to Severely Active Crohn's Disease",[88],"2005-03",462,[1529],[959],{"nctId":1576,"briefTitle":1577,"status":104,"phases":1578,"primaryCompletion":1579,"completion":1579,"start":1580,"enrollment":1581,"conditions":1582,"interventions":1583},"NCT01440101","Natalizumab (BG00002, Tysabri) Study in Japanese Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)",[87,88],"2012-08","2010-11",106,[15],[78],{"nctId":1585,"briefTitle":1586,"status":104,"phases":1587,"primaryCompletion":1545,"completion":1545,"start":1588,"conditions":1589,"interventions":1590},"NCT00032786","Safety and Efficacy of Natalizumab in the Treatment of Crohn's Disease",[88],"2002-03",[1529],[959],{"nctId":1592,"briefTitle":1593,"status":522,"phases":1594,"primaryCompletion":1595,"completion":1596,"start":1597,"enrollment":1036,"conditions":1598,"interventions":1599},"NCT05265728","A Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of Natalizumab (BG00002) Administered Subcutaneously to Japanese Participants With Relapsing-Remitting Multiple Sclerosis",[88],"2024-01-18","2024-05-27","2022-04-26",[27],[78],{"nctId":1601,"briefTitle":1602,"status":104,"phases":1603,"primaryCompletion":1604,"completion":1605,"start":1606,"enrollment":1607,"conditions":1608,"interventions":1609},"NCT00027300","Safety and Efficacy of Natalizumab in the Treatment of Multiple Sclerosis",[88],"2004-11","2005-01","2001-11",900,[27],[78],{"nctId":1611,"briefTitle":1612,"status":522,"phases":1613,"primaryCompletion":645,"completion":645,"start":1614,"enrollment":1615,"conditions":1616,"interventions":1617},"NCT00297232","Natalizumab (Tysabri) Re-Initiation of Dosing",[88],"2006-03",1094,[21],[78],{"nctId":1619,"briefTitle":1620,"status":104,"phases":1621,"primaryCompletion":1622,"completion":1623,"start":1624,"enrollment":1625,"conditions":1626,"interventions":1627},"NCT03689972","A Study to Evaluate Efficacy, Safety, and Tolerability of EID of Natalizumab (BG00002) in Participants With RRMS Switching From Treatment With Natalizumab SID in Relation to Continued SID Treatment- Followed by Extension Study Comprising SC and IV Natalizumab Administration",[88],"2023-01-31","2023-07-24","2018-11-27",585,[27],[78,78],{"nctId":1629,"briefTitle":1630,"status":104,"phases":1631,"primaryCompletion":1632,"completion":1633,"start":1634,"enrollment":1635,"conditions":1636,"interventions":1637},"NCT00030966","Safety and Efficacy of Natalizumab in Combination With Avonex in the Treatment of Multiple Sclerosis",[88],"2005-04","2005-12","2002-01",1200,[27],[78],{"nctId":1639,"briefTitle":1586,"status":104,"phases":1640,"primaryCompletion":1641,"completion":1641,"start":1642,"enrollment":1643,"conditions":1644,"interventions":1645},"NCT00032799",[88],"2003-09","2001-12",905,[1529],[959],{"nctId":1647,"briefTitle":1648,"status":522,"phases":1649,"primaryCompletion":1650,"completion":1651,"start":1652,"enrollment":1653,"conditions":1654,"interventions":1655},"NCT01416181","A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis",[88],"2015-07-28","2016-04-13","2011-09-13",889,[1465],[959],{"nctId":1657,"briefTitle":1658,"status":104,"phases":1659,"primaryCompletion":1660,"completion":1661,"start":1662,"enrollment":1663,"conditions":1664,"interventions":1665},"NCT00276172","Open-Label Natalizumab Safety Extension Study",[88],"2005-10","2006-01","2003-12",1615,[15],[78],{"trials":1667,"activeCount":98},[1668,1672,1680,1688,1695,1701],{"nctId":1145,"briefTitle":1146,"status":522,"phases":1669,"primaryCompletion":1148,"completion":1148,"start":1149,"enrollment":1150,"conditions":1670,"interventions":1671},[89],[21],[959,1153],{"nctId":1673,"briefTitle":1674,"status":104,"phases":1675,"primaryCompletion":1676,"completion":1676,"start":1677,"enrollment":325,"conditions":1678,"interventions":1679},"NCT00744679","A Pharmacokinetic (PK) Study of Natalizumab (Tysabri) at Steady State",[89],"2008-12","2008-11",[15],[78],{"nctId":1681,"briefTitle":1682,"status":522,"phases":1683,"primaryCompletion":1684,"completion":1684,"start":1685,"enrollment":149,"conditions":1686,"interventions":1687},"NCT05532163","A Study to Investigate the Radiological Onset of Action After Treatment Initiation With Subcutaneous (SC) Natalizumab in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)",[89],"2023-10-09","2023-01-23",[27],[78],{"nctId":1689,"briefTitle":1690,"status":522,"phases":1691,"primaryCompletion":681,"completion":681,"start":1692,"enrollment":990,"conditions":1693,"interventions":1694},"NCT02241785","Natalizumab as an Efficacy Switch in Participants With Relapsing Multiple Sclerosis After Failure on Other Therapies",[89],"2014-09-30",[1209],[959],{"nctId":1696,"briefTitle":1697,"status":705,"phases":1698,"primaryCompletion":1173,"start":1676,"enrollment":98,"conditions":1699,"interventions":1700},"NCT00801125","Study of Tysabri (Natalizumab) in Patients Who Failed Anti-TNF-α Therapy",[89],[1529],[959],{"nctId":1702,"briefTitle":1703,"status":104,"phases":1704,"primaryCompletion":1483,"completion":1483,"start":1705,"enrollment":1706,"conditions":1707,"interventions":1708},"NCT00280956","Open Label Natalizumab Safety Extension Study for Subjects With Crohn's Disease",[89],"2002-07",2000,[1529],[959],{"trials":1710,"activeCount":470,"soonestReadout":77},[1711,1719,1726,1734,1743,1748,1757,1767,1775,1783,1791,1795,1804,1808],{"nctId":1712,"briefTitle":1713,"status":104,"phases":1714,"primaryCompletion":1205,"completion":1205,"start":1715,"enrollment":1716,"conditions":1717,"interventions":1718},"NCT02137109","Safety and Efficacy in Pediatric MS Patients Prescribed Tysabri",[],"2014-03",400,[15],[959],{"nctId":1720,"briefTitle":1721,"status":104,"phases":1722,"primaryCompletion":846,"completion":846,"start":1535,"enrollment":1723,"conditions":1724,"interventions":1725},"NCT01070836","JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab",[],35895,[1209],[959],{"nctId":1727,"briefTitle":1728,"status":104,"phases":1729,"primaryCompletion":1730,"completion":1730,"start":1731,"enrollment":1519,"conditions":1732,"interventions":1733},"NCT02677077","Clinical Disease Activity With Long Term Natalizumab Treatment",[],"2016-08-18","2015-12-31",[21],[959],{"nctId":1735,"briefTitle":1736,"status":104,"phases":1737,"primaryCompletion":1738,"completion":1738,"start":1739,"enrollment":1740,"conditions":1741,"interventions":1742},"NCT01485003","Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JC Virus Antibody Negative Participants",[],"2018-11-26","2012-02-07",231,[21],[959],{"nctId":75,"briefTitle":76,"status":120,"phases":1744,"primaryCompletion":77,"completion":77,"start":1745,"enrollment":1716,"conditions":1746,"interventions":1747},[],"2023-06-30",[15],[78],{"nctId":1749,"briefTitle":1750,"status":104,"phases":1751,"primaryCompletion":1752,"completion":1752,"start":1753,"enrollment":1754,"conditions":1755,"interventions":1756},"NCT02386566","Observational Study to Assess the Correlation of EDSS With Quality of Life in MS Participants Treated With Natalizumab",[],"2018-01-28","2015-03-20",48,[15],[959],{"nctId":1758,"briefTitle":1759,"status":104,"phases":1760,"primaryCompletion":1761,"completion":1761,"start":1762,"enrollment":1763,"conditions":1764,"interventions":1766},"NCT05304520","A Study for Tysabri Participant Preference",[],"2024-04-30","2021-10-12",318,[1765],"Relapsing-Remitting Multiple Sclerosis (RRMS)",[78],{"nctId":1768,"briefTitle":1769,"status":104,"phases":1770,"primaryCompletion":1771,"completion":1771,"start":1772,"enrollment":808,"conditions":1773,"interventions":1774},"NCT04832399","Study of Tysabri in Early Relapsing Remitting Multiple Sclerosis Participants",[],"2023-10-02","2013-11-12",[699],[78],{"nctId":1776,"briefTitle":1777,"status":522,"phases":1778,"primaryCompletion":1779,"completion":1779,"start":1780,"enrollment":1027,"conditions":1781,"interventions":1782},"NCT05701423","A Study of End of Dose Phenomena in Subcutaneous Natalizumab Treated Multiple Sclerosis (MS) Participants",[],"2024-07-31","2023-02-08",[15],[78],{"nctId":1784,"briefTitle":1785,"status":104,"phases":1786,"primaryCompletion":1787,"completion":1787,"start":1015,"enrollment":1788,"conditions":1789,"interventions":1790},"NCT01943526","Ireland Natalizumab (TYSABRI) Observational Program",[],"2017-12-31",191,[21],[959],{"nctId":951,"briefTitle":952,"status":104,"phases":1792,"primaryCompletion":954,"completion":954,"start":955,"enrollment":956,"conditions":1793,"interventions":1794},[],[21],[959,624],{"nctId":1796,"briefTitle":1797,"status":522,"phases":1798,"primaryCompletion":1799,"completion":1799,"start":1800,"enrollment":1801,"conditions":1802,"interventions":1803},"NCT00707512","CD INFORM: Investigating Natalizumab Through Further Observational Research and Monitoring",[],"2015-05-28","2008-06-30",87,[1529],[959],{"nctId":542,"briefTitle":543,"status":120,"phases":1805,"primaryCompletion":545,"completion":545,"start":546,"enrollment":547,"conditions":1806,"interventions":1807},[],[15],[472,550,514,551,552,78,553,554,555,556,557,558],{"nctId":1809,"briefTitle":1810,"status":104,"phases":1811,"primaryCompletion":1812,"completion":1812,"start":1813,"enrollment":1814,"conditions":1815,"interventions":1816},"NCT05236777","TOPIK Study: A Study to Report Progressive Multifocal Leukoencephalopathy and Other Serious Opportunistic Infections in Natalizumab Treated Participants",[],"2025-04-30","2019-01-01",675,[15],[78],{"intervention":61,"totalTrials":577,"cells":1818},{"EARLY_PHASE1":1819,"PHASE1":1821,"PHASE2":1832,"PHASE3":1834,"PHASE4":1836,"NA":1838},{"trials":1820,"activeCount":98},[],{"trials":1822,"activeCount":98},[1823],{"nctId":1824,"briefTitle":1825,"status":104,"phases":1826,"primaryCompletion":380,"completion":380,"start":1827,"enrollment":1828,"conditions":1829,"interventions":1831},"NCT05655507","Zuranolone Pharmacokinetics (PK) and Safety Study Adolescent Participants With Major Depressive Disorder (MDD)",[86],"2023-04-19",19,[1830],"Major Depressive Disorder",[61],{"trials":1833,"activeCount":98},[],{"trials":1835,"activeCount":98},[],{"trials":1837,"activeCount":98},[],{"trials":1839,"activeCount":470,"soonestReadout":60},[1840,1850],{"nctId":1841,"briefTitle":1842,"status":155,"phases":1843,"primaryCompletion":1844,"completion":1844,"start":1845,"enrollment":1846,"conditions":1847,"interventions":1849},"NCT07398469","A Long-Term Study of Patient-Reported Changes in Postpartum Depression Symptoms in People Starting Zuranolone",[],"2027-03-29","2025-12-22",200,[1848],"Postpartum Depression",[61],{"nctId":58,"briefTitle":59,"status":155,"phases":1851,"primaryCompletion":60,"completion":60,"start":1852,"enrollment":1846,"conditions":1853,"interventions":1855},[],"2025-06-30",[1854],"Depression, Postpartum",[61],{"intervention":1857,"totalTrials":1858,"cells":1859},"peginterferon beta-1a",10,{"EARLY_PHASE1":1860,"PHASE1":1862,"PHASE2":1878,"PHASE3":1880,"PHASE4":1894,"NA":1926},{"trials":1861,"activeCount":98},[],{"trials":1863,"activeCount":98},[1864,1871],{"nctId":1865,"briefTitle":1866,"status":104,"phases":1867,"primaryCompletion":1868,"completion":1868,"start":653,"enrollment":1443,"conditions":1869,"interventions":1870},"NCT01978652","Pharmacokinetic Study of Peginterferon Beta-1a in Japanese and Caucasian Adult Healthy Participants.",[86],"2014-02",[18],[757],{"nctId":1872,"briefTitle":1873,"status":104,"phases":1874,"primaryCompletion":1473,"completion":1473,"start":1230,"enrollment":389,"conditions":1875,"interventions":1876},"NCT02269930","Study to Evaluate the Pharmacokinetic Profiles of BIIB017 (Peginterferon Beta-1a) and Rebif® (Interferon Beta-1a) in Healthy Volunteers",[86],[15],[1857,1877],"Rebif",{"trials":1879,"activeCount":98},[],{"trials":1881,"activeCount":98},[1882,1886],{"nctId":750,"briefTitle":751,"status":522,"phases":1883,"primaryCompletion":753,"completion":753,"start":754,"enrollment":400,"conditions":1884,"interventions":1885},[88],[27],[513,757],{"nctId":1887,"briefTitle":1888,"status":104,"phases":1889,"primaryCompletion":1205,"completion":1205,"start":1890,"enrollment":1891,"conditions":1892,"interventions":1893},"NCT01332019","Long-Term Safety and Efficacy Study of Peginterferon Beta-1a",[88],"2011-04",1077,[1209],[1857],{"trials":1895,"activeCount":98},[1896,1907,1917],{"nctId":1897,"briefTitle":1898,"status":104,"phases":1899,"primaryCompletion":1900,"completion":1900,"start":1901,"enrollment":1902,"conditions":1903,"interventions":1904},"NCT03177083","Evaluate Safety\u002FTolerability in Portuguese Participants With RRMS Transitioning From Current Therapy",[89],"2020-10-26","2017-01-30",80,[699],[1857,1905,1906],"interferon beta-1a","interferon beta-1b",{"nctId":1908,"briefTitle":1909,"status":104,"phases":1910,"primaryCompletion":1911,"completion":1912,"start":1913,"enrollment":1914,"conditions":1915,"interventions":1916},"NCT02587065","Plegridy Satisfaction Study in Participants",[89],"2017-10-02","2017-12-21","2016-02-03",193,[1765],[1857],{"nctId":1918,"briefTitle":1919,"status":705,"phases":1920,"primaryCompletion":1921,"completion":1921,"start":884,"enrollment":98,"conditions":1922,"interventions":1923},"NCT02568111","Brimonidine Tartrate for the Treatment of Injection Related Erythema",[89],"2016-08",[1765],[1857,1924,1925],"brimonidine tartrate","Vehicle Gel",{"trials":1927,"activeCount":149,"soonestReadout":545},[1928,1932,1941],{"nctId":893,"briefTitle":894,"status":104,"phases":1929,"primaryCompletion":896,"completion":896,"start":897,"enrollment":898,"conditions":1930,"interventions":1931},[],[15,900],[811,556],{"nctId":1933,"briefTitle":1934,"status":104,"phases":1935,"primaryCompletion":1936,"completion":1936,"start":1937,"enrollment":1938,"conditions":1939,"interventions":1940},"NCT02230969","Plegridy Observational Program",[],"2022-01-20","2014-11-12",1208,[500],[1857],{"nctId":542,"briefTitle":543,"status":120,"phases":1942,"primaryCompletion":545,"completion":545,"start":546,"enrollment":547,"conditions":1943,"interventions":1944},[],[15],[472,550,514,551,552,78,553,554,555,556,557,558],{"intervention":539,"totalTrials":182,"cells":1946},{"EARLY_PHASE1":1947,"PHASE1":1949,"PHASE2":1966,"PHASE3":1976,"PHASE4":1985,"NA":1987},{"trials":1948,"activeCount":98},[],{"trials":1950,"activeCount":98},[1951,1959],{"nctId":1952,"briefTitle":1953,"status":104,"phases":1954,"primaryCompletion":1955,"completion":1955,"start":1956,"enrollment":220,"conditions":1957,"interventions":1958},"NCT01119677","A Study of Avonex to Determine the Effects of Dose Titration on the Incidence of Flu Like Symptoms in Healthy Volunteers",[86],"2010-10-23","2010-05-05",[30],[539],{"nctId":1960,"briefTitle":1961,"status":104,"phases":1962,"primaryCompletion":1963,"completion":1963,"start":1172,"enrollment":947,"conditions":1964,"interventions":1965},"NCT01416207","A Multiple-Dose, Open-Label, Phase 1, Pharmacokinetic, Pharmacodynamic, and Safety Study of Avonex® in Chinese Healthy Volunteer Subjects",[86],"2011-10",[18],[539],{"trials":1967,"activeCount":98},[1968],{"nctId":1969,"briefTitle":1970,"status":104,"phases":1971,"primaryCompletion":771,"completion":885,"start":646,"enrollment":1972,"conditions":1973,"interventions":1974},"NCT01864148","Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Participants With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex",[87],419,[15],[1975,539],"BIIB033",{"trials":1977,"activeCount":98},[1978],{"nctId":1979,"briefTitle":1980,"status":104,"phases":1981,"primaryCompletion":1963,"completion":1963,"start":1982,"enrollment":808,"conditions":1983,"interventions":1984},"NCT01181115","Avonex Safety and Tolerability in Chinese Subjects With Relapsing Multiple Sclerosis (MS)",[88],"2010-04",[15],[539],{"trials":1986,"activeCount":98},[],{"trials":1988,"activeCount":149,"soonestReadout":534},[1989],{"nctId":531,"briefTitle":532,"status":155,"phases":1990,"primaryCompletion":534,"completion":534,"start":535,"enrollment":536,"conditions":1991,"interventions":1992},[],[15],[472,539,540,513],{"intervention":1540,"totalTrials":182,"cells":1994},{"EARLY_PHASE1":1995,"PHASE1":1997,"PHASE2":1999,"PHASE3":2015,"PHASE4":2035,"NA":2037},{"trials":1996,"activeCount":98},[],{"trials":1998,"activeCount":98},[],{"trials":2000,"activeCount":98},[2001,2005],{"nctId":1532,"briefTitle":1533,"status":104,"phases":2002,"primaryCompletion":1461,"completion":1461,"start":1535,"enrollment":654,"conditions":2003,"interventions":2004},[87],[699],[959,1538,1539,1540],{"nctId":2006,"briefTitle":2007,"status":705,"phases":2008,"primaryCompletion":2009,"completion":2009,"start":2010,"enrollment":98,"conditions":2011,"interventions":2012},"NCT04079088","Study to Evaluate Oral BIIB061 Added to Interferon-beta1 (IFN-β1) or Glatiramer Acetate in Relapsing Multiple Sclerosis (RMS)",[87],"2024-09-18","2021-06-30",[1209],[2013,2014,551],"BIIB061","Interferon-beta1",{"trials":2016,"activeCount":98},[2017,2025],{"nctId":2018,"briefTitle":2019,"status":522,"phases":2020,"primaryCompletion":2021,"completion":2021,"start":1535,"enrollment":838,"conditions":2022,"interventions":2023},"NCT01058005","Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple Sclerosis",[88],"2012-04",[699],[2024,1905,1540],"BG00002",{"nctId":2026,"briefTitle":2027,"status":104,"phases":2028,"primaryCompletion":1172,"completion":1172,"start":2029,"enrollment":2030,"conditions":2031,"interventions":2032},"NCT00451451","Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis",[88],"2007-06",1417,[21],[2033,2034],"BG00012","Glatiramer Acetate",{"trials":2036,"activeCount":98},[],{"trials":2038,"activeCount":149,"soonestReadout":545},[2039],{"nctId":542,"briefTitle":543,"status":120,"phases":2040,"primaryCompletion":545,"completion":545,"start":546,"enrollment":547,"conditions":2041,"interventions":2042},[],[15],[472,550,514,551,552,78,553,554,555,556,557,558],{"intervention":540,"totalTrials":577,"cells":2044},{"EARLY_PHASE1":2045,"PHASE1":2047,"PHASE2":2049,"PHASE3":2051,"PHASE4":2053,"NA":2055},{"trials":2046,"activeCount":98},[],{"trials":2048,"activeCount":98},[],{"trials":2050,"activeCount":98},[],{"trials":2052,"activeCount":98},[],{"trials":2054,"activeCount":98},[],{"trials":2056,"activeCount":149,"soonestReadout":534},[2057,2066,2076],{"nctId":2058,"briefTitle":2059,"status":104,"phases":2060,"primaryCompletion":2061,"completion":2061,"start":2062,"enrollment":2063,"conditions":2064,"interventions":2065},"NCT00493298","Tysabri Observational Program",[],"2023-11-01","2007-06-29",6620,[21],[540],{"nctId":2067,"briefTitle":2068,"status":104,"phases":2069,"primaryCompletion":2070,"completion":2070,"start":2071,"enrollment":2072,"conditions":2073,"interventions":2075},"NCT03399981","Tysabri Observational Cohort Study - Multiple Sclerosis (MS) Registries",[],"2023-12-31","2017-06-01",80327,[2074],"Progressive Multifocal Leukoencephalopathy",[540],{"nctId":531,"briefTitle":532,"status":155,"phases":2077,"primaryCompletion":534,"completion":534,"start":535,"enrollment":536,"conditions":2078,"interventions":2079},[],[15],[472,539,540,513],{"intervention":2081,"totalTrials":470,"cells":2082},"Nusinersen Sodium",{"EARLY_PHASE1":2083,"PHASE1":2085,"PHASE2":2087,"PHASE3":2089,"PHASE4":2091,"NA":2093},{"trials":2084,"activeCount":98},[],{"trials":2086,"activeCount":98},[],{"trials":2088,"activeCount":98},[],{"trials":2090,"activeCount":98},[],{"trials":2092,"activeCount":98},[],{"trials":2094,"activeCount":149,"soonestReadout":2107},[2095,2103],{"nctId":2096,"briefTitle":2097,"status":104,"phases":2098,"primaryCompletion":2099,"completion":2099,"start":1491,"enrollment":2100,"conditions":2101,"interventions":2102},"NCT04419233","Non-Interventional, Postmarketing Surveillance Study of Nusinersen Sodium Injection",[],"2023-11-21",50,[597],[2081],{"nctId":2104,"briefTitle":2105,"status":120,"phases":2106,"primaryCompletion":2107,"completion":2107,"start":2108,"enrollment":2109,"conditions":2110,"interventions":2111},"NCT04317794","Observational, Postmarketing Surveillance Study of Spinraza Injection (Nusinersen Sodium)",[],"2027-02-05","2019-07-02",74,[597],[2081],{"intervention":1233,"totalTrials":470,"cells":2113},{"EARLY_PHASE1":2114,"PHASE1":2116,"PHASE2":2118,"PHASE3":2120,"PHASE4":2122,"NA":2128},{"trials":2115,"activeCount":98},[],{"trials":2117,"activeCount":98},[],{"trials":2119,"activeCount":98},[],{"trials":2121,"activeCount":98},[],{"trials":2123,"activeCount":98},[2124],{"nctId":1225,"briefTitle":1226,"status":705,"phases":2125,"primaryCompletion":1228,"completion":1229,"start":1230,"enrollment":98,"conditions":2126,"interventions":2127},[89],[1209],[1233,1161],{"trials":2129,"activeCount":149,"soonestReadout":545},[2130],{"nctId":542,"briefTitle":543,"status":120,"phases":2131,"primaryCompletion":545,"completion":545,"start":546,"enrollment":547,"conditions":2132,"interventions":2133},[],[15],[472,550,514,551,552,78,553,554,555,556,557,558],{"intervention":550,"totalTrials":149,"cells":2135},{"EARLY_PHASE1":2136,"PHASE1":2138,"PHASE2":2140,"PHASE3":2142,"PHASE4":2144,"NA":2146},{"trials":2137,"activeCount":98},[],{"trials":2139,"activeCount":98},[],{"trials":2141,"activeCount":98},[],{"trials":2143,"activeCount":98},[],{"trials":2145,"activeCount":98},[],{"trials":2147,"activeCount":149,"soonestReadout":545},[2148],{"nctId":542,"briefTitle":543,"status":120,"phases":2149,"primaryCompletion":545,"completion":545,"start":546,"enrollment":547,"conditions":2150,"interventions":2151},[],[15],[472,550,514,551,552,78,553,554,555,556,557,558],{"intervention":553,"totalTrials":149,"cells":2153},{"EARLY_PHASE1":2154,"PHASE1":2156,"PHASE2":2158,"PHASE3":2160,"PHASE4":2162,"NA":2164},{"trials":2155,"activeCount":98},[],{"trials":2157,"activeCount":98},[],{"trials":2159,"activeCount":98},[],{"trials":2161,"activeCount":98},[],{"trials":2163,"activeCount":98},[],{"trials":2165,"activeCount":149,"soonestReadout":545},[2166],{"nctId":542,"briefTitle":543,"status":120,"phases":2167,"primaryCompletion":545,"completion":545,"start":546,"enrollment":547,"conditions":2168,"interventions":2169},[],[15],[472,550,514,551,552,78,553,554,555,556,557,558],{"intervention":554,"totalTrials":149,"cells":2171},{"EARLY_PHASE1":2172,"PHASE1":2174,"PHASE2":2176,"PHASE3":2178,"PHASE4":2180,"NA":2182},{"trials":2173,"activeCount":98},[],{"trials":2175,"activeCount":98},[],{"trials":2177,"activeCount":98},[],{"trials":2179,"activeCount":98},[],{"trials":2181,"activeCount":98},[],{"trials":2183,"activeCount":149,"soonestReadout":545},[2184],{"nctId":542,"briefTitle":543,"status":120,"phases":2185,"primaryCompletion":545,"completion":545,"start":546,"enrollment":547,"conditions":2186,"interventions":2187},[],[15],[472,550,514,551,552,78,553,554,555,556,557,558],{"intervention":555,"totalTrials":149,"cells":2189},{"EARLY_PHASE1":2190,"PHASE1":2192,"PHASE2":2194,"PHASE3":2196,"PHASE4":2198,"NA":2200},{"trials":2191,"activeCount":98},[],{"trials":2193,"activeCount":98},[],{"trials":2195,"activeCount":98},[],{"trials":2197,"activeCount":98},[],{"trials":2199,"activeCount":98},[],{"trials":2201,"activeCount":149,"soonestReadout":545},[2202],{"nctId":542,"briefTitle":543,"status":120,"phases":2203,"primaryCompletion":545,"completion":545,"start":546,"enrollment":547,"conditions":2204,"interventions":2205},[],[15],[472,550,514,551,552,78,553,554,555,556,557,558],{"intervention":557,"totalTrials":149,"cells":2207},{"EARLY_PHASE1":2208,"PHASE1":2210,"PHASE2":2212,"PHASE3":2214,"PHASE4":2216,"NA":2218},{"trials":2209,"activeCount":98},[],{"trials":2211,"activeCount":98},[],{"trials":2213,"activeCount":98},[],{"trials":2215,"activeCount":98},[],{"trials":2217,"activeCount":98},[],{"trials":2219,"activeCount":149,"soonestReadout":545},[2220],{"nctId":542,"briefTitle":543,"status":120,"phases":2221,"primaryCompletion":545,"completion":545,"start":546,"enrollment":547,"conditions":2222,"interventions":2223},[],[15],[472,550,514,551,552,78,553,554,555,556,557,558],{"intervention":558,"totalTrials":149,"cells":2225},{"EARLY_PHASE1":2226,"PHASE1":2228,"PHASE2":2230,"PHASE3":2232,"PHASE4":2234,"NA":2236},{"trials":2227,"activeCount":98},[],{"trials":2229,"activeCount":98},[],{"trials":2231,"activeCount":98},[],{"trials":2233,"activeCount":98},[],{"trials":2235,"activeCount":98},[],{"trials":2237,"activeCount":149,"soonestReadout":545},[2238],{"nctId":542,"briefTitle":543,"status":120,"phases":2239,"primaryCompletion":545,"completion":545,"start":546,"enrollment":547,"conditions":2240,"interventions":2241},[],[15],[472,550,514,551,552,78,553,554,555,556,557,558],{"intervention":576,"totalTrials":149,"cells":2243},{"EARLY_PHASE1":2244,"PHASE1":2246,"PHASE2":2248,"PHASE3":2250,"PHASE4":2252,"NA":2254},{"trials":2245,"activeCount":98},[],{"trials":2247,"activeCount":98},[],{"trials":2249,"activeCount":98},[],{"trials":2251,"activeCount":98},[],{"trials":2253,"activeCount":98},[],{"trials":2255,"activeCount":149,"soonestReadout":571},[2256],{"nctId":568,"briefTitle":569,"status":120,"phases":2257,"primaryCompletion":571,"completion":571,"start":572,"enrollment":573,"conditions":2258,"interventions":2259},[],[15],[472,513,576],{"intervention":2033,"totalTrials":109,"cells":2261},{"EARLY_PHASE1":2262,"PHASE1":2264,"PHASE2":2283,"PHASE3":2302,"PHASE4":2327,"NA":2337},{"trials":2263,"activeCount":98},[],{"trials":2265,"activeCount":98},[2266,2275],{"nctId":2267,"briefTitle":2268,"status":104,"phases":2269,"primaryCompletion":2270,"completion":2271,"start":2270,"enrollment":2272,"conditions":2273,"interventions":2274},"NCT01069913","Pharmacokinetics Profile Study of BG00012 Standard Formulation and BG00012 Active Pharmaceutical Ingredient",[86],"2009-10","2010-01",14,[18],[2033],{"nctId":2276,"briefTitle":2277,"status":104,"phases":2278,"primaryCompletion":2279,"completion":2279,"start":2280,"enrollment":1754,"conditions":2281,"interventions":2282},"NCT00837785","A 24-Hour Pharmacokinetic Determination of BG00012 After Single-Day Oral Administration in Subjects With MS",[86],"2009-10-31","2009-02-28",[699],[2033,2033],{"trials":2284,"activeCount":98},[2285,2294],{"nctId":2286,"briefTitle":2287,"status":104,"phases":2288,"primaryCompletion":2289,"completion":2289,"start":2290,"enrollment":2291,"conditions":2292,"interventions":2293},"NCT00168701","Efficacy and Safety of BG00012 in MS",[87],"2006-03-31","2004-10-01",260,[15],[2033],{"nctId":2295,"briefTitle":2296,"status":104,"phases":2297,"primaryCompletion":2298,"completion":1535,"start":1676,"enrollment":2299,"conditions":2300,"interventions":2301},"NCT00810836","Efficacy and Safety Study of BG00012 With Methotrexate in Patients With Active Rheumatoid Arthritis",[87],"2010-02",153,[32],[2033,2033],{"trials":2303,"activeCount":98},[2304,2314,2318],{"nctId":2305,"briefTitle":2306,"status":104,"phases":2307,"primaryCompletion":1216,"completion":1216,"start":2021,"enrollment":2308,"conditions":2309,"interventions":2310},"NCT01568112","Effect of Aspirin Pretreatment or Slow Dose Titration on Flushing and Gastrointestinal Events in Healthy Volunteers Receiving Delayed-release Dimethyl Fumarate",[88],173,[18],[2033,2311,2312,2313],"BG00012 placebo","ASA","ASA placebo",{"nctId":2026,"briefTitle":2027,"status":104,"phases":2315,"primaryCompletion":1172,"completion":1172,"start":2029,"enrollment":2030,"conditions":2316,"interventions":2317},[88],[21],[2033,2034],{"nctId":2319,"briefTitle":2320,"status":104,"phases":2321,"primaryCompletion":2322,"completion":2322,"start":2323,"enrollment":2324,"conditions":2325,"interventions":2326},"NCT00420212","Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis",[88],"2011-02","2007-01",1234,[21],[2033],{"trials":2328,"activeCount":98},[2329],{"nctId":2330,"briefTitle":2331,"status":104,"phases":2332,"primaryCompletion":1206,"completion":1206,"start":2333,"enrollment":2334,"conditions":2335,"interventions":2336},"NCT01873417","Phase 4 Gastrointestinal Tolerability Study of Dimethyl Fumarate in Patients With Relapsing Forms of Multiple Sclerosis in the United States",[89],"2013-05",237,[500],[2033],{"trials":2338,"activeCount":98},[],{"intervention":2024,"totalTrials":1162,"cells":2340},{"EARLY_PHASE1":2341,"PHASE1":2343,"PHASE2":2345,"PHASE3":2356,"PHASE4":2370,"NA":2400},{"trials":2342,"activeCount":98},[],{"trials":2344,"activeCount":98},[],{"trials":2346,"activeCount":98},[2347],{"nctId":2348,"briefTitle":2349,"status":522,"phases":2350,"primaryCompletion":2351,"completion":2351,"start":2352,"enrollment":1162,"conditions":2353,"interventions":2355},"NCT00675428","Study of Natalizumab in Relapsed\u002FRefractory Multiple Myeloma",[86,87],"2009-12","2008-09",[2354],"Multiple Myeloma",[2024],{"trials":2357,"activeCount":98},[2358,2366],{"nctId":2359,"briefTitle":2360,"status":104,"phases":2361,"primaryCompletion":2362,"completion":2363,"start":1614,"enrollment":260,"conditions":2364,"interventions":2365},"NCT00306592","Natalizumab Re-Initiation of Dosing",[88],"2007-12","2008-02",[27],[2024],{"nctId":2018,"briefTitle":2019,"status":522,"phases":2367,"primaryCompletion":2021,"completion":2021,"start":1535,"enrollment":838,"conditions":2368,"interventions":2369},[88],[699],[2024,1905,1540],{"trials":2371,"activeCount":98},[2372,2382,2390],{"nctId":2373,"briefTitle":2374,"status":104,"phases":2375,"primaryCompletion":2376,"completion":2351,"start":2377,"enrollment":808,"conditions":2378,"interventions":2379},"NCT00536120","The Effects of Tysabri Treatment on Vaccination Response and Lymphocyte Subsets in Subjects With Relapsing Forms of Multiple Sclerosis",[89],"2009-11","2008-01",[15],[2024,2380,2381],"keyhole limpet hemocyanin","tetanus diphtheria toxoid vaccine",{"nctId":2383,"briefTitle":2384,"status":104,"phases":2385,"primaryCompletion":653,"completion":653,"start":2386,"enrollment":2387,"conditions":2388,"interventions":2389},"NCT02142205","Safety and Efficacy of Natalizumab (BG00002, Tysabri®) in Russian Participants With Relapsing Remitting Multiple Sclerosis (RRMS)",[89],"2012-05",100,[21],[2024],{"nctId":2391,"briefTitle":2392,"status":104,"phases":2393,"primaryCompletion":2394,"completion":2394,"start":2395,"enrollment":2396,"conditions":2397,"interventions":2399},"NCT00871780","A Prospective, Open-label, Non-randomized, Clinical Trial to Determine if Natalizumab (Tysabri®) Improves Ambulatory Measures in Relapsing-remitting Multiple Sclerosis (RRMS) Patients",[89],"2012-07","2009-08",224,[2398],"Relapsing Remitting Multiple Sclerosis (RRMS)",[2024],{"trials":2401,"activeCount":98},[],{"intervention":1539,"totalTrials":182,"cells":2403},{"EARLY_PHASE1":2404,"PHASE1":2406,"PHASE2":2408,"PHASE3":2429,"PHASE4":2431,"NA":2460},{"trials":2405,"activeCount":98},[],{"trials":2407,"activeCount":98},[],{"trials":2409,"activeCount":98},[2410,2414],{"nctId":1532,"briefTitle":1533,"status":104,"phases":2411,"primaryCompletion":1461,"completion":1461,"start":1535,"enrollment":654,"conditions":2412,"interventions":2413},[87],[699],[959,1538,1539,1540],{"nctId":2415,"briefTitle":2416,"status":522,"phases":2417,"primaryCompletion":2418,"completion":2419,"start":2420,"enrollment":2421,"conditions":2422,"interventions":2423},"NCT00298272","Safety and Tolerability of Rituxan With Methotrexate and Etanercept or Methotrexate and Adalimumab in Patients With Active Rheumatoid Arthritis",[87],"2009-04","2011-07","2006-05",54,[32],[2424,2425,2426,2427,2428],"IDEC-C2B8","Methotrexate","Etanercept","Adalimumab","Methylprednisolone",{"trials":2430,"activeCount":98},[],{"trials":2432,"activeCount":98},[2433,2444,2453],{"nctId":2434,"briefTitle":2435,"status":522,"phases":2436,"primaryCompletion":2437,"completion":2437,"start":2438,"enrollment":577,"conditions":2439,"interventions":2442},"NCT01211665","Corticosteroids for Immune Reconstitution Inflammatory Syndrome (IRIS)",[89],"2012-02","2010-09",[2440,2441],"Immune Reconstitution Inflammatory Syndrome","Leukoencephalopathy, Progressive Multifocal",[2428,2443],"Prednisolone",{"nctId":2445,"briefTitle":2446,"status":104,"phases":2447,"primaryCompletion":2448,"completion":2448,"start":2449,"enrollment":2272,"conditions":2450,"interventions":2451},"NCT00492466","Investigating if Interferon-Beta Can be Used in Patients With MS After They Have Developed Neutralizing Antibodies",[89],"2006-08","2003-03",[21],[2452,1539],"Interferon-beta-1a",{"nctId":2454,"briefTitle":2455,"status":104,"phases":2456,"primaryCompletion":2351,"completion":2351,"start":2457,"enrollment":325,"conditions":2458,"interventions":2459},"NCT00493116","Is IFN-beta Treatment in MS Useful After a Washout Period in Patients With Neutralizing Antibodies to Interferon Beta",[89],"2003-10",[21],[2452,1539],{"trials":2461,"activeCount":98},[],{"intervention":2452,"totalTrials":577,"cells":2463},{"EARLY_PHASE1":2464,"PHASE1":2466,"PHASE2":2468,"PHASE3":2470,"PHASE4":2472,"NA":2491},{"trials":2465,"activeCount":98},[],{"trials":2467,"activeCount":98},[],{"trials":2469,"activeCount":98},[],{"trials":2471,"activeCount":98},[],{"trials":2473,"activeCount":98},[2474,2483,2487],{"nctId":2475,"briefTitle":2476,"status":104,"phases":2477,"primaryCompletion":1982,"completion":1982,"start":2478,"enrollment":2479,"conditions":2480,"interventions":2481},"NCT00492765","Simvastatin as an Add-on Treatment to Interferon-beta-1a for the Treatment of Relapsing-Remitting Multiple Sclerosis",[89],"2006-02",380,[15],[2452,2482],"Simvastatin",{"nctId":2445,"briefTitle":2446,"status":104,"phases":2484,"primaryCompletion":2448,"completion":2448,"start":2449,"enrollment":2272,"conditions":2485,"interventions":2486},[89],[21],[2452,1539],{"nctId":2454,"briefTitle":2455,"status":104,"phases":2488,"primaryCompletion":2351,"completion":2351,"start":2457,"enrollment":325,"conditions":2489,"interventions":2490},[89],[21],[2452,1539],{"trials":2492,"activeCount":98},[],{"intervention":2494,"totalTrials":470,"cells":2495},"rituximab",{"EARLY_PHASE1":2496,"PHASE1":2498,"PHASE2":2500,"PHASE3":2502,"PHASE4":2513,"NA":2524},{"trials":2497,"activeCount":98},[],{"trials":2499,"activeCount":98},[],{"trials":2501,"activeCount":98},[],{"trials":2503,"activeCount":98},[2504],{"nctId":2505,"briefTitle":2506,"status":104,"phases":2507,"start":2508,"enrollment":2509,"conditions":2510,"interventions":2512},"NCT00168740","Treatment of Relapsed Low-Grade or Follicular Lymphoma With Rituximab (Also Known as Rituxan, IDEC-C2B8, IDEC-102)",[88],"1995-04",150,[2511],"Low-Grade or Follicular B-Cell Non-Hodgkin's Lymphoma",[2494],{"trials":2514,"activeCount":98},[2515],{"nctId":2516,"briefTitle":2517,"status":104,"phases":2518,"primaryCompletion":2029,"completion":2519,"start":2457,"enrollment":2520,"conditions":2521,"interventions":2523},"NCT00090038","Effect of Rituximab on Immunological Recall Response to Specific Antigens in the Treatment of Non-Hodgkin's Lymphoma",[89],"2007-11",168,[2522],"Non-Hodgkin's Lymphoma",[2494],{"trials":2525,"activeCount":98},[],{"intervention":2425,"totalTrials":470,"cells":2527},{"EARLY_PHASE1":2528,"PHASE1":2530,"PHASE2":2532,"PHASE3":2538,"PHASE4":2540,"NA":2552},{"trials":2529,"activeCount":98},[],{"trials":2531,"activeCount":98},[],{"trials":2533,"activeCount":98},[2534],{"nctId":2415,"briefTitle":2416,"status":522,"phases":2535,"primaryCompletion":2418,"completion":2419,"start":2420,"enrollment":2421,"conditions":2536,"interventions":2537},[87],[32],[2424,2425,2426,2427,2428],{"trials":2539,"activeCount":98},[],{"trials":2541,"activeCount":98},[2542],{"nctId":2543,"briefTitle":2544,"status":104,"phases":2545,"primaryCompletion":2546,"completion":2547,"start":1546,"enrollment":2548,"conditions":2549,"interventions":2550},"NCT00112034","AVONEX® Combination Trial - \"ACT\"",[89],"2006-06","2007-05",350,[27],[2425,2551],"IV methylprednisolone",{"trials":2553,"activeCount":98},[],{"intervention":1906,"totalTrials":149,"cells":2555},{"EARLY_PHASE1":2556,"PHASE1":2558,"PHASE2":2560,"PHASE3":2562,"PHASE4":2564,"NA":2570},{"trials":2557,"activeCount":98},[],{"trials":2559,"activeCount":98},[],{"trials":2561,"activeCount":98},[],{"trials":2563,"activeCount":98},[],{"trials":2565,"activeCount":98},[2566],{"nctId":1897,"briefTitle":1898,"status":104,"phases":2567,"primaryCompletion":1900,"completion":1900,"start":1901,"enrollment":1902,"conditions":2568,"interventions":2569},[89],[699],[1857,1905,1906],{"trials":2571,"activeCount":98},[],{"intervention":822,"totalTrials":149,"cells":2573},{"EARLY_PHASE1":2574,"PHASE1":2576,"PHASE2":2578,"PHASE3":2580,"PHASE4":2582,"NA":2588},{"trials":2575,"activeCount":98},[],{"trials":2577,"activeCount":98},[],{"trials":2579,"activeCount":98},[],{"trials":2581,"activeCount":98},[],{"trials":2583,"activeCount":98},[2584],{"nctId":813,"briefTitle":814,"status":104,"phases":2585,"primaryCompletion":816,"completion":817,"start":818,"enrollment":819,"conditions":2586,"interventions":2587},[89],[15],[624,822],{"trials":2589,"activeCount":98},[],{"intervention":2482,"totalTrials":149,"cells":2591},{"EARLY_PHASE1":2592,"PHASE1":2594,"PHASE2":2596,"PHASE3":2598,"PHASE4":2600,"NA":2606},{"trials":2593,"activeCount":98},[],{"trials":2595,"activeCount":98},[],{"trials":2597,"activeCount":98},[],{"trials":2599,"activeCount":98},[],{"trials":2601,"activeCount":98},[2602],{"nctId":2475,"briefTitle":2476,"status":104,"phases":2603,"primaryCompletion":1982,"completion":1982,"start":2478,"enrollment":2479,"conditions":2604,"interventions":2605},[89],[15],[2452,2482],{"trials":2607,"activeCount":98},[],{"intervention":2380,"totalTrials":149,"cells":2609},{"EARLY_PHASE1":2610,"PHASE1":2612,"PHASE2":2614,"PHASE3":2616,"PHASE4":2618,"NA":2624},{"trials":2611,"activeCount":98},[],{"trials":2613,"activeCount":98},[],{"trials":2615,"activeCount":98},[],{"trials":2617,"activeCount":98},[],{"trials":2619,"activeCount":98},[2620],{"nctId":2373,"briefTitle":2374,"status":104,"phases":2621,"primaryCompletion":2376,"completion":2351,"start":2377,"enrollment":808,"conditions":2622,"interventions":2623},[89],[15],[2024,2380,2381],{"trials":2625,"activeCount":98},[],{"intervention":2381,"totalTrials":149,"cells":2627},{"EARLY_PHASE1":2628,"PHASE1":2630,"PHASE2":2632,"PHASE3":2634,"PHASE4":2636,"NA":2642},{"trials":2629,"activeCount":98},[],{"trials":2631,"activeCount":98},[],{"trials":2633,"activeCount":98},[],{"trials":2635,"activeCount":98},[],{"trials":2637,"activeCount":98},[2638],{"nctId":2373,"briefTitle":2374,"status":104,"phases":2639,"primaryCompletion":2376,"completion":2351,"start":2377,"enrollment":808,"conditions":2640,"interventions":2641},[89],[15],[2024,2380,2381],{"trials":2643,"activeCount":98},[],{"intervention":2645,"totalTrials":149,"cells":2646},"Interferon-beta-1a (Avonex) plus methylprednisolone",{"EARLY_PHASE1":2647,"PHASE1":2649,"PHASE2":2651,"PHASE3":2653,"PHASE4":2655,"NA":2666},{"trials":2648,"activeCount":98},[],{"trials":2650,"activeCount":98},[],{"trials":2652,"activeCount":98},[],{"trials":2654,"activeCount":98},[],{"trials":2656,"activeCount":98},[2657],{"nctId":2658,"briefTitle":2659,"status":104,"phases":2660,"primaryCompletion":1677,"completion":1677,"start":2661,"enrollment":2662,"conditions":2663,"interventions":2665},"NCT00168766","Avonex (Interferon-beta-1a) and Avonex Plus Methylprednisolone for the Treatment of Relapsing-remitting MS",[89],"2003-01",345,[2664],"Relapsing-remitting Multiple Sclerosis",[2645],{"trials":2667,"activeCount":98},[],{"intervention":2551,"totalTrials":149,"cells":2669},{"EARLY_PHASE1":2670,"PHASE1":2672,"PHASE2":2674,"PHASE3":2676,"PHASE4":2678,"NA":2684},{"trials":2671,"activeCount":98},[],{"trials":2673,"activeCount":98},[],{"trials":2675,"activeCount":98},[],{"trials":2677,"activeCount":98},[],{"trials":2679,"activeCount":98},[2680],{"nctId":2543,"briefTitle":2544,"status":104,"phases":2681,"primaryCompletion":2546,"completion":2547,"start":1546,"enrollment":2548,"conditions":2682,"interventions":2683},[89],[27],[2425,2551],{"trials":2685,"activeCount":98},[],{"intervention":2687,"totalTrials":149,"cells":2688},"ibritumomab tiuxetan",{"EARLY_PHASE1":2689,"PHASE1":2691,"PHASE2":2693,"PHASE3":2695,"PHASE4":2697,"NA":2709},{"trials":2690,"activeCount":98},[],{"trials":2692,"activeCount":98},[],{"trials":2694,"activeCount":98},[],{"trials":2696,"activeCount":98},[],{"trials":2698,"activeCount":98},[2699],{"nctId":2700,"briefTitle":2701,"status":104,"phases":2702,"completion":2703,"start":2704,"enrollment":159,"conditions":2705,"interventions":2708},"NCT00168727","Zevalin® Followed by Rituxan® Maintenance in Previously Treated Low Grade Non-Hodgkin's Lymphoma",[89],"2005-10-31","2003-06-01",[2706,2707],"Lymphoma, Non-Hodgkin","Lymphoma, Low-Grade",[2687],{"trials":2710,"activeCount":98},[],{"intervention":851,"totalTrials":149,"cells":2712},{"EARLY_PHASE1":2713,"PHASE1":2715,"PHASE2":2717,"PHASE3":2719,"PHASE4":2721,"NA":2727},{"trials":2714,"activeCount":98},[],{"trials":2716,"activeCount":98},[],{"trials":2718,"activeCount":98},[],{"trials":2720,"activeCount":98},[],{"trials":2722,"activeCount":98},[2723],{"nctId":842,"briefTitle":843,"status":104,"phases":2724,"primaryCompletion":845,"completion":846,"start":847,"enrollment":848,"conditions":2725,"interventions":2726},[89],[21],[624,851,852],{"trials":2728,"activeCount":98},[],{"intervention":852,"totalTrials":149,"cells":2730},{"EARLY_PHASE1":2731,"PHASE1":2733,"PHASE2":2735,"PHASE3":2737,"PHASE4":2739,"NA":2745},{"trials":2732,"activeCount":98},[],{"trials":2734,"activeCount":98},[],{"trials":2736,"activeCount":98},[],{"trials":2738,"activeCount":98},[],{"trials":2740,"activeCount":98},[2741],{"nctId":842,"briefTitle":843,"status":104,"phases":2742,"primaryCompletion":845,"completion":846,"start":847,"enrollment":848,"conditions":2743,"interventions":2744},[89],[21],[624,851,852],{"trials":2746,"activeCount":98},[],{"intervention":2443,"totalTrials":149,"cells":2748},{"EARLY_PHASE1":2749,"PHASE1":2751,"PHASE2":2753,"PHASE3":2755,"PHASE4":2757,"NA":2763},{"trials":2750,"activeCount":98},[],{"trials":2752,"activeCount":98},[],{"trials":2754,"activeCount":98},[],{"trials":2756,"activeCount":98},[],{"trials":2758,"activeCount":98},[2759],{"nctId":2434,"briefTitle":2435,"status":522,"phases":2760,"primaryCompletion":2437,"completion":2437,"start":2438,"enrollment":577,"conditions":2761,"interventions":2762},[89],[2440,2441],[2428,2443],{"trials":2764,"activeCount":98},[],{"intervention":879,"totalTrials":149,"cells":2766},{"EARLY_PHASE1":2767,"PHASE1":2769,"PHASE2":2771,"PHASE3":2773,"PHASE4":2775,"NA":2781},{"trials":2768,"activeCount":98},[],{"trials":2770,"activeCount":98},[],{"trials":2772,"activeCount":98},[],{"trials":2774,"activeCount":98},[],{"trials":2776,"activeCount":98},[2777],{"nctId":871,"briefTitle":872,"status":104,"phases":2778,"primaryCompletion":874,"completion":874,"start":875,"enrollment":876,"conditions":2779,"interventions":2780},[89],[27],[624,879],{"trials":2782,"activeCount":98},[],{"intervention":1924,"totalTrials":149,"cells":2784},{"EARLY_PHASE1":2785,"PHASE1":2787,"PHASE2":2789,"PHASE3":2791,"PHASE4":2793,"NA":2799},{"trials":2786,"activeCount":98},[],{"trials":2788,"activeCount":98},[],{"trials":2790,"activeCount":98},[],{"trials":2792,"activeCount":98},[],{"trials":2794,"activeCount":98},[2795],{"nctId":1918,"briefTitle":1919,"status":705,"phases":2796,"primaryCompletion":1921,"completion":1921,"start":884,"enrollment":98,"conditions":2797,"interventions":2798},[89],[1765],[1857,1924,1925],{"trials":2800,"activeCount":98},[],{"intervention":1925,"totalTrials":149,"cells":2802},{"EARLY_PHASE1":2803,"PHASE1":2805,"PHASE2":2807,"PHASE3":2809,"PHASE4":2811,"NA":2817},{"trials":2804,"activeCount":98},[],{"trials":2806,"activeCount":98},[],{"trials":2808,"activeCount":98},[],{"trials":2810,"activeCount":98},[],{"trials":2812,"activeCount":98},[2813],{"nctId":1918,"briefTitle":1919,"status":705,"phases":2814,"primaryCompletion":1921,"completion":1921,"start":884,"enrollment":98,"conditions":2815,"interventions":2816},[89],[1765],[1857,1924,1925],{"trials":2818,"activeCount":98},[],{"intervention":2820,"totalTrials":149,"cells":2821},"TYSABRI and AVONEX",{"EARLY_PHASE1":2822,"PHASE1":2824,"PHASE2":2826,"PHASE3":2828,"PHASE4":2830,"NA":2841},{"trials":2823,"activeCount":98},[],{"trials":2825,"activeCount":98},[],{"trials":2827,"activeCount":98},[],{"trials":2829,"activeCount":98},[],{"trials":2831,"activeCount":98},[2832],{"nctId":2833,"briefTitle":2834,"status":705,"phases":2835,"primaryCompletion":2836,"completion":2837,"start":2838,"enrollment":98,"conditions":2839,"interventions":2840},"NCT00771043","A Proof-of-Concept Study to Correlate Retinal Nerve Fiber Layer Changes in Patients With Multiple Sclerosis Treated With Natalizumab or Interferon Beta 1-a",[89],"2009-08-01","2010-06-01","2008-11-01",[2664],[2820],{"trials":2842,"activeCount":98},[],{"intervention":2844,"totalTrials":149,"cells":2845},"Blood Sample",{"EARLY_PHASE1":2846,"PHASE1":2848,"PHASE2":2850,"PHASE3":2852,"PHASE4":2854,"NA":2863},{"trials":2847,"activeCount":98},[],{"trials":2849,"activeCount":98},[],{"trials":2851,"activeCount":98},[],{"trials":2853,"activeCount":98},[],{"trials":2855,"activeCount":98},[2856],{"nctId":2857,"briefTitle":2858,"status":104,"phases":2859,"primaryCompletion":1963,"start":2860,"enrollment":231,"conditions":2861,"interventions":2862},"NCT01556685","MATRIX: Measuring Neutralizing Antibodies in the Patients Treated With Interferon Beta 1a IM, in Mexico and Colombia",[89],"2011-03",[15],[2844],{"trials":2864,"activeCount":98},[],{"intervention":2866,"totalTrials":149,"cells":2867},"low immunogenic interferon-beta-1a",{"EARLY_PHASE1":2868,"PHASE1":2870,"PHASE2":2872,"PHASE3":2874,"PHASE4":2876,"NA":2884},{"trials":2869,"activeCount":98},[],{"trials":2871,"activeCount":98},[],{"trials":2873,"activeCount":98},[],{"trials":2875,"activeCount":98},[],{"trials":2877,"activeCount":98},[2878],{"nctId":2879,"briefTitle":2880,"status":104,"phases":2881,"primaryCompletion":2420,"completion":2420,"start":1509,"enrollment":577,"conditions":2882,"interventions":2883},"NCT00493077","Safety of Avonex Treatment in Multiple Sclerosis Patients With Neutralizing Antibodies to Interferon Beta Therapy",[89],[15],[2866],{"trials":2885,"activeCount":98},[],{"intervention":2887,"totalTrials":1000,"cells":2888},"Bardoxolone methyl",{"EARLY_PHASE1":2889,"PHASE1":2891,"PHASE2":2954,"PHASE3":3032,"PHASE4":3082,"NA":3084},{"trials":2890,"activeCount":98},[],{"trials":2892,"activeCount":98},[2893,2904,2913,2920,2930,2936,2947],{"nctId":2894,"briefTitle":2895,"status":705,"phases":2896,"primaryCompletion":2897,"completion":2897,"start":2898,"enrollment":98,"conditions":2899,"interventions":2902},"NCT01551446","Pilot Assessment of the Effects of Bardoxolone Methyl on Renal Perfusion, Systemic Haemodynamics and Cardiac Function in Patients With Chronic Kidney Disease and Type 2 Diabetes",[86],"2012-11-30","2012-04-30",[2900,2901],"Renal Insufficiency, Chronic","Diabetes Mellitus, Type 2",[2903],"Bardoxolone Methyl",{"nctId":2905,"briefTitle":2906,"status":104,"phases":2907,"primaryCompletion":2908,"completion":2908,"start":2909,"enrollment":336,"conditions":2910,"interventions":2911},"NCT01461161","A Single-Dose, Open-Label, Randomized, Food Effect and Blinded, Randomized, Dose Proportionality Study in Healthy Volunteers With Bardoxolone Methyl",[86],"2011-12-31","2011-10-31",[30],[2912],"bardoxolone methyl",{"nctId":2914,"briefTitle":2915,"status":104,"phases":2916,"primaryCompletion":2908,"completion":2908,"start":2917,"enrollment":1162,"conditions":2918,"interventions":2919},"NCT01503866","A Phase I Study to Investigate the Absorption, Metabolism and Excretion in Healthy Male Subjects",[86],"2011-12-01",[18],[2912],{"nctId":2921,"briefTitle":2922,"status":104,"phases":2923,"primaryCompletion":2924,"completion":2924,"start":2925,"enrollment":990,"conditions":2926,"interventions":2929},"NCT00529438","RTA 402 in Patients With Advanced Solid Tumors or Lymphoid Malignancies",[86],"2008-12-01","2006-04-30",[2927,2928],"Advanced Solid Tumors","Lymphoid Malignancies",[2887],{"nctId":2931,"briefTitle":2932,"status":522,"phases":2933,"primaryCompletion":2897,"completion":829,"start":2898,"enrollment":947,"conditions":2934,"interventions":2935},"NCT01549769","Pharmacokinetic and Pharmacodynamic Study of Bardoxolone Methyl in Patients With Chronic Kidney Disease and Type 2 Diabetes",[86],[2900,2901],[2903],{"nctId":2937,"briefTitle":2938,"status":522,"phases":2939,"primaryCompletion":2940,"completion":2940,"start":2941,"enrollment":11,"conditions":2942,"interventions":2945},"NCT00529113","Study With Gemcitabine and RTA 402 for Patients With Unresectable Pancreatic Cancer",[86],"2009-11-01","2007-09-30",[2943,2944],"Pancreatic Neoplasms","Pancreatic Cancer",[2887,2887,2887,2887,2887,2887,2887,2946,2887],"Gemcitabine",{"nctId":2948,"briefTitle":2949,"status":104,"phases":2950,"primaryCompletion":2897,"completion":2897,"start":2898,"enrollment":1027,"conditions":2951,"interventions":2953},"NCT01563562","Single-Dose, Open-Label Pharmacokinetic Study of Bardoxolone Methyl in Subjects With Mild, Moderate, and Severe Hepatic Impairment and Normal Hepatic Function",[86],[2952,18],"Hepatic Impairment",[2903],{"trials":2955,"activeCount":98},[2956,2966,2978,3000,3011,3018],{"nctId":2957,"briefTitle":2958,"status":104,"phases":2959,"primaryCompletion":2960,"completion":2961,"start":2962,"enrollment":2963,"conditions":2964,"interventions":2965},"NCT01053936","Phase II Pharmacodynamic Trial to Determine the Effects of Bardoxolone Methyl on eGFR in Patients With Type 2 Diabetes and Chronic Kidney Disease",[87],"2010-12-31","2011-02-28","2010-01-31",129,[2900,2901],[2887],{"nctId":2967,"briefTitle":2968,"status":104,"phases":2969,"primaryCompletion":2970,"completion":2960,"start":2971,"enrollment":2972,"conditions":2973,"interventions":2977},"NCT00811889","Trial to Determine the Effects of Bardoxolone Methyl on eGFR in Patients With Type 2 Diabetes and Chronic Kidney Disease",[87],"2010-05-31","2009-04-30",227,[2974,2975,2976],"Chronic Kidney Disease","Type 2 Diabetes","Diabetic Nephropathy",[2903],{"nctId":2979,"briefTitle":2980,"status":104,"phases":2981,"primaryCompletion":2982,"completion":2983,"start":2984,"enrollment":2985,"conditions":2986,"interventions":2999},"NCT02036970","Bardoxolone Methyl Evaluation in Patients With Pulmonary Hypertension (PH) - LARIAT",[87],"2018-01-19","2018-05-16","2014-05-31",166,[2987,2988,2989,2990,2991,2992,2993,2994,2995,2996,2997,2998],"Pulmonary Arterial Hypertension","Pulmonary Hypertension","Interstitial Lung Disease","Idiopathic Interstitial Pneumonia","Idiopathic Pulmonary Fibrosis","Sarcoidosis","Respiratory Bronchiolitis Associated Interstitial Lung Disease","Desquamative Interstitial Pneumonia","Cryptogenic Organizing Pneumonia","Acute Interstitial Pneumonitis","Idiopathic Lymphoid Interstitial Pneumonia","Idiopathic Pleuroparenchymal Fibroelastosis",[2887],{"nctId":3001,"briefTitle":3002,"status":104,"phases":3003,"primaryCompletion":3004,"completion":3005,"start":3006,"enrollment":196,"conditions":3007,"interventions":3009},"NCT04702997","A Trial of Bardoxolone Methyl in Patients With CKD at Risk of Rapid Progression (MERLIN)",[87],"2021-10-20","2021-11-23","2021-02-09",[3008],"Chronic Kidney Diseases",[3010],"Bardoxolone methyl oral",{"nctId":3012,"briefTitle":3013,"status":705,"phases":3014,"primaryCompletion":1026,"completion":1026,"start":3015,"enrollment":98,"conditions":3016,"interventions":3017},"NCT01655186","A Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Effects of Bardoxolone Methyl on Body Composition in Patients With Stage 4 Chronic Kidney Disease and Type 2 Diabetes Mellitus",[87],"2012-09-30",[2900,2901],[2903],{"nctId":3019,"briefTitle":3020,"status":104,"phases":3021,"primaryCompletion":3022,"completion":3023,"start":3024,"enrollment":3025,"conditions":3026,"interventions":3031},"NCT03366337","A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases - PHOENIX",[87],"2019-01-02","2019-01-29","2017-12-26",103,[3027,3028,3029,3030],"IgA Nephropathy","CKD Associated With Type 1 Diabetes","Focal Segmental Glomerulosclerosis","Autosomal Dominant Polycystic Kidney",[2887],{"trials":3033,"activeCount":98},[3034,3044,3054,3063,3073],{"nctId":3035,"briefTitle":3036,"status":522,"phases":3037,"primaryCompletion":3038,"completion":3038,"start":3039,"enrollment":3040,"conditions":3041,"interventions":3043},"NCT02657356","Bardoxolone Methyl in Patients With Connective Tissue Disease-associated Pulmonary Arterial Hypertension - CATALYST",[88],"2020-05-07","2016-10-04",202,[3042],"Connective Tissue Disease-Associated Pulmonary Arterial Hypertension",[2887],{"nctId":3045,"briefTitle":3046,"status":522,"phases":3047,"primaryCompletion":3048,"completion":3048,"start":3049,"enrollment":3050,"conditions":3051,"interventions":3053},"NCT03918447","A Trial of Bardoxolone Methyl in Patients With ADPKD - FALCON",[88],"2023-08-08","2019-05-29",667,[3030,3052],"ADPKD",[3010],{"nctId":3055,"briefTitle":3056,"status":522,"phases":3057,"primaryCompletion":3058,"completion":3058,"start":3059,"enrollment":3060,"conditions":3061,"interventions":3062},"NCT03068130","Extended Access Program to Assess Long-term Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension RANGER",[88],"2020-09-30","2017-04-18",261,[2988],[2887],{"nctId":3064,"briefTitle":3065,"status":522,"phases":3066,"primaryCompletion":3067,"completion":3067,"start":3068,"enrollment":3069,"conditions":3070,"interventions":3072},"NCT03749447","An Extended Access Program for Bardoxolone Methyl in Patients With CKD (EAGLE)",[88],"2023-08-23","2019-03-08",270,[3008,3071,3030],"Alport Syndrome",[2887],{"nctId":3074,"briefTitle":3075,"status":104,"phases":3076,"primaryCompletion":3077,"completion":3078,"start":922,"enrollment":3079,"conditions":3080,"interventions":3081},"NCT03019185","A Phase 2\u002F3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients With Alport Syndrome - CARDINAL",[87,88],"2020-10-06","2020-10-30",187,[3071],[2903],{"trials":3083,"activeCount":98},[],{"trials":3085,"activeCount":98},[],{"intervention":3087,"totalTrials":159,"cells":3088},"BIIB074",{"EARLY_PHASE1":3089,"PHASE1":3091,"PHASE2":3143,"PHASE3":3186,"PHASE4":3205,"NA":3207},{"trials":3090,"activeCount":98},[],{"trials":3092,"activeCount":98},[3093,3102,3112,3120,3130,3136],{"nctId":3094,"briefTitle":3095,"status":705,"phases":3096,"primaryCompletion":1089,"completion":1089,"start":3058,"enrollment":98,"conditions":3097,"interventions":3099},"NCT04106050","Pharmacodynamic Study of BIIB095 and BIIB074 in Healthy Participants and Participants With Painful Diabetic Polyneuropathy",[86],[30,3098],"Diabetic Neuropathies",[3100,3087,3101],"BIIB095","Lidocaine",{"nctId":3103,"briefTitle":3104,"status":104,"phases":3105,"primaryCompletion":3106,"completion":3106,"start":3107,"enrollment":389,"conditions":3108,"interventions":3110},"NCT03385525","Study to Evaluate the Effect of UGT Inhibition by Valproic Acid on the Pharmacokinetics of BIIB074",[86],"2017-10-13","2017-09-12",[3109],"Drug Interaction",[3087,3111],"Valproic Acid",{"nctId":3113,"briefTitle":3114,"status":104,"phases":3115,"primaryCompletion":3116,"completion":3116,"start":884,"enrollment":978,"conditions":3117,"interventions":3119},"NCT02698267","Effect of Itraconazole on the Pharmacokinetics of BIIB074",[86],"2016-04",[3118],"Neuropathic Pain",[3087,372],{"nctId":3121,"briefTitle":3122,"status":104,"phases":3123,"primaryCompletion":3124,"completion":3124,"start":3125,"enrollment":876,"conditions":3126,"interventions":3128},"NCT03324685","A Drug Interaction Study of BIIB074 and an Oral Contraceptive Regimen",[86],"2018-03-15","2017-11-11",[3127],"Drug Interactions",[3087,3129],"OC",{"nctId":3131,"briefTitle":3132,"status":104,"phases":3133,"primaryCompletion":708,"completion":708,"start":3116,"enrollment":1162,"conditions":3134,"interventions":3135},"NCT02751905","Absorption, Metabolism, and Excretion Study of BIIB074",[86],[3118],[3087],{"nctId":3137,"briefTitle":3138,"status":104,"phases":3139,"primaryCompletion":1228,"completion":1228,"start":1921,"enrollment":526,"conditions":3140,"interventions":3142},"NCT02831517","PK and Safety Study of BIIB074 in Healthy Japanese and Caucasian Participants",[86],[18,3141],"Trigeminal Neuralgia",[3087],{"trials":3144,"activeCount":98},[3145,3156,3166,3176],{"nctId":3146,"briefTitle":3147,"status":522,"phases":3148,"primaryCompletion":3149,"completion":3149,"start":3150,"enrollment":3151,"conditions":3152,"interventions":3155},"NCT03339336","Efficacy and Safety Study of BIIB074 in Participants With Small Fiber Neuropathy",[87],"2021-04-12","2018-05-31",265,[3153,3154],"Small Fiber Neuropathy","Diabetes Mellitus",[3087],{"nctId":3157,"briefTitle":3158,"status":104,"phases":3159,"primaryCompletion":3160,"completion":3160,"start":3161,"enrollment":3162,"conditions":3163,"interventions":3165},"NCT02935608","Study to Evaluate the Efficacy and Safety of BIIB074 in Neuropathic Pain From Lumbosacral Radiculopathy",[87],"2018-08-06","2016-10-31",502,[3164],"Lumbosacral Radiculopathy",[3087],{"nctId":3167,"briefTitle":3168,"status":522,"phases":3169,"primaryCompletion":3170,"completion":3170,"start":3171,"enrollment":3172,"conditions":3173,"interventions":3175},"NCT02957617","Extension Study to Evaluate the Long-Term Safety, Tolerability, and Maintenance of Effect of BIIB074",[87],"2019-02-07","2017-02-10",302,[3174],"Neuropathic Pain From Lumbosacral Radiculopathy",[3087],{"nctId":3177,"briefTitle":3178,"status":104,"phases":3179,"primaryCompletion":3180,"completion":3181,"start":3182,"enrollment":109,"conditions":3183,"interventions":3185},"NCT02917187","A Phase 2a Study of BIIB074 in the Treatment of Erythromelalgia",[87],"2016-12-27","2017-01-05","2016-09-09",[3184],"Primary Inherited Erythromelalgia",[3087],{"trials":3187,"activeCount":98},[3188,3196],{"nctId":3189,"briefTitle":3190,"status":705,"phases":3191,"primaryCompletion":3192,"completion":3193,"start":1827,"enrollment":98,"conditions":3194,"interventions":3195},"NCT03070132","802NP301 Efficacy and Safety Study of BIIB074 in Participants With Trigeminal Neuralgia",[88],"2025-10-14","2026-08-21",[3141],[3087],{"nctId":3197,"briefTitle":3198,"status":705,"phases":3199,"primaryCompletion":3200,"completion":3201,"start":3202,"enrollment":98,"conditions":3203,"interventions":3204},"NCT03637387","802NP302 Efficacy and Safety Study of BIIB074 in Participants With Trigeminal Neuralgia",[88],"2025-08-18","2026-09-29","2023-03-01",[3141],[3087],{"trials":3206,"activeCount":98},[],{"trials":3208,"activeCount":98},[],{"intervention":3210,"totalTrials":400,"cells":3211},"SAGE-217",{"EARLY_PHASE1":3212,"PHASE1":3214,"PHASE2":3216,"PHASE3":3260,"PHASE4":3335,"NA":3337},{"trials":3213,"activeCount":98},[],{"trials":3215,"activeCount":98},[],{"trials":3217,"activeCount":98},[3218,3230,3239,3250],{"nctId":3219,"briefTitle":3220,"status":104,"phases":3221,"primaryCompletion":3222,"completion":3222,"start":3223,"enrollment":3224,"conditions":3225,"interventions":3227},"NCT03000569","A Study to Evaluate SAGE-217 in Participants With Parkinson's Disease",[87],"2017-09-11","2016-11-30",29,[3226],"Parkinson Disease",[3210,3228,3229],"Levodopa","Antiparkinsonian Agent",{"nctId":3231,"briefTitle":3232,"status":104,"phases":3233,"primaryCompletion":1257,"completion":3234,"start":3235,"enrollment":819,"conditions":3236,"interventions":3238},"NCT03000530","A Study to Evaluate SAGE-217 in Participants With Moderate to Severe Major Depressive Disorder",[87],"2017-11-08","2016-12-07",[3237],"Major Depression",[3210],{"nctId":3240,"briefTitle":3241,"status":104,"phases":3242,"primaryCompletion":3243,"completion":3243,"start":3244,"enrollment":1174,"conditions":3245,"interventions":3249},"NCT03692910","A Study to Evaluate SAGE-217 in Participants With Bipolar I\u002FII Disorder With a Current Major Depressive Episode",[87],"2019-05-21","2018-08-23",[3246,3247,3248],"Bipolar Disorder I","Bipolar Disorder II","Major Depressive Episode",[3210],{"nctId":3251,"briefTitle":3252,"status":104,"phases":3253,"primaryCompletion":3254,"completion":3255,"start":3256,"enrollment":1027,"conditions":3257,"interventions":3259},"NCT02978781","A Study to Evaluate SAGE-217 in Participants With Essential Tremor",[87],"2017-11-22","2017-12-05","2017-03-24",[3258],"Essential Tremor",[3210,3210],{"trials":3261,"activeCount":98},[3262,3272,3282,3291,3302,3311,3320],{"nctId":3263,"briefTitle":3264,"status":104,"phases":3265,"primaryCompletion":3266,"completion":3267,"start":3268,"enrollment":3269,"conditions":3270,"interventions":3271},"NCT03672175","A Study to Evaluate the Efficacy of SAGE-217 in the Treatment of Adult Participants With Major Depressive Disorder",[88],"2019-09-24","2020-03-17","2018-11-19",581,[1830],[3210],{"nctId":3273,"briefTitle":3274,"status":522,"phases":3275,"primaryCompletion":3276,"completion":3277,"start":3278,"enrollment":1801,"conditions":3279,"interventions":3281},"NCT03771664","A Study to Evaluate the Safety, Tolerability, and Efficacy of SAGE-217 Compared to Placebo in Adult Participants With Comorbid Major Depressive Disorder (MDD) and Insomnia",[88],"2019-12-20","2020-01-17","2019-02-04",[1830,3280],"Insomnia",[3210],{"nctId":3283,"briefTitle":3284,"status":104,"phases":3285,"primaryCompletion":3286,"completion":3287,"start":3288,"enrollment":1846,"conditions":3289,"interventions":3290},"NCT04442503","A Study to Evaluate the Efficacy and Safety of SAGE-217 in Participants With Severe Postpartum Depression (PPD)",[88],"2022-03-15","2022-04-12","2020-06-08",[1854],[3210],{"nctId":3292,"briefTitle":3293,"status":104,"phases":3294,"primaryCompletion":3295,"completion":3296,"start":3297,"enrollment":3298,"conditions":3299,"interventions":3301},"NCT04442490","A Study to Evaluate the Efficacy of Sage-217 in the Treatment of Adult Participants With Major Depressive Disorder (MDD)",[88],"2021-03-26","2021-04-21","2020-05-12",543,[3300],"Depressive Disorder, Major",[3210],{"nctId":3303,"briefTitle":3304,"status":104,"phases":3305,"primaryCompletion":3306,"completion":3306,"start":3307,"enrollment":3308,"conditions":3309,"interventions":3310},"NCT03864614","A Study to Evaluate SAGE-217 in Adult Participants With Major Depressive Disorder (MDD)",[88],"2023-06-22","2019-02-27",1515,[1830],[3210],{"nctId":3312,"briefTitle":3313,"status":522,"phases":3314,"primaryCompletion":3315,"completion":3315,"start":3316,"enrollment":3317,"conditions":3318,"interventions":3319},"NCT04007367","A Study to Evaluate SAGE-217 for Prevention of Relapse in Adult Participants With Major Depressive Disorder",[88],"2020-01-06","2019-08-06",53,[1830],[3210],{"nctId":3321,"briefTitle":3322,"status":104,"phases":3323,"primaryCompletion":3324,"completion":3325,"start":3326,"enrollment":3327,"conditions":3328,"interventions":3329},"NCT04476030","A Comparative Study of Sage-217 Plus an Antidepressant (ADT) Versus Placebo Plus an ADT in Adults With Major Depressive Disorder",[88],"2021-10-25","2021-12-22","2020-11-09",440,[3300],[3210,3330,3331,3332,3333,3334],"Sertraline","Escitalopram","Citalopram","Duloxetine","Desvenlafaxine",{"trials":3336,"activeCount":98},[],{"trials":3338,"activeCount":98},[],{"intervention":3340,"totalTrials":1858,"cells":3341},"Aducanumab",{"EARLY_PHASE1":3342,"PHASE1":3344,"PHASE2":3388,"PHASE3":3398,"PHASE4":3435,"NA":3437},{"trials":3343,"activeCount":98},[],{"trials":3345,"activeCount":98},[3346,3356,3363,3371,3379],{"nctId":3347,"briefTitle":3348,"status":522,"phases":3349,"primaryCompletion":3350,"completion":3350,"start":3351,"enrollment":3352,"conditions":3353,"interventions":3355},"NCT01677572","Multiple Dose Study of Aducanumab (BIIB037) (Recombinant, Fully Human Anti-Aβ IgG1 mAb) in Participants With Prodromal or Mild Alzheimer's Disease",[86],"2019-07-31","2012-10-05",197,[3354],"Alzheimer's Disease",[3340],{"nctId":3357,"briefTitle":3358,"status":104,"phases":3359,"primaryCompletion":3360,"completion":3360,"start":2010,"enrollment":389,"conditions":3361,"interventions":3362},"NCT04924140","A Study to Assess Absolute Bioavailability of Aducanumab in Healthy Volunteers",[86],"2021-10-01",[30],[3340],{"nctId":3364,"briefTitle":3365,"status":104,"phases":3366,"primaryCompletion":3367,"completion":3367,"start":3368,"enrollment":1036,"conditions":3369,"interventions":3370},"NCT02434718","Single and Multiple Ascending Dose Study of Aducanumab (BIIB037) in Japanese Participants With Alzheimer's Disease",[86],"2016-12-09","2015-06-24",[3354],[3340],{"nctId":3372,"briefTitle":3373,"status":104,"phases":3374,"primaryCompletion":3375,"completion":3375,"start":708,"enrollment":1016,"conditions":3376,"interventions":3377},"NCT02782975","Absolute Bioavailability of a Single, Fixed Subcutaneous Dose of Aducanumab in Healthy Participants",[86],"2016-11",[3354],[3378],"aducanumab",{"nctId":3380,"briefTitle":3381,"status":104,"phases":3382,"primaryCompletion":3383,"completion":3383,"start":3384,"enrollment":3385,"conditions":3386,"interventions":3387},"NCT05216887","A Study to Assess the Pharmacokinetic (PK) Comparability of 2 Fixed Subcutaneous (SC) Doses of Aducanumab (BIIB037) With a Single, Weight-Based Intravenous (IV) Dose in Healthy Volunteers",[86],"2022-07-27","2022-02-01",123,[24],[3340],{"trials":3389,"activeCount":98},[3390],{"nctId":3391,"briefTitle":3392,"status":522,"phases":3393,"primaryCompletion":3394,"completion":3394,"start":108,"enrollment":12,"conditions":3395,"interventions":3397},"NCT03639987","A Study of Aducanumab in Participants With Mild Cognitive Impairment Due to Alzheimer's Disease or With Mild Alzheimer's Disease Dementia to Evaluate the Safety of Continued Dosing in Participants With Asymptomatic Amyloid-Related Imaging Abnormalities",[87],"2019-07-30",[3396,3354],"Cognitive Dysfunction",[3340],{"trials":3399,"activeCount":98},[3400,3409,3418,3427],{"nctId":3401,"briefTitle":3402,"status":522,"phases":3403,"primaryCompletion":3404,"completion":3404,"start":3405,"enrollment":3406,"conditions":3407,"interventions":3408},"NCT04241068","A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205",[88],"2024-07-22","2020-03-02",1696,[3354],[3340],{"nctId":3410,"briefTitle":3411,"status":522,"phases":3412,"primaryCompletion":3413,"completion":3413,"start":3414,"enrollment":3415,"conditions":3416,"interventions":3417},"NCT02484547","221AD302 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease",[88],"2019-08-05","2015-09-15",1643,[3354],[3340,3340],{"nctId":3419,"briefTitle":3420,"status":522,"phases":3421,"primaryCompletion":3422,"completion":3422,"start":3423,"enrollment":3424,"conditions":3425,"interventions":3426},"NCT02477800","221AD301 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease",[88],"2019-08-08","2015-08-13",1653,[3354],[3340,3340],{"nctId":3428,"briefTitle":3429,"status":522,"phases":3430,"primaryCompletion":143,"completion":143,"start":3431,"enrollment":3432,"conditions":3433,"interventions":3434},"NCT05310071","A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease",[88],"2022-06-02",1027,[3354],[3340],{"trials":3436,"activeCount":98},[],{"trials":3438,"activeCount":98},[],{"intervention":3440,"totalTrials":1162,"cells":3441},"BIIB019",{"EARLY_PHASE1":3442,"PHASE1":3444,"PHASE2":3446,"PHASE3":3474,"PHASE4":3504,"NA":3506},{"trials":3443,"activeCount":98},[],{"trials":3445,"activeCount":98},[],{"trials":3447,"activeCount":98},[3448,3456,3464],{"nctId":3449,"briefTitle":3450,"status":104,"phases":3451,"primaryCompletion":3452,"completion":1172,"start":2363,"enrollment":3453,"conditions":3454,"interventions":3455},"NCT00390221","Safety and Efficacy Study of Daclizumab High Yield Process (DAC HYP) to Treat Relapsing-Remitting Multiple Sclerosis",[87],"2011-05",621,[21],[3440],{"nctId":3457,"briefTitle":3458,"status":104,"phases":3459,"primaryCompletion":2386,"completion":1216,"start":3460,"enrollment":3461,"conditions":3462,"interventions":3463},"NCT00870740","Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) in Participants With Multiple Sclerosis Who Have Completed Study 205MS201 (NCT00390221) to Treat Relapsing-Remitting Multiple Sclerosis",[87],"2009-02",517,[21],[3440],{"nctId":3465,"briefTitle":3466,"status":104,"phases":3467,"primaryCompletion":3468,"completion":3468,"start":3469,"enrollment":3470,"conditions":3471,"interventions":3472},"NCT01051349","Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) (BIIB019) in Participants Who Have Completed Study 205MS202 (NCT00870740) to Treat Relapsing Remitting Multiple Sclerosis",[87],"2016-08-25","2010-03-31",410,[21],[3440,3473],"trivalent seasonal influenza vaccine",{"trials":3475,"activeCount":98},[3476,3486,3494],{"nctId":3477,"briefTitle":3478,"status":104,"phases":3479,"primaryCompletion":715,"completion":715,"start":1461,"enrollment":3480,"conditions":3481,"interventions":3482},"NCT01462318","An Open-Label Immunogenicity and Pharmacokinetics Study of Daclizumab High Yield Process Prefilled Syringe in Relapsing Remitting Multiple Sclerosis",[88],133,[21],[3483,3484,348,3485,3440],"Midazolam","S-warfarin","Dextromethorphan",{"nctId":3487,"briefTitle":3488,"status":522,"phases":3489,"primaryCompletion":725,"completion":725,"start":3490,"enrollment":3491,"conditions":3492,"interventions":3493},"NCT01797965","Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019",[88],"2013-02-15",1501,[21,15],[3440],{"nctId":3495,"briefTitle":3496,"status":104,"phases":3497,"primaryCompletion":1715,"completion":955,"start":1173,"enrollment":3498,"conditions":3499,"interventions":3500},"NCT01064401","Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis",[88],1841,[21],[3440,3501,3502,3503],"Interferon beta-1a Placebo","Interferon beta-1a","Daclizumab High Yield Process Placebo",{"trials":3505,"activeCount":98},[],{"trials":3507,"activeCount":98},[],{"intervention":3509,"totalTrials":182,"cells":3510},"BIIB122",{"EARLY_PHASE1":3511,"PHASE1":3513,"PHASE2":3541,"PHASE3":3552,"PHASE4":3562,"NA":3564},{"trials":3512,"activeCount":98},[],{"trials":3514,"activeCount":98},[3515,3523,3532],{"nctId":3516,"briefTitle":3517,"status":104,"phases":3518,"primaryCompletion":3519,"completion":3519,"start":3520,"enrollment":838,"conditions":3521,"interventions":3522},"NCT05229562","A Study to See How BIIB122 Works in the Human Body, and to Evaluate it's Safety, and Tolerability in Healthy Adult Japanese, Chinese, and Caucasian Participants",[86],"2022-09-07","2022-02-17",[24],[3509],{"nctId":3524,"briefTitle":3525,"status":104,"phases":3526,"primaryCompletion":3527,"completion":3527,"start":3528,"enrollment":1000,"conditions":3529,"interventions":3530},"NCT06264440","A Study to Assess the Potential for Gastric-pH Dependent Drug-Drug Interactions of BIIB122 With a Proton Pump Inhibitor in Healthy Participants",[86],"2024-06-18","2024-02-12",[24],[3509,3531],"Rabeprazole",{"nctId":3533,"briefTitle":3534,"status":104,"phases":3535,"primaryCompletion":3536,"completion":3536,"start":3537,"enrollment":109,"conditions":3538,"interventions":3539},"NCT05005338","A Study to Determine the Absolute Bioavailability of BIIB122\u002FDNL151 in Healthy Subjects",[86],"2021-09-23","2021-07-28",[30],[3509,3540],"[14C] BIIB122",{"trials":3542,"activeCount":98},[3543],{"nctId":3544,"briefTitle":3545,"status":104,"phases":3546,"primaryCompletion":3547,"completion":3547,"start":3548,"enrollment":3549,"conditions":3550,"interventions":3551},"NCT05348785","A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80",[87],"2026-03-09","2022-04-19",650,[3226],[3509],{"trials":3553,"activeCount":98},[3554],{"nctId":3555,"briefTitle":3556,"status":522,"phases":3557,"primaryCompletion":3558,"completion":3558,"start":3559,"enrollment":94,"conditions":3560,"interventions":3561},"NCT05418673","A Study to Assess if BIIB122 Tablets Are Safe and Can Slow Worsening of Early-Stage Parkinson's Disease in Participants With Specific LRRK2 Genetic Variants Between the Ages of 30 and 80 Using the Movement Disorder Society-Unified Parkinson's Disease Rating Scale",[88],"2023-07-27","2022-08-26",[3226],[3509],{"trials":3563,"activeCount":98},[],{"trials":3565,"activeCount":98},[],{"intervention":3567,"totalTrials":243,"cells":3568},"BIIB041",{"EARLY_PHASE1":3569,"PHASE1":3571,"PHASE2":3579,"PHASE3":3588,"PHASE4":3608,"NA":3610},{"trials":3570,"activeCount":98},[],{"trials":3572,"activeCount":98},[3573],{"nctId":3574,"briefTitle":3575,"status":104,"phases":3576,"primaryCompletion":1580,"completion":1580,"start":1474,"enrollment":876,"conditions":3577,"interventions":3578},"NCT01215084","A Pharmacokinetics (PK) and Safety Study of Oral Fampridine-PR 10 mg in Chinese, Japanese, and Caucasian Adult Healthy Volunteers",[86],[18],[3567],{"trials":3580,"activeCount":98},[3581],{"nctId":3582,"briefTitle":3583,"status":104,"phases":3584,"primaryCompletion":646,"completion":646,"start":1579,"enrollment":3585,"conditions":3586,"interventions":3587},"NCT01597297","Exploratory Study to Assess the Effect of Fampridine (BIIB041) on Walking Ability and Balance in Participants With Multiple Sclerosis.",[87],132,[15],[3567],{"trials":3589,"activeCount":98},[3590,3600],{"nctId":3591,"briefTitle":3592,"status":104,"phases":3593,"primaryCompletion":1205,"completion":3594,"start":646,"enrollment":3595,"conditions":3596,"interventions":3599},"NCT01917019","A Safety and Efficacy Study of Oral Prolonged-Release Fampridine (BIIB041) in Japanese Participants With Multiple Sclerosis",[88],"2017-03",101,[3597,3598,21,1465,15],"Multiple Sclerosis, Remittent Progressive","Multiple Sclerosis, Primary Progressive",[3567],{"nctId":3601,"briefTitle":3602,"status":104,"phases":3603,"primaryCompletion":3604,"completion":3604,"start":3605,"enrollment":625,"conditions":3606,"interventions":3607},"NCT01235221","Open Label Extension Study to Evaluate the Safety and Tolerability of Oral Fampridine-Sustained Release (SR) in Canadian Participants With Multiple Sclerosis Who Participated in Acorda Extension Trials.",[88],"2012-06","2010-12",[15],[3567],{"trials":3609,"activeCount":98},[],{"trials":3611,"activeCount":98},[],{"intervention":701,"totalTrials":470,"cells":3613},{"EARLY_PHASE1":3614,"PHASE1":3616,"PHASE2":3618,"PHASE3":3620,"PHASE4":3636,"NA":3638},{"trials":3615,"activeCount":98},[],{"trials":3617,"activeCount":98},[],{"trials":3619,"activeCount":98},[],{"trials":3621,"activeCount":98},[3622,3626],{"nctId":693,"briefTitle":694,"status":104,"phases":3623,"primaryCompletion":696,"completion":696,"start":697,"enrollment":6,"conditions":3624,"interventions":3625},[88],[699],[701,513],{"nctId":3627,"briefTitle":3628,"status":104,"phases":3629,"primaryCompletion":3630,"completion":3631,"start":3632,"enrollment":3633,"conditions":3634,"interventions":3635},"NCT02634307","A Study of ALKS 8700 in Adults With Relapsing Remitting Multiple Sclerosis (MS) EVOLVE-MS-1",[88],"2021-06-01","2021-11-11","2015-12-10",1057,[15],[701],{"trials":3637,"activeCount":98},[],{"trials":3639,"activeCount":98},[],{"intervention":348,"totalTrials":470,"cells":3641},{"EARLY_PHASE1":3642,"PHASE1":3644,"PHASE2":3650,"PHASE3":3652,"PHASE4":3658,"NA":3660},{"trials":3643,"activeCount":98},[],{"trials":3645,"activeCount":98},[3646],{"nctId":341,"briefTitle":342,"status":104,"phases":3647,"primaryCompletion":344,"completion":344,"start":345,"enrollment":28,"conditions":3648,"interventions":3649},[86],[24],[41,348],{"trials":3651,"activeCount":98},[],{"trials":3653,"activeCount":98},[3654],{"nctId":3477,"briefTitle":3478,"status":104,"phases":3655,"primaryCompletion":715,"completion":715,"start":1461,"enrollment":3480,"conditions":3656,"interventions":3657},[88],[21],[3483,3484,348,3485,3440],{"trials":3659,"activeCount":98},[],{"trials":3661,"activeCount":98},[],{"intervention":3663,"totalTrials":470,"cells":3664},"Tonapofylline",{"EARLY_PHASE1":3665,"PHASE1":3667,"PHASE2":3669,"PHASE3":3678,"PHASE4":3692,"NA":3694},{"trials":3666,"activeCount":98},[],{"trials":3668,"activeCount":98},[],{"trials":3670,"activeCount":98},[3671],{"nctId":3672,"briefTitle":3673,"status":522,"phases":3674,"primaryCompletion":2271,"completion":2271,"start":3460,"enrollment":1027,"conditions":3675,"interventions":3677},"NCT00745316","Oral Tonapofylline (BG9928) in Patients With Heart Failure and Renal Insufficiency",[87],[1176,3676],"Heart Failure",[3663],{"trials":3679,"activeCount":98},[3680],{"nctId":3681,"briefTitle":3682,"status":104,"phases":3683,"primaryCompletion":3684,"completion":3685,"start":3686,"enrollment":3687,"conditions":3688,"interventions":3690},"NCT00709865","Study to Assess the Safety and Tolerability of IV Tonapofylline in Subjects With Acute Decompensated Heart Failure (ADHF) and Renal Insufficiency",[88],"2009-10-30","2009-12-31","2008-07-31",420,[1176,3689],"Congestive Heart Failure",[3691],"tonapofylline",{"trials":3693,"activeCount":98},[],{"trials":3695,"activeCount":98},[],{"intervention":3697,"totalTrials":470,"cells":3698},"BIIB111",{"EARLY_PHASE1":3699,"PHASE1":3701,"PHASE2":3703,"PHASE3":3714,"PHASE4":3725,"NA":3727},{"trials":3700,"activeCount":98},[],{"trials":3702,"activeCount":98},[],{"trials":3704,"activeCount":98},[3705],{"nctId":3706,"briefTitle":3707,"status":104,"phases":3708,"primaryCompletion":483,"completion":483,"start":3709,"enrollment":3710,"conditions":3711,"interventions":3713},"NCT03507686","A Safety Study of Retinal Gene Therapy for Choroideremia With Administration of BIIB111",[87],"2017-11-29",66,[3712],"Choroideremia",[3697],{"trials":3715,"activeCount":98},[3716],{"nctId":3717,"briefTitle":3718,"status":104,"phases":3719,"primaryCompletion":3720,"completion":3720,"start":3721,"enrollment":3722,"conditions":3723,"interventions":3724},"NCT03496012","Efficacy and Safety of BIIB111 for the Treatment of Choroideremia",[88],"2020-12-01","2017-12-11",169,[3712],[3697],{"trials":3726,"activeCount":98},[],{"trials":3728,"activeCount":98},[],{"intervention":3730,"totalTrials":470,"cells":3731},"Galiximab in combination with rituximab",{"EARLY_PHASE1":3732,"PHASE1":3734,"PHASE2":3736,"PHASE3":3738,"PHASE4":3757,"NA":3759},{"trials":3733,"activeCount":98},[],{"trials":3735,"activeCount":98},[],{"trials":3737,"activeCount":98},[],{"trials":3739,"activeCount":98},[3740,3750],{"nctId":3741,"briefTitle":3742,"status":522,"phases":3743,"primaryCompletion":2271,"completion":1982,"start":3744,"enrollment":3745,"conditions":3746,"interventions":3748},"NCT00363636","A Study of Galiximab + Rituximab Versus Rituximab + Placebo in Follicular Non-Hodgkin's Lymphoma (NHL)",[88],"2006-09",340,[3747],"Lymphoma, Non-Hodgkin's",[3730,3749],"Rituximab in combination with placebo",{"nctId":3751,"briefTitle":3752,"status":522,"phases":3753,"primaryCompletion":2271,"completion":2271,"start":2519,"enrollment":978,"conditions":3754,"interventions":3755},"NCT00384150","Retreatment Study of Galiximab + Rituximab in Follicular Non-Hodgkin's Lymphoma (NHL)",[88],[3747],[3756],"galiximab in combination with rituximab",{"trials":3758,"activeCount":98},[],{"trials":3760,"activeCount":98},[],{"intervention":1211,"totalTrials":149,"cells":3762},{"EARLY_PHASE1":3763,"PHASE1":3765,"PHASE2":3767,"PHASE3":3769,"PHASE4":3775,"NA":3777},{"trials":3764,"activeCount":98},[],{"trials":3766,"activeCount":98},[],{"trials":3768,"activeCount":98},[],{"trials":3770,"activeCount":98},[3771],{"nctId":1202,"briefTitle":1203,"status":104,"phases":3772,"primaryCompletion":1205,"completion":846,"start":1206,"enrollment":1207,"conditions":3773,"interventions":3774},[88],[1209],[1161,1211],{"trials":3776,"activeCount":98},[],{"trials":3778,"activeCount":98},[],{"intervention":2311,"totalTrials":149,"cells":3780},{"EARLY_PHASE1":3781,"PHASE1":3783,"PHASE2":3785,"PHASE3":3787,"PHASE4":3793,"NA":3795},{"trials":3782,"activeCount":98},[],{"trials":3784,"activeCount":98},[],{"trials":3786,"activeCount":98},[],{"trials":3788,"activeCount":98},[3789],{"nctId":2305,"briefTitle":2306,"status":104,"phases":3790,"primaryCompletion":1216,"completion":1216,"start":2021,"enrollment":2308,"conditions":3791,"interventions":3792},[88],[18],[2033,2311,2312,2313],{"trials":3794,"activeCount":98},[],{"trials":3796,"activeCount":98},[],{"intervention":2312,"totalTrials":149,"cells":3798},{"EARLY_PHASE1":3799,"PHASE1":3801,"PHASE2":3803,"PHASE3":3805,"PHASE4":3811,"NA":3813},{"trials":3800,"activeCount":98},[],{"trials":3802,"activeCount":98},[],{"trials":3804,"activeCount":98},[],{"trials":3806,"activeCount":98},[3807],{"nctId":2305,"briefTitle":2306,"status":104,"phases":3808,"primaryCompletion":1216,"completion":1216,"start":2021,"enrollment":2308,"conditions":3809,"interventions":3810},[88],[18],[2033,2311,2312,2313],{"trials":3812,"activeCount":98},[],{"trials":3814,"activeCount":98},[],{"intervention":2313,"totalTrials":149,"cells":3816},{"EARLY_PHASE1":3817,"PHASE1":3819,"PHASE2":3821,"PHASE3":3823,"PHASE4":3829,"NA":3831},{"trials":3818,"activeCount":98},[],{"trials":3820,"activeCount":98},[],{"trials":3822,"activeCount":98},[],{"trials":3824,"activeCount":98},[3825],{"nctId":2305,"briefTitle":2306,"status":104,"phases":3826,"primaryCompletion":1216,"completion":1216,"start":2021,"enrollment":2308,"conditions":3827,"interventions":3828},[88],[18],[2033,2311,2312,2313],{"trials":3830,"activeCount":98},[],{"trials":3832,"activeCount":98},[],{"intervention":3834,"totalTrials":149,"cells":3835},"Daclizumab",{"EARLY_PHASE1":3836,"PHASE1":3838,"PHASE2":3840,"PHASE3":3842,"PHASE4":3851,"NA":3853},{"trials":3837,"activeCount":98},[],{"trials":3839,"activeCount":98},[],{"trials":3841,"activeCount":98},[],{"trials":3843,"activeCount":98},[3844],{"nctId":3845,"briefTitle":3846,"status":522,"phases":3847,"primaryCompletion":3848,"completion":3848,"start":3059,"enrollment":422,"conditions":3849,"interventions":3850},"NCT02881567","Efficacy and Safety of Daclizumab in Participants With RRMS Switching From Natalizumab",[88],"2018-09-12",[1765],[3834],{"trials":3852,"activeCount":98},[],{"trials":3854,"activeCount":98},[],{"intervention":3856,"totalTrials":149,"cells":3857},"SAGE-217 15\u002F20 mg Oral Solution",{"EARLY_PHASE1":3858,"PHASE1":3860,"PHASE2":3862,"PHASE3":3864,"PHASE4":3877,"NA":3879},{"trials":3859,"activeCount":98},[],{"trials":3861,"activeCount":98},[],{"trials":3863,"activeCount":98},[],{"trials":3865,"activeCount":98},[3866],{"nctId":3867,"briefTitle":3868,"status":104,"phases":3869,"primaryCompletion":3870,"completion":3871,"start":3872,"enrollment":3873,"conditions":3874,"interventions":3875},"NCT02978326","A Study to Evaluate SAGE-217 in Participants With Severe Postpartum Depression",[88],"2018-11-15","2018-12-11","2017-01-04",276,[1848],[3856,3876],"SAGE 217 30 mg",{"trials":3878,"activeCount":98},[],{"trials":3880,"activeCount":98},[],{"intervention":3876,"totalTrials":149,"cells":3882},{"EARLY_PHASE1":3883,"PHASE1":3885,"PHASE2":3887,"PHASE3":3889,"PHASE4":3895,"NA":3897},{"trials":3884,"activeCount":98},[],{"trials":3886,"activeCount":98},[],{"trials":3888,"activeCount":98},[],{"trials":3890,"activeCount":98},[3891],{"nctId":3867,"briefTitle":3868,"status":104,"phases":3892,"primaryCompletion":3870,"completion":3871,"start":3872,"enrollment":3873,"conditions":3893,"interventions":3894},[88],[1848],[3856,3876],{"trials":3896,"activeCount":98},[],{"trials":3898,"activeCount":98},[],{"intervention":3900,"totalTrials":149,"cells":3901},"Zevalin",{"EARLY_PHASE1":3902,"PHASE1":3904,"PHASE2":3906,"PHASE3":3908,"PHASE4":3917,"NA":3919},{"trials":3903,"activeCount":98},[],{"trials":3905,"activeCount":98},[],{"trials":3907,"activeCount":98},[],{"trials":3909,"activeCount":98},[3910],{"nctId":3911,"briefTitle":3912,"status":522,"phases":3913,"start":2449,"enrollment":1716,"conditions":3914,"interventions":3915},"NCT00057343","Safety and Efficacy of Zevalin in the Treatment of Non-Hodgkin's Lymphoma",[88],[2522],[3900,3916],"Rituxan",{"trials":3918,"activeCount":98},[],{"trials":3920,"activeCount":98},[],{"intervention":3916,"totalTrials":149,"cells":3922},{"EARLY_PHASE1":3923,"PHASE1":3925,"PHASE2":3927,"PHASE3":3929,"PHASE4":3935,"NA":3937},{"trials":3924,"activeCount":98},[],{"trials":3926,"activeCount":98},[],{"trials":3928,"activeCount":98},[],{"trials":3930,"activeCount":98},[3931],{"nctId":3911,"briefTitle":3912,"status":522,"phases":3932,"start":2449,"enrollment":1716,"conditions":3933,"interventions":3934},[88],[2522],[3900,3916],{"trials":3936,"activeCount":98},[],{"trials":3938,"activeCount":98},[],{"intervention":3940,"totalTrials":149,"cells":3941},"Alefacept",{"EARLY_PHASE1":3942,"PHASE1":3944,"PHASE2":3946,"PHASE3":3948,"PHASE4":3959,"NA":3961},{"trials":3943,"activeCount":98},[],{"trials":3945,"activeCount":98},[],{"trials":3947,"activeCount":98},[],{"trials":3949,"activeCount":98},[3950],{"nctId":3951,"briefTitle":3952,"status":104,"phases":3953,"completion":3954,"start":3955,"enrollment":1716,"conditions":3956,"interventions":3958},"NCT00233662","Safety and Tolerability of Repeat Courses of IM Alefacept",[88],"2005-12-01","2002-12-01",[3957],"Chronic Plaque Psoriasis",[3940],{"trials":3960,"activeCount":98},[],{"trials":3962,"activeCount":98},[],{"intervention":3483,"totalTrials":149,"cells":3964},{"EARLY_PHASE1":3965,"PHASE1":3967,"PHASE2":3969,"PHASE3":3971,"PHASE4":3977,"NA":3979},{"trials":3966,"activeCount":98},[],{"trials":3968,"activeCount":98},[],{"trials":3970,"activeCount":98},[],{"trials":3972,"activeCount":98},[3973],{"nctId":3477,"briefTitle":3478,"status":104,"phases":3974,"primaryCompletion":715,"completion":715,"start":1461,"enrollment":3480,"conditions":3975,"interventions":3976},[88],[21],[3483,3484,348,3485,3440],{"trials":3978,"activeCount":98},[],{"trials":3980,"activeCount":98},[],{"intervention":3484,"totalTrials":149,"cells":3982},{"EARLY_PHASE1":3983,"PHASE1":3985,"PHASE2":3987,"PHASE3":3989,"PHASE4":3995,"NA":3997},{"trials":3984,"activeCount":98},[],{"trials":3986,"activeCount":98},[],{"trials":3988,"activeCount":98},[],{"trials":3990,"activeCount":98},[3991],{"nctId":3477,"briefTitle":3478,"status":104,"phases":3992,"primaryCompletion":715,"completion":715,"start":1461,"enrollment":3480,"conditions":3993,"interventions":3994},[88],[21],[3483,3484,348,3485,3440],{"trials":3996,"activeCount":98},[],{"trials":3998,"activeCount":98},[],{"intervention":3485,"totalTrials":149,"cells":4000},{"EARLY_PHASE1":4001,"PHASE1":4003,"PHASE2":4005,"PHASE3":4007,"PHASE4":4013,"NA":4015},{"trials":4002,"activeCount":98},[],{"trials":4004,"activeCount":98},[],{"trials":4006,"activeCount":98},[],{"trials":4008,"activeCount":98},[4009],{"nctId":3477,"briefTitle":3478,"status":104,"phases":4010,"primaryCompletion":715,"completion":715,"start":1461,"enrollment":3480,"conditions":4011,"interventions":4012},[88],[21],[3483,3484,348,3485,3440],{"trials":4014,"activeCount":98},[],{"trials":4016,"activeCount":98},[],{"intervention":3749,"totalTrials":149,"cells":4018},{"EARLY_PHASE1":4019,"PHASE1":4021,"PHASE2":4023,"PHASE3":4025,"PHASE4":4031,"NA":4033},{"trials":4020,"activeCount":98},[],{"trials":4022,"activeCount":98},[],{"trials":4024,"activeCount":98},[],{"trials":4026,"activeCount":98},[4027],{"nctId":3741,"briefTitle":3742,"status":522,"phases":4028,"primaryCompletion":2271,"completion":1982,"start":3744,"enrollment":3745,"conditions":4029,"interventions":4030},[88],[3747],[3730,3749],{"trials":4032,"activeCount":98},[],{"trials":4034,"activeCount":98},[],{"intervention":3330,"totalTrials":149,"cells":4036},{"EARLY_PHASE1":4037,"PHASE1":4039,"PHASE2":4041,"PHASE3":4043,"PHASE4":4049,"NA":4051},{"trials":4038,"activeCount":98},[],{"trials":4040,"activeCount":98},[],{"trials":4042,"activeCount":98},[],{"trials":4044,"activeCount":98},[4045],{"nctId":3321,"briefTitle":3322,"status":104,"phases":4046,"primaryCompletion":3324,"completion":3325,"start":3326,"enrollment":3327,"conditions":4047,"interventions":4048},[88],[3300],[3210,3330,3331,3332,3333,3334],{"trials":4050,"activeCount":98},[],{"trials":4052,"activeCount":98},[],{"intervention":3331,"totalTrials":149,"cells":4054},{"EARLY_PHASE1":4055,"PHASE1":4057,"PHASE2":4059,"PHASE3":4061,"PHASE4":4067,"NA":4069},{"trials":4056,"activeCount":98},[],{"trials":4058,"activeCount":98},[],{"trials":4060,"activeCount":98},[],{"trials":4062,"activeCount":98},[4063],{"nctId":3321,"briefTitle":3322,"status":104,"phases":4064,"primaryCompletion":3324,"completion":3325,"start":3326,"enrollment":3327,"conditions":4065,"interventions":4066},[88],[3300],[3210,3330,3331,3332,3333,3334],{"trials":4068,"activeCount":98},[],{"trials":4070,"activeCount":98},[],{"intervention":3332,"totalTrials":149,"cells":4072},{"EARLY_PHASE1":4073,"PHASE1":4075,"PHASE2":4077,"PHASE3":4079,"PHASE4":4085,"NA":4087},{"trials":4074,"activeCount":98},[],{"trials":4076,"activeCount":98},[],{"trials":4078,"activeCount":98},[],{"trials":4080,"activeCount":98},[4081],{"nctId":3321,"briefTitle":3322,"status":104,"phases":4082,"primaryCompletion":3324,"completion":3325,"start":3326,"enrollment":3327,"conditions":4083,"interventions":4084},[88],[3300],[3210,3330,3331,3332,3333,3334],{"trials":4086,"activeCount":98},[],{"trials":4088,"activeCount":98},[],{"intervention":3333,"totalTrials":149,"cells":4090},{"EARLY_PHASE1":4091,"PHASE1":4093,"PHASE2":4095,"PHASE3":4097,"PHASE4":4103,"NA":4105},{"trials":4092,"activeCount":98},[],{"trials":4094,"activeCount":98},[],{"trials":4096,"activeCount":98},[],{"trials":4098,"activeCount":98},[4099],{"nctId":3321,"briefTitle":3322,"status":104,"phases":4100,"primaryCompletion":3324,"completion":3325,"start":3326,"enrollment":3327,"conditions":4101,"interventions":4102},[88],[3300],[3210,3330,3331,3332,3333,3334],{"trials":4104,"activeCount":98},[],{"trials":4106,"activeCount":98},[],{"intervention":3334,"totalTrials":149,"cells":4108},{"EARLY_PHASE1":4109,"PHASE1":4111,"PHASE2":4113,"PHASE3":4115,"PHASE4":4121,"NA":4123},{"trials":4110,"activeCount":98},[],{"trials":4112,"activeCount":98},[],{"trials":4114,"activeCount":98},[],{"trials":4116,"activeCount":98},[4117],{"nctId":3321,"briefTitle":3322,"status":104,"phases":4118,"primaryCompletion":3324,"completion":3325,"start":3326,"enrollment":3327,"conditions":4119,"interventions":4120},[88],[3300],[3210,3330,3331,3332,3333,3334],{"trials":4122,"activeCount":98},[],{"trials":4124,"activeCount":98},[],{"intervention":4126,"totalTrials":149,"cells":4127},"Bardoxolone Methyl: 20 mg",{"EARLY_PHASE1":4128,"PHASE1":4130,"PHASE2":4132,"PHASE3":4134,"PHASE4":4145,"NA":4147},{"trials":4129,"activeCount":98},[],{"trials":4131,"activeCount":98},[],{"trials":4133,"activeCount":98},[],{"trials":4135,"activeCount":98},[4136],{"nctId":4137,"briefTitle":4138,"status":522,"phases":4139,"primaryCompletion":1026,"completion":4140,"start":4141,"enrollment":4142,"conditions":4143,"interventions":4144},"NCT01351675","Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes",[88],"2012-12-31","2011-06-30",2185,[2900,2901],[4126],{"trials":4146,"activeCount":98},[],{"trials":4148,"activeCount":98},[],{"intervention":798,"totalTrials":149,"cells":4150},{"EARLY_PHASE1":4151,"PHASE1":4153,"PHASE2":4155,"PHASE3":4157,"PHASE4":4163,"NA":4165},{"trials":4152,"activeCount":98},[],{"trials":4154,"activeCount":98},[],{"trials":4156,"activeCount":98},[],{"trials":4158,"activeCount":98},[4159],{"nctId":790,"briefTitle":791,"status":104,"phases":4160,"primaryCompletion":793,"completion":793,"start":794,"enrollment":795,"conditions":4161,"interventions":4162},[88],[21],[624,798],{"trials":4164,"activeCount":98},[],{"trials":4166,"activeCount":98},[],{"intervention":3501,"totalTrials":149,"cells":4168},{"EARLY_PHASE1":4169,"PHASE1":4171,"PHASE2":4173,"PHASE3":4175,"PHASE4":4181,"NA":4183},{"trials":4170,"activeCount":98},[],{"trials":4172,"activeCount":98},[],{"trials":4174,"activeCount":98},[],{"trials":4176,"activeCount":98},[4177],{"nctId":3495,"briefTitle":3496,"status":104,"phases":4178,"primaryCompletion":1715,"completion":955,"start":1173,"enrollment":3498,"conditions":4179,"interventions":4180},[88],[21],[3440,3501,3502,3503],{"trials":4182,"activeCount":98},[],{"trials":4184,"activeCount":98},[],{"intervention":3503,"totalTrials":149,"cells":4186},{"EARLY_PHASE1":4187,"PHASE1":4189,"PHASE2":4191,"PHASE3":4193,"PHASE4":4199,"NA":4201},{"trials":4188,"activeCount":98},[],{"trials":4190,"activeCount":98},[],{"trials":4192,"activeCount":98},[],{"trials":4194,"activeCount":98},[4195],{"nctId":3495,"briefTitle":3496,"status":104,"phases":4196,"primaryCompletion":1715,"completion":955,"start":1173,"enrollment":3498,"conditions":4197,"interventions":4198},[88],[21],[3440,3501,3502,3503],{"trials":4200,"activeCount":98},[],{"trials":4202,"activeCount":98},[],{"intervention":4204,"totalTrials":159,"cells":4205},"PF-04958242",{"EARLY_PHASE1":4206,"PHASE1":4208,"PHASE2":4298,"PHASE3":4309,"PHASE4":4311,"NA":4313},{"trials":4207,"activeCount":98},[],{"trials":4209,"activeCount":98},[4210,4219,4227,4236,4244,4251,4259,4267,4275,4283,4290],{"nctId":4211,"briefTitle":4212,"status":104,"phases":4213,"primaryCompletion":4214,"completion":4214,"start":4215,"enrollment":1443,"conditions":4216,"interventions":4218},"NCT01518920","A Study Of The Effects Of PF-04958242 In Subjects With Age-Related Hearing Loss",[86],"2013-02","2011-12",[4217],"Hearing Loss, Sensorineural",[4204,4204],{"nctId":4220,"briefTitle":4221,"status":104,"phases":4222,"primaryCompletion":4223,"completion":4223,"start":4224,"enrollment":159,"conditions":4225,"interventions":4226},"NCT02228395","Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of Single Doses Of PF-04958242 In Healthy Volunteers",[86],"2014-11-13","2014-09-22",[18],[4204],{"nctId":4228,"briefTitle":4229,"status":104,"phases":4230,"primaryCompletion":4231,"completion":4231,"start":4232,"enrollment":4233,"conditions":4234,"interventions":4235},"NCT01365338","A Study To Assess Effects Of PF-04958242 On Bold Functional Magnetic Resonance Imaging During Working Memory Activation And Arterial Spin Labeling At Rest In Healthy Subjects",[86],"2012-12-14","2011-06-24",112,[24],[4204],{"nctId":4237,"briefTitle":4238,"status":104,"phases":4239,"primaryCompletion":4240,"completion":4240,"start":2394,"enrollment":159,"conditions":4241,"interventions":4242},"NCT01646840","Study Of The PF-04958242 Blood Concentrations Of A Capsule Formulation Of PF-04958242 Compared To A Solution Formulation",[86],"2012-09",[18],[4204,4243],"PF-04958242 oral solution",{"nctId":4245,"briefTitle":4246,"status":104,"phases":4247,"primaryCompletion":672,"completion":672,"start":1461,"enrollment":389,"conditions":4248,"interventions":4250},"NCT01518894","A Study To Examine The Safety, Tolerability And Pharmacokinetics Of PF-04958242 In Psychiatrically Stable Subjects With Schizophrenia",[86],[4249],"Schizophrenia",[4204,4204,4204],{"nctId":4252,"briefTitle":4253,"status":104,"phases":4254,"primaryCompletion":4255,"completion":4255,"start":4256,"enrollment":33,"conditions":4257,"interventions":4258},"NCT02341482","A Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of PF-04958242 in Healthy Subjects",[86],"2015-03-31","2015-02-05",[18],[4204,372],{"nctId":4260,"briefTitle":4261,"status":104,"phases":4262,"primaryCompletion":4263,"completion":4263,"start":4264,"enrollment":947,"conditions":4265,"interventions":4266},"NCT01159483","First-in-Human Study of PF-04958242 in Healthy Volunteers",[86],"2010-10-16","2010-07-15",[24],[4204],{"nctId":4268,"briefTitle":4269,"status":104,"phases":4270,"primaryCompletion":4271,"completion":4271,"start":4272,"enrollment":8,"conditions":4273,"interventions":4274},"NCT02332798","Multiple Ascending Doses of PF-04958242 in Subjects With Stable Schizophrenia",[86],"2015-04-15","2015-01-06",[4249],[4204],{"nctId":4276,"briefTitle":4277,"status":104,"phases":4278,"primaryCompletion":1868,"completion":1868,"start":4279,"enrollment":3224,"conditions":4280,"interventions":4281},"NCT01749098","A Study To Examine The Effects Of PF-04958242 On Ketamine-Induced Cognitive Impairment In Healthy Volunteers",[86],"2012-12",[4249],[4204,4282,4282],"Ketamine",{"nctId":4284,"briefTitle":4285,"status":104,"phases":4286,"primaryCompletion":1461,"completion":1461,"start":4287,"enrollment":8,"conditions":4288,"interventions":4289},"NCT01511510","Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Repeated Doses of PF-04958242 in Healthy Volunteers",[86],"2011-06",[4249],[4204,4204,4204,4204],{"nctId":4291,"briefTitle":4292,"status":522,"phases":4293,"primaryCompletion":4294,"completion":4294,"start":4295,"enrollment":325,"conditions":4296,"interventions":4297},"NCT01238679","Study to Evaluate the Safety, Tolerability and Pharmacokinetics of PF-04958242 in Healthy Adult Volunteers",[86],"2011-05-03","2010-11-24",[30],[4204],{"trials":4299,"activeCount":98},[4300],{"nctId":4301,"briefTitle":4302,"status":522,"phases":4303,"primaryCompletion":4304,"completion":4304,"start":4305,"enrollment":1174,"conditions":4306,"interventions":4308},"NCT02855411","A Study To Evaluate The Safety And Efficacy Of PF-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS)",[87],"2016-09-26","2016-08-29",[4307],"Cognitive Impairment Associated With Schizophrenia (CIAS)",[4204],{"trials":4310,"activeCount":98},[],{"trials":4312,"activeCount":98},[],{"trials":4314,"activeCount":98},[],{"intervention":1975,"totalTrials":94,"cells":4316},{"EARLY_PHASE1":4317,"PHASE1":4319,"PHASE2":4350,"PHASE3":4372,"PHASE4":4374,"NA":4376},{"trials":4318,"activeCount":98},[],{"trials":4320,"activeCount":98},[4321,4329,4337,4343],{"nctId":4322,"briefTitle":4323,"status":104,"phases":4324,"primaryCompletion":4325,"completion":4325,"start":884,"enrollment":947,"conditions":4326,"interventions":4328},"NCT02641041","Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of BIIB033 in Healthy Japanese Participants",[86],"2016-09",[4327,15],"Central Nervous System (CNS) Demyelinating Disease",[1975],{"nctId":4330,"briefTitle":4331,"status":104,"phases":4332,"primaryCompletion":3375,"completion":3375,"start":4333,"enrollment":1016,"conditions":4334,"interventions":4336},"NCT02833142","Pharmacokinetics, Safety and Tolerability of Single Doses of BIIB033 (Opicinumab) Produced by 2 Manufacturing Processes",[86],"2016-07",[15,4335],"Acute Optic Neuritis",[1975],{"nctId":4338,"briefTitle":4339,"status":104,"phases":4340,"primaryCompletion":2021,"completion":2021,"start":1474,"enrollment":990,"conditions":4341,"interventions":4342},"NCT01244139","Safety Study of BIIB033 in Subjects With Multiple Sclerosis",[86],[21,15],[1975],{"nctId":4344,"briefTitle":4345,"status":104,"phases":4346,"primaryCompletion":1963,"completion":1963,"start":2271,"enrollment":4347,"conditions":4348,"interventions":4349},"NCT01052506","BIIB033 Single Ascending Dose Study in Healthy Volunteer Subjects",[86],72,[18],[1975],{"trials":4351,"activeCount":98},[4352,4356,4363],{"nctId":1969,"briefTitle":1970,"status":104,"phases":4353,"primaryCompletion":771,"completion":885,"start":646,"enrollment":1972,"conditions":4354,"interventions":4355},[87],[15],[1975,539],{"nctId":4357,"briefTitle":4358,"status":104,"phases":4359,"primaryCompletion":1230,"completion":1230,"start":4279,"enrollment":4360,"conditions":4361,"interventions":4362},"NCT01721161","BIIB033 In Acute Optic Neuritis (AON)",[87],82,[4335],[1975],{"nctId":4364,"briefTitle":4365,"status":522,"phases":4366,"primaryCompletion":4367,"completion":4367,"start":4368,"enrollment":4369,"conditions":4370,"interventions":4371},"NCT03222973","Efficacy and Safety of BIIB033 (Opicinumab) as an Add-on Therapy to Disease-Modifying Therapies (DMTs) in Relapsing Multiple Sclerosis (MS)",[87],"2021-02-12","2017-11-15",263,[15],[1975],{"trials":4373,"activeCount":98},[],{"trials":4375,"activeCount":98},[],{"trials":4377,"activeCount":98},[],{"intervention":4379,"totalTrials":182,"cells":4380},"BIIB091",{"EARLY_PHASE1":4381,"PHASE1":4383,"PHASE2":4419,"PHASE3":4431,"PHASE4":4433,"NA":4435},{"trials":4382,"activeCount":98},[],{"trials":4384,"activeCount":98},[4385,4393,4401,4411],{"nctId":4386,"briefTitle":4387,"status":104,"phases":4388,"primaryCompletion":4389,"completion":4389,"start":4390,"enrollment":526,"conditions":4391,"interventions":4392},"NCT03943056","A Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of BIIB091, a Bruton's Tyrosine Kinase (BTK) Inhibitor, in Healthy Adult Participants",[86],"2020-01-10","2019-05-13",[24],[4379],{"nctId":4394,"briefTitle":4395,"status":104,"phases":4396,"primaryCompletion":3519,"completion":3519,"start":4397,"enrollment":4398,"conditions":4399,"interventions":4400},"NCT04564612","Study of BIIB091 Formulations in Healthy Participants",[86],"2020-09-28",59,[30],[4379,3531,372],{"nctId":4402,"briefTitle":4403,"status":104,"phases":4404,"primaryCompletion":4405,"completion":4405,"start":4406,"enrollment":1184,"conditions":4407,"interventions":4408},"NCT06574828","A Study to Find Out How Multiple Doses of BIIB091 Affect the Electrical Activity of the Heart in Healthy Participants",[86],"2025-03-22","2024-08-29",[24],[4379,393,4409,4410],"BIIB091-matched Placebo","Moxifloxacin-matched Placebo",{"nctId":4412,"briefTitle":4413,"status":104,"phases":4414,"primaryCompletion":4415,"completion":4415,"start":4416,"enrollment":25,"conditions":4417,"interventions":4418},"NCT06640933","A Study to Find Out How Different Forms of BIIB091 is Processed in The Body With and Without Food in Healthy Participants",[86],"2025-02-07","2024-10-16",[24],[4379],{"trials":4420,"activeCount":98},[4421],{"nctId":4422,"briefTitle":4423,"status":104,"phases":4424,"primaryCompletion":4425,"completion":4425,"start":4426,"enrollment":4427,"conditions":4428,"interventions":4429},"NCT05798520","A Study to Learn About the Safety of BIIB091 and Its Effect on Brain Inflammation When Taken Alone or With Diroximel Fumarate (DRF) in Adults With Relapsing Forms of Multiple Sclerosis (MS)",[87],"2026-02-10","2023-07-25",127,[500],[4379,4430],"DRF",{"trials":4432,"activeCount":98},[],{"trials":4434,"activeCount":98},[],{"trials":4436,"activeCount":98},[],{"intervention":4438,"totalTrials":243,"cells":4439},"BIIB092",{"EARLY_PHASE1":4440,"PHASE1":4442,"PHASE2":4461,"PHASE3":4481,"PHASE4":4483,"NA":4485},{"trials":4441,"activeCount":98},[],{"trials":4443,"activeCount":98},[4444,4452],{"nctId":4445,"briefTitle":4446,"status":522,"phases":4447,"primaryCompletion":4448,"completion":4448,"start":726,"enrollment":990,"conditions":4449,"interventions":4451},"NCT02658916","Extension Study of BIIB092 in Participants With Progressive Supranuclear Palsy (PSP) Who Participated in CN002003",[86],"2020-03-31",[4450],"Supranuclear Palsy, Progressive",[4438],{"nctId":4453,"briefTitle":4454,"status":104,"phases":4455,"primaryCompletion":4456,"completion":4456,"start":4457,"enrollment":1754,"conditions":4458,"interventions":4460},"NCT02460094","Multiple Ascending Dose Study of Intravenously Administered BMS-986168 (BIIB092) in Patients With Progressive Supranuclear Palsy",[86],"2016-10-19","2015-10-02",[4459],"Progressive Supranuclear Palsy",[4438],{"trials":4462,"activeCount":98},[4463,4472],{"nctId":4464,"briefTitle":4465,"status":522,"phases":4466,"primaryCompletion":4467,"completion":4468,"start":2071,"enrollment":4469,"conditions":4470,"interventions":4471},"NCT03068468","Study of BIIB092 in Participants With Progressive Supranuclear Palsy",[87],"2019-09-06","2020-02-07",490,[4450],[4438],{"nctId":4473,"briefTitle":4474,"status":522,"phases":4475,"primaryCompletion":4476,"completion":4476,"start":4477,"enrollment":4478,"conditions":4479,"interventions":4480},"NCT03352557","Phase 2 Study of BIIB092 in Participants With Early Alzheimer's Disease",[87],"2021-08-30","2018-05-03",654,[3354],[4438],{"trials":4482,"activeCount":98},[],{"trials":4484,"activeCount":98},[],{"trials":4486,"activeCount":98},[],{"intervention":4488,"totalTrials":243,"cells":4489},"CNV1014802",{"EARLY_PHASE1":4490,"PHASE1":4492,"PHASE2":4511,"PHASE3":4531,"PHASE4":4533,"NA":4535},{"trials":4491,"activeCount":98},[],{"trials":4493,"activeCount":98},[4494,4503],{"nctId":4495,"briefTitle":4496,"status":104,"phases":4497,"primaryCompletion":4498,"completion":4499,"start":4500,"enrollment":876,"conditions":4501,"interventions":4502},"NCT02551497","Study to Evaluate the Interaction Between a Drug and CNV1014802 in Healthy Subjects",[86],"2016-08-16","2016-08-26","2015-04-30",[18],[4488],{"nctId":4504,"briefTitle":4505,"status":104,"phases":4506,"primaryCompletion":4507,"completion":4507,"start":4508,"enrollment":336,"conditions":4509,"interventions":4510},"NCT02359344","PK & Tolerability of CNV1014802 in Young and Elderly Healthy Volunteers",[86],"2015-04-20","2015-02-03",[3141],[4488],{"trials":4512,"activeCount":98},[4513,4522],{"nctId":4514,"briefTitle":4515,"status":104,"phases":4516,"primaryCompletion":4517,"completion":4518,"start":4519,"enrollment":4360,"conditions":4520,"interventions":4521},"NCT01561027","Crossover Study of CNV1014802 in Subjects With Neuropathic Pain From Lumbosacral Radiculopathy",[87],"2012-06-30","2012-08-31","2011-04-30",[3164],[4488],{"nctId":4523,"briefTitle":4524,"status":104,"phases":4525,"primaryCompletion":4526,"completion":4527,"start":4528,"enrollment":1493,"conditions":4529,"interventions":4530},"NCT01540630","A Phase IIa Withdrawal Study of CNV1014802 in Patients With Trigeminal Neuralgia",[87],"2014-03-31","2014-06-30","2012-03-31",[3141],[4488],{"trials":4532,"activeCount":98},[],{"trials":4534,"activeCount":98},[],{"trials":4536,"activeCount":98},[],{"intervention":2013,"totalTrials":243,"cells":4538},{"EARLY_PHASE1":4539,"PHASE1":4541,"PHASE2":4564,"PHASE3":4570,"PHASE4":4572,"NA":4574},{"trials":4540,"activeCount":98},[],{"trials":4542,"activeCount":98},[4543,4550,4557],{"nctId":4544,"briefTitle":4545,"status":104,"phases":4546,"primaryCompletion":708,"completion":708,"start":4547,"enrollment":637,"conditions":4548,"interventions":4549},"NCT02228707","Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB061 in Healthy Adult Volunteers",[86],"2014-08",[18],[2013],{"nctId":4551,"briefTitle":4552,"status":104,"phases":4553,"primaryCompletion":4554,"completion":4554,"start":859,"enrollment":109,"conditions":4555,"interventions":4556},"NCT02521545","Single-Dose Study of a New Formulation of BIIB061",[86],"2015-08",[15],[2013],{"nctId":4558,"briefTitle":4559,"status":104,"phases":4560,"primaryCompletion":1453,"completion":1453,"start":653,"enrollment":8,"conditions":4561,"interventions":4562},"NCT02071121","Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of BIIB061 in Healthy Adult Volunteers Including Absolute Bioavailability and Food Effect",[86],[18],[2013,4563],"14C-BIIB061",{"trials":4565,"activeCount":98},[4566],{"nctId":2006,"briefTitle":2007,"status":705,"phases":4567,"primaryCompletion":2009,"completion":2009,"start":2010,"enrollment":98,"conditions":4568,"interventions":4569},[87],[1209],[2013,2014,551],{"trials":4571,"activeCount":98},[],{"trials":4573,"activeCount":98},[],{"trials":4575,"activeCount":98},[],{"intervention":4577,"totalTrials":243,"cells":4578},"BIIB023",{"EARLY_PHASE1":4579,"PHASE1":4581,"PHASE2":4596,"PHASE3":4613,"PHASE4":4615,"NA":4617},{"trials":4580,"activeCount":98},[],{"trials":4582,"activeCount":98},[4583,4590],{"nctId":4584,"briefTitle":4585,"status":104,"phases":4586,"primaryCompletion":1890,"completion":1890,"start":4587,"enrollment":3317,"conditions":4588,"interventions":4589},"NCT00771329","BIIB023 (Anti-TWEAK) in Subjects With Rheumatoid Arthritis",[86],"2008-10",[32],[4577],{"nctId":4591,"briefTitle":4592,"status":104,"phases":4593,"primaryCompletion":1561,"completion":847,"start":1217,"enrollment":1027,"conditions":4594,"interventions":4595},"NCT01943513","A Study of the Effect of BIIB023 on Muscle Atrophy in Healthy Male Volunteers",[86],[18],[4577],{"trials":4597,"activeCount":98},[4598,4607],{"nctId":4599,"briefTitle":4600,"status":522,"phases":4601,"primaryCompletion":715,"completion":715,"start":1206,"enrollment":1801,"conditions":4602,"interventions":4604},"NCT01930890","BIIB023 Long-Term Extension Study in Subjects With Lupus Nephritis",[87],[4603],"Lupus Nephritis",[4577,4605,4606],"mycophenolate mofetil","oral corticosteroids",{"nctId":4608,"briefTitle":4609,"status":522,"phases":4610,"primaryCompletion":771,"completion":771,"start":2394,"enrollment":3873,"conditions":4611,"interventions":4612},"NCT01499355","BIIB023 Proof-of-Concept Study in Participants With Lupus Nephritis",[87],[4603],[4577,4605,4606],{"trials":4614,"activeCount":98},[],{"trials":4616,"activeCount":98},[],{"trials":4618,"activeCount":98},[],{"intervention":4620,"totalTrials":243,"cells":4621},"BIIB014",{"EARLY_PHASE1":4622,"PHASE1":4624,"PHASE2":4641,"PHASE3":4658,"PHASE4":4660,"NA":4662},{"trials":4623,"activeCount":98},[],{"trials":4625,"activeCount":98},[4626,4633],{"nctId":4627,"briefTitle":4628,"status":104,"phases":4629,"primaryCompletion":4630,"completion":4630,"start":2940,"enrollment":1016,"conditions":4631,"interventions":4632},"NCT01017666","BIIB014 Effects on the Pharmacokinetics (PK) of Rosiglitazone, Warfarin, and Midazolam",[86],"2010-06-02",[18],[4620],{"nctId":4634,"briefTitle":4635,"status":104,"phases":4636,"primaryCompletion":4637,"completion":4637,"start":4638,"enrollment":336,"conditions":4639,"interventions":4640},"NCT00531193","Using PET Scans to Study Brain Receptor Occupancy of BIIB014 in Healthy Male Volunteers",[86],"2008-04","2007-09",[18],[4620],{"trials":4642,"activeCount":98},[4643,4651],{"nctId":4644,"briefTitle":4645,"status":104,"phases":4646,"primaryCompletion":2418,"completion":2418,"start":4647,"enrollment":16,"conditions":4648,"interventions":4650},"NCT00438607","Dose-Finding Safety Study of BIIB014 in Combination With Levodopa in Moderate to Late Stage Parkinson's Disease",[87],"2007-04",[4649],"Parkinson's Disease",[4620],{"nctId":4652,"briefTitle":4653,"status":104,"phases":4654,"primaryCompletion":1676,"completion":1676,"start":4655,"enrollment":876,"conditions":4656,"interventions":4657},"NCT00442780","Dose-Finding Safety Study of BIIB014 in Early-Stage Parkinson's Disease",[87],"2007-08",[4649],[4620],{"trials":4659,"activeCount":98},[],{"trials":4661,"activeCount":98},[],{"trials":4663,"activeCount":98},[],{"intervention":4665,"totalTrials":243,"cells":4666},"BIIB104",{"EARLY_PHASE1":4667,"PHASE1":4669,"PHASE2":4696,"PHASE3":4708,"PHASE4":4710,"NA":4712},{"trials":4668,"activeCount":98},[],{"trials":4670,"activeCount":98},[4671,4680,4688],{"nctId":4672,"briefTitle":4673,"status":104,"phases":4674,"primaryCompletion":4675,"completion":4676,"start":3005,"enrollment":4677,"conditions":4678,"interventions":4679},"NCT05148481","A Study to Evaluate Safety and Pharmacokinetics of BIIB104 in Healthy Japanese and Non-Japanese Participants",[86],"2022-01-30","2022-02-12",31,[24],[4665],{"nctId":4681,"briefTitle":4682,"status":104,"phases":4683,"primaryCompletion":4684,"completion":4684,"start":4685,"enrollment":389,"conditions":4686,"interventions":4687},"NCT04068532","A Study to Explore Pharmacodynamic Effects of BIIB104 on Brain Circuitry in Healthy Participants",[86],"2020-11-11","2019-11-15",[30],[4665],{"nctId":4689,"briefTitle":4690,"status":104,"phases":4691,"primaryCompletion":4692,"completion":4692,"start":4693,"enrollment":4677,"conditions":4694,"interventions":4695},"NCT04079101","Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB104 in Healthy Japanese and Non-Japanese Participants",[86],"2019-12-27","2019-10-02",[30],[4665],{"trials":4697,"activeCount":98},[4698],{"nctId":4699,"briefTitle":4700,"status":104,"phases":4701,"primaryCompletion":4702,"completion":4703,"start":3870,"enrollment":4704,"conditions":4705,"interventions":4707},"NCT03745820","A Study to Evaluate the Safety and Efficacy of BIIB104 in Participants With Cognitive Impairment Associated With Schizophrenia (CIAS)",[87],"2022-03-23","2022-04-07",195,[4706],"Cognitive Impairment Associated With Schizophrenia",[4665],{"trials":4709,"activeCount":98},[],{"trials":4711,"activeCount":98},[],{"trials":4713,"activeCount":98},[],{"intervention":4715,"totalTrials":577,"cells":4716},"BG00010",{"EARLY_PHASE1":4717,"PHASE1":4719,"PHASE2":4734,"PHASE3":4747,"PHASE4":4749,"NA":4751},{"trials":4718,"activeCount":98},[],{"trials":4720,"activeCount":98},[4721,4728],{"nctId":4722,"briefTitle":4723,"status":104,"phases":4724,"primaryCompletion":4240,"completion":4240,"start":2419,"enrollment":637,"conditions":4725,"interventions":4727},"NCT01405833","Study of the Safety, Tolerability, Pharmacokinetics and Safety of BG00010 (Neublastin) in Subjects With Sciatica.",[86],[4726],"Sciatica",[4715],{"nctId":4729,"briefTitle":4730,"status":104,"phases":4731,"primaryCompletion":2437,"completion":2437,"start":2395,"enrollment":1754,"conditions":4732,"interventions":4733},"NCT00961766","Evaluate the Safety, Tolerability and Pharmacokinetics of BG00010 (Neublastin) Administered to Sciatica Participants",[86],[4726],[4715],{"trials":4735,"activeCount":98},[4736],{"nctId":4737,"briefTitle":4738,"status":104,"phases":4739,"primaryCompletion":4740,"completion":4740,"start":4741,"enrollment":4742,"conditions":4743,"interventions":4746},"NCT01873404","BG00010 (Neublastin) Phase 2 Multiple Dose Adaptive Design in Participants With Painful Lumbar Radiculopathy",[87],"2015-03","2013-06",183,[4744,4726,4745],"Painful Lumbar Radiculopathy","Radiculopathy",[4715],{"trials":4748,"activeCount":98},[],{"trials":4750,"activeCount":98},[],{"trials":4752,"activeCount":98},[],{"intervention":4754,"totalTrials":577,"cells":4755},"BG9924",{"EARLY_PHASE1":4756,"PHASE1":4758,"PHASE2":4760,"PHASE3":4782,"PHASE4":4784,"NA":4786},{"trials":4757,"activeCount":98},[],{"trials":4759,"activeCount":98},[],{"trials":4761,"activeCount":98},[4762,4768,4775],{"nctId":4763,"briefTitle":4764,"status":522,"phases":4765,"primaryCompletion":4587,"completion":4587,"start":4655,"enrollment":4347,"conditions":4766,"interventions":4767},"NCT00523328","BG9924 in Combination With Methotrexate Extension of Study 104RA203 (NCT 00458861)",[87],[32],[4754],{"nctId":4769,"briefTitle":4770,"status":522,"phases":4771,"primaryCompletion":4587,"completion":4587,"start":4772,"enrollment":1096,"conditions":4773,"interventions":4774},"NCT00458861","BG9924 in Combination With Methotrexate for Participants With Active Rheumatoid Arthritis",[87],"2007-03",[32],[4754],{"nctId":4776,"briefTitle":4777,"status":104,"phases":4778,"primaryCompletion":2547,"completion":2547,"start":4779,"enrollment":2100,"conditions":4780,"interventions":4781},"NCT00292422","Dose-Escalating Study of BG9924 in Combination With Methotrexate in Active Rheumatoid Arthritis",[87],"2005-11",[32],[4754],{"trials":4783,"activeCount":98},[],{"trials":4785,"activeCount":98},[],{"trials":4787,"activeCount":98},[],{"intervention":4789,"totalTrials":577,"cells":4790},"BIIB021",{"EARLY_PHASE1":4791,"PHASE1":4793,"PHASE2":4803,"PHASE3":4820,"PHASE4":4822,"NA":4824},{"trials":4792,"activeCount":98},[],{"trials":4794,"activeCount":98},[4795],{"nctId":4796,"briefTitle":4797,"status":104,"phases":4798,"primaryCompletion":4799,"completion":3605,"start":2363,"enrollment":4800,"conditions":4801,"interventions":4802},"NCT00618735","Once or Twice Daily Administration of BIIB021 to Subjects With Advanced Solid Tumors",[86],"2010-07",68,[2927],[4789,4789],{"trials":4804,"activeCount":98},[4805,4813],{"nctId":4806,"briefTitle":4807,"status":104,"phases":4808,"primaryCompletion":1963,"completion":1963,"start":2376,"enrollment":2421,"conditions":4809,"interventions":4811},"NCT01004081","Hormone Receptor Positive Metastatic Breast Cancer (HR+ mBC) BIIB021 Plus Aromasin Schedule Finding",[87],[4810],"Breast Cancer",[4789,4789,4812],"exemestane",{"nctId":4814,"briefTitle":4815,"status":104,"phases":4816,"primaryCompletion":1982,"completion":1982,"start":2363,"enrollment":325,"conditions":4817,"interventions":4819},"NCT00618319","An Open-Label, 18FDG-PET Pharmacodynamic Assessment of the Effect of BIIB021 in Subjects With Gastrointestinal Stromal Tumors (GIST)",[87],[4818],"GIST",[4789],{"trials":4821,"activeCount":98},[],{"trials":4823,"activeCount":98},[],{"trials":4825,"activeCount":98},[],{"intervention":4827,"totalTrials":577,"cells":4828},"BIIB054",{"EARLY_PHASE1":4829,"PHASE1":4831,"PHASE2":4848,"PHASE3":4859,"PHASE4":4861,"NA":4863},{"trials":4830,"activeCount":98},[],{"trials":4832,"activeCount":98},[4833,4840],{"nctId":4834,"briefTitle":4835,"status":104,"phases":4836,"primaryCompletion":1517,"completion":1517,"start":4837,"enrollment":3710,"conditions":4838,"interventions":4839},"NCT02459886","Single-Ascending Dose Study of BIIB054 in Healthy Participants and Early Parkinson's Disease",[86],"2015-07-01",[4649,18],[4827],{"nctId":4841,"briefTitle":4842,"status":522,"phases":4843,"primaryCompletion":4844,"completion":4844,"start":4845,"enrollment":947,"conditions":4846,"interventions":4847},"NCT03716570","A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Japanese Participants With Parkinson's Disease",[86],"2021-04-23","2019-03-12",[4649],[4827],{"trials":4849,"activeCount":98},[4850],{"nctId":4851,"briefTitle":4852,"status":522,"phases":4853,"primaryCompletion":1900,"completion":4854,"start":4855,"enrollment":4856,"conditions":4857,"interventions":4858},"NCT03318523","Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Participants With Parkinson's Disease",[87],"2021-04-29","2018-01-10",357,[4649],[4827],{"trials":4860,"activeCount":98},[],{"trials":4862,"activeCount":98},[],{"trials":4864,"activeCount":98},[],{"intervention":4866,"totalTrials":470,"cells":4867},"Omaveloxolone Capsules, 2.5 mg",{"EARLY_PHASE1":4868,"PHASE1":4870,"PHASE2":4872,"PHASE3":4908,"PHASE4":4910,"NA":4912},{"trials":4869,"activeCount":98},[],{"trials":4871,"activeCount":98},[],{"trials":4873,"activeCount":98},[4874,4891],{"nctId":4875,"briefTitle":4876,"status":104,"phases":4877,"primaryCompletion":4878,"completion":4879,"start":1025,"enrollment":4880,"conditions":4881,"interventions":4882},"NCT02255435","A Study to Learn About the Effects and Safety of RTA 408 (Omaveloxolone) in People Aged 16 to 40 With Friedreich's Ataxia",[87],"2019-10-31","2025-12-19",172,[354],[4866,4883,4884,4885,4886,4887,4888,4889,4890],"Omaveloxolone Capsules, 5 mg","Omaveloxolone Capsules, 10 mg","Omaveloxolone Capsules, 20 mg","Omaveloxolone Capsules, 40 mg","Omaveloxolone Capsules, 80 mg","Omaveloxolone Capsules, 160 mg","Omaveloxolone Capsules, 300 mg","Omaveloxolone Capsules, 150 mg",{"nctId":4892,"briefTitle":4893,"status":104,"phases":4894,"primaryCompletion":4895,"completion":4896,"start":4897,"enrollment":3317,"conditions":4898,"interventions":4900},"NCT02255422","RTA 408 Capsules in Patients With Mitochondrial Myopathy - MOTOR",[87],"2017-11-02","2017-11-30","2015-05-05",[4899],"MItochondrial Myopathies",[4901,4902,4903,4904,4905,4906,4907],"Omaveloxolone capsules, 2.5 mg","omaveloxolone capsules, 5 mg","omaveloxolone capsules, 10 mg","omaveloxolone capsules, 20 mg","omaveloxolone capsules, 40 mg","omaveloxolone capsules, 80 mg","omaveloxolone capsules, 160 mg",{"trials":4909,"activeCount":98},[],{"trials":4911,"activeCount":98},[],{"trials":4913,"activeCount":98},[],{"intervention":4883,"totalTrials":470,"cells":4915},{"EARLY_PHASE1":4916,"PHASE1":4918,"PHASE2":4920,"PHASE3":4930,"PHASE4":4932,"NA":4934},{"trials":4917,"activeCount":98},[],{"trials":4919,"activeCount":98},[],{"trials":4921,"activeCount":98},[4922,4926],{"nctId":4875,"briefTitle":4876,"status":104,"phases":4923,"primaryCompletion":4878,"completion":4879,"start":1025,"enrollment":4880,"conditions":4924,"interventions":4925},[87],[354],[4866,4883,4884,4885,4886,4887,4888,4889,4890],{"nctId":4892,"briefTitle":4893,"status":104,"phases":4927,"primaryCompletion":4895,"completion":4896,"start":4897,"enrollment":3317,"conditions":4928,"interventions":4929},[87],[4899],[4901,4902,4903,4904,4905,4906,4907],{"trials":4931,"activeCount":98},[],{"trials":4933,"activeCount":98},[],{"trials":4935,"activeCount":98},[],{"intervention":4884,"totalTrials":470,"cells":4937},{"EARLY_PHASE1":4938,"PHASE1":4940,"PHASE2":4942,"PHASE3":4952,"PHASE4":4954,"NA":4956},{"trials":4939,"activeCount":98},[],{"trials":4941,"activeCount":98},[],{"trials":4943,"activeCount":98},[4944,4948],{"nctId":4875,"briefTitle":4876,"status":104,"phases":4945,"primaryCompletion":4878,"completion":4879,"start":1025,"enrollment":4880,"conditions":4946,"interventions":4947},[87],[354],[4866,4883,4884,4885,4886,4887,4888,4889,4890],{"nctId":4892,"briefTitle":4893,"status":104,"phases":4949,"primaryCompletion":4895,"completion":4896,"start":4897,"enrollment":3317,"conditions":4950,"interventions":4951},[87],[4899],[4901,4902,4903,4904,4905,4906,4907],{"trials":4953,"activeCount":98},[],{"trials":4955,"activeCount":98},[],{"trials":4957,"activeCount":98},[],{"intervention":4885,"totalTrials":470,"cells":4959},{"EARLY_PHASE1":4960,"PHASE1":4962,"PHASE2":4964,"PHASE3":4974,"PHASE4":4976,"NA":4978},{"trials":4961,"activeCount":98},[],{"trials":4963,"activeCount":98},[],{"trials":4965,"activeCount":98},[4966,4970],{"nctId":4875,"briefTitle":4876,"status":104,"phases":4967,"primaryCompletion":4878,"completion":4879,"start":1025,"enrollment":4880,"conditions":4968,"interventions":4969},[87],[354],[4866,4883,4884,4885,4886,4887,4888,4889,4890],{"nctId":4892,"briefTitle":4893,"status":104,"phases":4971,"primaryCompletion":4895,"completion":4896,"start":4897,"enrollment":3317,"conditions":4972,"interventions":4973},[87],[4899],[4901,4902,4903,4904,4905,4906,4907],{"trials":4975,"activeCount":98},[],{"trials":4977,"activeCount":98},[],{"trials":4979,"activeCount":98},[],{"intervention":4886,"totalTrials":470,"cells":4981},{"EARLY_PHASE1":4982,"PHASE1":4984,"PHASE2":4986,"PHASE3":4996,"PHASE4":4998,"NA":5000},{"trials":4983,"activeCount":98},[],{"trials":4985,"activeCount":98},[],{"trials":4987,"activeCount":98},[4988,4992],{"nctId":4875,"briefTitle":4876,"status":104,"phases":4989,"primaryCompletion":4878,"completion":4879,"start":1025,"enrollment":4880,"conditions":4990,"interventions":4991},[87],[354],[4866,4883,4884,4885,4886,4887,4888,4889,4890],{"nctId":4892,"briefTitle":4893,"status":104,"phases":4993,"primaryCompletion":4895,"completion":4896,"start":4897,"enrollment":3317,"conditions":4994,"interventions":4995},[87],[4899],[4901,4902,4903,4904,4905,4906,4907],{"trials":4997,"activeCount":98},[],{"trials":4999,"activeCount":98},[],{"trials":5001,"activeCount":98},[],{"intervention":4887,"totalTrials":470,"cells":5003},{"EARLY_PHASE1":5004,"PHASE1":5006,"PHASE2":5008,"PHASE3":5018,"PHASE4":5020,"NA":5022},{"trials":5005,"activeCount":98},[],{"trials":5007,"activeCount":98},[],{"trials":5009,"activeCount":98},[5010,5014],{"nctId":4875,"briefTitle":4876,"status":104,"phases":5011,"primaryCompletion":4878,"completion":4879,"start":1025,"enrollment":4880,"conditions":5012,"interventions":5013},[87],[354],[4866,4883,4884,4885,4886,4887,4888,4889,4890],{"nctId":4892,"briefTitle":4893,"status":104,"phases":5015,"primaryCompletion":4895,"completion":4896,"start":4897,"enrollment":3317,"conditions":5016,"interventions":5017},[87],[4899],[4901,4902,4903,4904,4905,4906,4907],{"trials":5019,"activeCount":98},[],{"trials":5021,"activeCount":98},[],{"trials":5023,"activeCount":98},[],{"intervention":4888,"totalTrials":470,"cells":5025},{"EARLY_PHASE1":5026,"PHASE1":5028,"PHASE2":5030,"PHASE3":5040,"PHASE4":5042,"NA":5044},{"trials":5027,"activeCount":98},[],{"trials":5029,"activeCount":98},[],{"trials":5031,"activeCount":98},[5032,5036],{"nctId":4875,"briefTitle":4876,"status":104,"phases":5033,"primaryCompletion":4878,"completion":4879,"start":1025,"enrollment":4880,"conditions":5034,"interventions":5035},[87],[354],[4866,4883,4884,4885,4886,4887,4888,4889,4890],{"nctId":4892,"briefTitle":4893,"status":104,"phases":5037,"primaryCompletion":4895,"completion":4896,"start":4897,"enrollment":3317,"conditions":5038,"interventions":5039},[87],[4899],[4901,4902,4903,4904,4905,4906,4907],{"trials":5041,"activeCount":98},[],{"trials":5043,"activeCount":98},[],{"trials":5045,"activeCount":98},[],{"intervention":5047,"totalTrials":470,"cells":5048},"RTA 402",{"EARLY_PHASE1":5049,"PHASE1":5051,"PHASE2":5053,"PHASE3":5072,"PHASE4":5074,"NA":5076},{"trials":5050,"activeCount":98},[],{"trials":5052,"activeCount":98},[],{"trials":5054,"activeCount":98},[5055,5063],{"nctId":5056,"briefTitle":5057,"status":104,"phases":5058,"primaryCompletion":5059,"completion":5059,"start":5060,"enrollment":1902,"conditions":5061,"interventions":5062},"NCT00664027","Phase IIa Trial to Determine the Effects of Bardoxolone Methyl on Renal Function in Patients With Diabetic Nephropathy",[87],"2009-05-31","2008-04-30",[2976],[5047],{"nctId":5064,"briefTitle":5065,"status":522,"phases":5066,"primaryCompletion":5067,"completion":5067,"start":5068,"enrollment":978,"conditions":5069,"interventions":5071},"NCT00550849","Study to Assess the Safety, Tolerability, and Pharmacodynamics of RTA 402 in Patients With Hepatic Dysfunction",[86,87],"2007-11-30","2007-04-30",[5070],"Liver Disease",[5047,5047,5047],{"trials":5073,"activeCount":98},[],{"trials":5075,"activeCount":98},[],{"trials":5077,"activeCount":98},[],{"intervention":5079,"totalTrials":470,"cells":5080},"BG00011",{"EARLY_PHASE1":5081,"PHASE1":5083,"PHASE2":5085,"PHASE3":5103,"PHASE4":5105,"NA":5107},{"trials":5082,"activeCount":98},[],{"trials":5084,"activeCount":98},[],{"trials":5086,"activeCount":98},[5087,5096],{"nctId":5088,"briefTitle":5089,"status":104,"phases":5090,"primaryCompletion":5091,"completion":5091,"start":5092,"enrollment":422,"conditions":5093,"interventions":5095},"NCT01371305","STX-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)",[87],"2017-03-31","2012-07-16",[5094],"Idiopathic Pulmonary Fibrosis (IPF)",[5079],{"nctId":5097,"briefTitle":5098,"status":522,"phases":5099,"primaryCompletion":5100,"completion":5100,"start":725,"enrollment":1248,"conditions":5101,"interventions":5102},"NCT03573505","An Efficacy and Safety Study of BG00011 in Participants With Idiopathic Pulmonary Fibrosis",[87],"2019-11-14",[2991],[5079],{"trials":5104,"activeCount":98},[],{"trials":5106,"activeCount":98},[],{"trials":5108,"activeCount":98},[],{"intervention":4605,"totalTrials":470,"cells":5110},{"EARLY_PHASE1":5111,"PHASE1":5113,"PHASE2":5115,"PHASE3":5125,"PHASE4":5127,"NA":5129},{"trials":5112,"activeCount":98},[],{"trials":5114,"activeCount":98},[],{"trials":5116,"activeCount":98},[5117,5121],{"nctId":4599,"briefTitle":4600,"status":522,"phases":5118,"primaryCompletion":715,"completion":715,"start":1206,"enrollment":1801,"conditions":5119,"interventions":5120},[87],[4603],[4577,4605,4606],{"nctId":4608,"briefTitle":4609,"status":522,"phases":5122,"primaryCompletion":771,"completion":771,"start":2394,"enrollment":3873,"conditions":5123,"interventions":5124},[87],[4603],[4577,4605,4606],{"trials":5126,"activeCount":98},[],{"trials":5128,"activeCount":98},[],{"trials":5130,"activeCount":98},[],{"intervention":4606,"totalTrials":470,"cells":5132},{"EARLY_PHASE1":5133,"PHASE1":5135,"PHASE2":5137,"PHASE3":5147,"PHASE4":5149,"NA":5151},{"trials":5134,"activeCount":98},[],{"trials":5136,"activeCount":98},[],{"trials":5138,"activeCount":98},[5139,5143],{"nctId":4599,"briefTitle":4600,"status":522,"phases":5140,"primaryCompletion":715,"completion":715,"start":1206,"enrollment":1801,"conditions":5141,"interventions":5142},[87],[4603],[4577,4605,4606],{"nctId":4608,"briefTitle":4609,"status":522,"phases":5144,"primaryCompletion":771,"completion":771,"start":2394,"enrollment":3873,"conditions":5145,"interventions":5146},[87],[4603],[4577,4605,4606],{"trials":5148,"activeCount":98},[],{"trials":5150,"activeCount":98},[],{"trials":5152,"activeCount":98},[],{"intervention":5154,"totalTrials":470,"cells":5155},"IDEC-114",{"EARLY_PHASE1":5156,"PHASE1":5158,"PHASE2":5160,"PHASE3":5176,"PHASE4":5178,"NA":5180},{"trials":5157,"activeCount":98},[],{"trials":5159,"activeCount":98},[],{"trials":5161,"activeCount":98},[5162,5169],{"nctId":5163,"briefTitle":5164,"status":104,"phases":5165,"primaryCompletion":5166,"completion":1580,"start":1634,"enrollment":616,"conditions":5167,"interventions":5168},"NCT00575068","Safety and Efficacy of IDEC-114 in the Treatment of Non-Hodgkin's Lymphoma",[86,87],"2002-09",[2522],[5154],{"nctId":5170,"briefTitle":5171,"status":104,"phases":5172,"primaryCompletion":1545,"completion":1580,"start":5173,"enrollment":606,"conditions":5174,"interventions":5175},"NCT00048555","Safety and Efficacy of IDEC-114 in Combination With Rituxan in the Treatment of Non-Hodgkin's Lymphoma",[86,87],"2002-11",[2522],[5154],{"trials":5177,"activeCount":98},[],{"trials":5179,"activeCount":98},[],{"trials":5181,"activeCount":98},[],{"intervention":5183,"totalTrials":470,"cells":5184},"FCR",{"EARLY_PHASE1":5185,"PHASE1":5187,"PHASE2":5189,"PHASE3":5208,"PHASE4":5210,"NA":5212},{"trials":5186,"activeCount":98},[],{"trials":5188,"activeCount":98},[],{"trials":5190,"activeCount":98},[5191,5199],{"nctId":5192,"briefTitle":5193,"status":522,"phases":5194,"primaryCompletion":673,"completion":2438,"start":2363,"enrollment":22,"conditions":5195,"interventions":5197},"NCT00801060","Evaluation of Safety and Efficacy of Fludarabine, Cyclophosphamide, and Rituximab (FCR) +\u002F- Lumiliximab in Subjects With Previously Untreated Chronic Lymphocytic Leukemia (CLL)",[87],[5196],"Chronic Lymphocytic Leukemia",[5198,5183],"Lumiliximab + FCR",{"nctId":5200,"briefTitle":5201,"status":522,"phases":5202,"primaryCompletion":4799,"completion":3605,"start":5203,"enrollment":5204,"conditions":5205,"interventions":5206},"NCT00391066","Lumiliximab With Fludarabine, Cyclophosphamide, and Rituximab (FCR) Versus FCR Alone in Subjects With Relapsed Chronic Lymphocytic Leukemia (CLL)",[87],"2006-11",627,[5196],[5207,5183],"FCR + Lumiliximab",{"trials":5209,"activeCount":98},[],{"trials":5211,"activeCount":98},[],{"trials":5213,"activeCount":98},[],{"intervention":3228,"totalTrials":149,"cells":5215},{"EARLY_PHASE1":5216,"PHASE1":5218,"PHASE2":5220,"PHASE3":5226,"PHASE4":5228,"NA":5230},{"trials":5217,"activeCount":98},[],{"trials":5219,"activeCount":98},[],{"trials":5221,"activeCount":98},[5222],{"nctId":3219,"briefTitle":3220,"status":104,"phases":5223,"primaryCompletion":3222,"completion":3222,"start":3223,"enrollment":3224,"conditions":5224,"interventions":5225},[87],[3226],[3210,3228,3229],{"trials":5227,"activeCount":98},[],{"trials":5229,"activeCount":98},[],{"trials":5231,"activeCount":98},[],{"intervention":3229,"totalTrials":149,"cells":5233},{"EARLY_PHASE1":5234,"PHASE1":5236,"PHASE2":5238,"PHASE3":5244,"PHASE4":5246,"NA":5248},{"trials":5235,"activeCount":98},[],{"trials":5237,"activeCount":98},[],{"trials":5239,"activeCount":98},[5240],{"nctId":3219,"briefTitle":3220,"status":104,"phases":5241,"primaryCompletion":3222,"completion":3222,"start":3223,"enrollment":3224,"conditions":5242,"interventions":5243},[87],[3226],[3210,3228,3229],{"trials":5245,"activeCount":98},[],{"trials":5247,"activeCount":98},[],{"trials":5249,"activeCount":98},[],{"intervention":4889,"totalTrials":149,"cells":5251},{"EARLY_PHASE1":5252,"PHASE1":5254,"PHASE2":5256,"PHASE3":5262,"PHASE4":5264,"NA":5266},{"trials":5253,"activeCount":98},[],{"trials":5255,"activeCount":98},[],{"trials":5257,"activeCount":98},[5258],{"nctId":4875,"briefTitle":4876,"status":104,"phases":5259,"primaryCompletion":4878,"completion":4879,"start":1025,"enrollment":4880,"conditions":5260,"interventions":5261},[87],[354],[4866,4883,4884,4885,4886,4887,4888,4889,4890],{"trials":5263,"activeCount":98},[],{"trials":5265,"activeCount":98},[],{"trials":5267,"activeCount":98},[],{"intervention":4890,"totalTrials":149,"cells":5269},{"EARLY_PHASE1":5270,"PHASE1":5272,"PHASE2":5274,"PHASE3":5280,"PHASE4":5282,"NA":5284},{"trials":5271,"activeCount":98},[],{"trials":5273,"activeCount":98},[],{"trials":5275,"activeCount":98},[5276],{"nctId":4875,"briefTitle":4876,"status":104,"phases":5277,"primaryCompletion":4878,"completion":4879,"start":1025,"enrollment":4880,"conditions":5278,"interventions":5279},[87],[354],[4866,4883,4884,4885,4886,4887,4888,4889,4890],{"trials":5281,"activeCount":98},[],{"trials":5283,"activeCount":98},[],{"trials":5285,"activeCount":98},[],{"intervention":5287,"totalTrials":149,"cells":5288},"Baminercept alfa 1",{"EARLY_PHASE1":5289,"PHASE1":5291,"PHASE2":5293,"PHASE3":5307,"PHASE4":5309,"NA":5311},{"trials":5290,"activeCount":98},[],{"trials":5292,"activeCount":98},[],{"trials":5294,"activeCount":98},[5295],{"nctId":5296,"briefTitle":5297,"status":104,"phases":5298,"primaryCompletion":4587,"completion":4587,"start":5299,"enrollment":5300,"conditions":5301,"interventions":5302},"NCT00664716","Assessment Of The Safety And Efficacy Of BG9924 In Rheumatoid Arthritis (RA) Participants",[87],"2007-07",391,[32],[5287,5303,5304,5305,5306],"Baminercept alfa 2","Baminercept alfa 3","Baminercept alfa 4","Baminercept alfa 5",{"trials":5308,"activeCount":98},[],{"trials":5310,"activeCount":98},[],{"trials":5312,"activeCount":98},[],{"intervention":5303,"totalTrials":149,"cells":5314},{"EARLY_PHASE1":5315,"PHASE1":5317,"PHASE2":5319,"PHASE3":5325,"PHASE4":5327,"NA":5329},{"trials":5316,"activeCount":98},[],{"trials":5318,"activeCount":98},[],{"trials":5320,"activeCount":98},[5321],{"nctId":5296,"briefTitle":5297,"status":104,"phases":5322,"primaryCompletion":4587,"completion":4587,"start":5299,"enrollment":5300,"conditions":5323,"interventions":5324},[87],[32],[5287,5303,5304,5305,5306],{"trials":5326,"activeCount":98},[],{"trials":5328,"activeCount":98},[],{"trials":5330,"activeCount":98},[],{"intervention":5304,"totalTrials":149,"cells":5332},{"EARLY_PHASE1":5333,"PHASE1":5335,"PHASE2":5337,"PHASE3":5343,"PHASE4":5345,"NA":5347},{"trials":5334,"activeCount":98},[],{"trials":5336,"activeCount":98},[],{"trials":5338,"activeCount":98},[5339],{"nctId":5296,"briefTitle":5297,"status":104,"phases":5340,"primaryCompletion":4587,"completion":4587,"start":5299,"enrollment":5300,"conditions":5341,"interventions":5342},[87],[32],[5287,5303,5304,5305,5306],{"trials":5344,"activeCount":98},[],{"trials":5346,"activeCount":98},[],{"trials":5348,"activeCount":98},[],{"intervention":5305,"totalTrials":149,"cells":5350},{"EARLY_PHASE1":5351,"PHASE1":5353,"PHASE2":5355,"PHASE3":5361,"PHASE4":5363,"NA":5365},{"trials":5352,"activeCount":98},[],{"trials":5354,"activeCount":98},[],{"trials":5356,"activeCount":98},[5357],{"nctId":5296,"briefTitle":5297,"status":104,"phases":5358,"primaryCompletion":4587,"completion":4587,"start":5299,"enrollment":5300,"conditions":5359,"interventions":5360},[87],[32],[5287,5303,5304,5305,5306],{"trials":5362,"activeCount":98},[],{"trials":5364,"activeCount":98},[],{"trials":5366,"activeCount":98},[],{"intervention":5306,"totalTrials":149,"cells":5368},{"EARLY_PHASE1":5369,"PHASE1":5371,"PHASE2":5373,"PHASE3":5379,"PHASE4":5381,"NA":5383},{"trials":5370,"activeCount":98},[],{"trials":5372,"activeCount":98},[],{"trials":5374,"activeCount":98},[5375],{"nctId":5296,"briefTitle":5297,"status":104,"phases":5376,"primaryCompletion":4587,"completion":4587,"start":5299,"enrollment":5300,"conditions":5377,"interventions":5378},[87],[32],[5287,5303,5304,5305,5306],{"trials":5380,"activeCount":98},[],{"trials":5382,"activeCount":98},[],{"trials":5384,"activeCount":98},[],{"intervention":5386,"totalTrials":149,"cells":5387},"Unconjugated IDEC-159",{"EARLY_PHASE1":5388,"PHASE1":5390,"PHASE2":5392,"PHASE3":5404,"PHASE4":5406,"NA":5408},{"trials":5389,"activeCount":98},[],{"trials":5391,"activeCount":98},[],{"trials":5393,"activeCount":98},[5394],{"nctId":5395,"briefTitle":5396,"status":522,"phases":5397,"primaryCompletion":1661,"completion":1661,"start":1605,"enrollment":389,"conditions":5398,"interventions":5401},"NCT00102024","Safety and Activity of 90Y-Labeled IDEC-159 in Subjects With Metastatic Colorectal Adenocarcinoma",[86,87],[5399,5400],"Colorectal Cancer","Metastases",[5386,5402,5403],"111In-IDEC-159","90Y-IDEC-159",{"trials":5405,"activeCount":98},[],{"trials":5407,"activeCount":98},[],{"trials":5409,"activeCount":98},[],{"intervention":5402,"totalTrials":149,"cells":5411},{"EARLY_PHASE1":5412,"PHASE1":5414,"PHASE2":5416,"PHASE3":5422,"PHASE4":5424,"NA":5426},{"trials":5413,"activeCount":98},[],{"trials":5415,"activeCount":98},[],{"trials":5417,"activeCount":98},[5418],{"nctId":5395,"briefTitle":5396,"status":522,"phases":5419,"primaryCompletion":1661,"completion":1661,"start":1605,"enrollment":389,"conditions":5420,"interventions":5421},[86,87],[5399,5400],[5386,5402,5403],{"trials":5423,"activeCount":98},[],{"trials":5425,"activeCount":98},[],{"trials":5427,"activeCount":98},[],{"intervention":5403,"totalTrials":149,"cells":5429},{"EARLY_PHASE1":5430,"PHASE1":5432,"PHASE2":5434,"PHASE3":5440,"PHASE4":5442,"NA":5444},{"trials":5431,"activeCount":98},[],{"trials":5433,"activeCount":98},[],{"trials":5435,"activeCount":98},[5436],{"nctId":5395,"briefTitle":5396,"status":522,"phases":5437,"primaryCompletion":1661,"completion":1661,"start":1605,"enrollment":389,"conditions":5438,"interventions":5439},[86,87],[5399,5400],[5386,5402,5403],{"trials":5441,"activeCount":98},[],{"trials":5443,"activeCount":98},[],{"trials":5445,"activeCount":98},[],{"intervention":5447,"totalTrials":149,"cells":5448},"BIIB112",{"EARLY_PHASE1":5449,"PHASE1":5451,"PHASE2":5453,"PHASE3":5462,"PHASE4":5464,"NA":5466},{"trials":5450,"activeCount":98},[],{"trials":5452,"activeCount":98},[],{"trials":5454,"activeCount":98},[5455],{"nctId":5456,"briefTitle":5457,"status":104,"phases":5458,"primaryCompletion":1491,"completion":1491,"start":144,"enrollment":2100,"conditions":5459,"interventions":5461},"NCT03116113","A Clinical Trial of Retinal Gene Therapy for X-linked Retinitis Pigmentosa Using BIIB112",[86,87],[5460],"X-Linked Retinitis Pigmentosa",[5447],{"trials":5463,"activeCount":98},[],{"trials":5465,"activeCount":98},[],{"trials":5467,"activeCount":98},[],{"intervention":5469,"totalTrials":149,"cells":5470},"Omaveloxolone Lotion 0.5%",{"EARLY_PHASE1":5471,"PHASE1":5473,"PHASE2":5475,"PHASE3":5485,"PHASE4":5487,"NA":5489},{"trials":5472,"activeCount":98},[],{"trials":5474,"activeCount":98},[],{"trials":5476,"activeCount":98},[5477],{"nctId":5478,"briefTitle":5479,"status":104,"phases":5480,"primaryCompletion":4500,"completion":4500,"start":4527,"enrollment":3079,"conditions":5481,"interventions":5482},"NCT02142959","RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE",[87],[4810],[5469,5483,5484],"Omaveloxolone Lotion 3%","Vehicle Lotion",{"trials":5486,"activeCount":98},[],{"trials":5488,"activeCount":98},[],{"trials":5490,"activeCount":98},[],{"intervention":5483,"totalTrials":149,"cells":5492},{"EARLY_PHASE1":5493,"PHASE1":5495,"PHASE2":5497,"PHASE3":5503,"PHASE4":5505,"NA":5507},{"trials":5494,"activeCount":98},[],{"trials":5496,"activeCount":98},[],{"trials":5498,"activeCount":98},[5499],{"nctId":5478,"briefTitle":5479,"status":104,"phases":5500,"primaryCompletion":4500,"completion":4500,"start":4527,"enrollment":3079,"conditions":5501,"interventions":5502},[87],[4810],[5469,5483,5484],{"trials":5504,"activeCount":98},[],{"trials":5506,"activeCount":98},[],{"trials":5508,"activeCount":98},[],{"intervention":5484,"totalTrials":149,"cells":5510},{"EARLY_PHASE1":5511,"PHASE1":5513,"PHASE2":5515,"PHASE3":5521,"PHASE4":5523,"NA":5525},{"trials":5512,"activeCount":98},[],{"trials":5514,"activeCount":98},[],{"trials":5516,"activeCount":98},[5517],{"nctId":5478,"briefTitle":5479,"status":104,"phases":5518,"primaryCompletion":4500,"completion":4500,"start":4527,"enrollment":3079,"conditions":5519,"interventions":5520},[87],[4810],[5469,5483,5484],{"trials":5522,"activeCount":98},[],{"trials":5524,"activeCount":98},[],{"trials":5526,"activeCount":98},[],{"intervention":4812,"totalTrials":149,"cells":5528},{"EARLY_PHASE1":5529,"PHASE1":5531,"PHASE2":5533,"PHASE3":5539,"PHASE4":5541,"NA":5543},{"trials":5530,"activeCount":98},[],{"trials":5532,"activeCount":98},[],{"trials":5534,"activeCount":98},[5535],{"nctId":4806,"briefTitle":4807,"status":104,"phases":5536,"primaryCompletion":1963,"completion":1963,"start":2376,"enrollment":2421,"conditions":5537,"interventions":5538},[87],[4810],[4789,4789,4812],{"trials":5540,"activeCount":98},[],{"trials":5542,"activeCount":98},[],{"trials":5544,"activeCount":98},[],{"intervention":5546,"totalTrials":149,"cells":5547},"Omaveloxolone Ophthalmic Suspension 1.0%",{"EARLY_PHASE1":5548,"PHASE1":5550,"PHASE2":5552,"PHASE3":5562,"PHASE4":5564,"NA":5566},{"trials":5549,"activeCount":98},[],{"trials":5551,"activeCount":98},[],{"trials":5553,"activeCount":98},[5554],{"nctId":5555,"briefTitle":5556,"status":104,"phases":5557,"primaryCompletion":1692,"completion":1692,"start":998,"enrollment":1248,"conditions":5558,"interventions":5560},"NCT02065375","RTA 408 Ophthalmic Suspension for the Treatment of Ocular Inflammation and Pain Following Ocular Surgery",[87],[5559],"Inflammation and Pain Following Ocular Surgery",[5546,5561],"Omaveloxolone Opthalmic Suspension 0.5%",{"trials":5563,"activeCount":98},[],{"trials":5565,"activeCount":98},[],{"trials":5567,"activeCount":98},[],{"intervention":5561,"totalTrials":149,"cells":5569},{"EARLY_PHASE1":5570,"PHASE1":5572,"PHASE2":5574,"PHASE3":5580,"PHASE4":5582,"NA":5584},{"trials":5571,"activeCount":98},[],{"trials":5573,"activeCount":98},[],{"trials":5575,"activeCount":98},[5576],{"nctId":5555,"briefTitle":5556,"status":104,"phases":5577,"primaryCompletion":1692,"completion":1692,"start":998,"enrollment":1248,"conditions":5578,"interventions":5579},[87],[5559],[5546,5561],{"trials":5581,"activeCount":98},[],{"trials":5583,"activeCount":98},[],{"trials":5585,"activeCount":98},[],{"intervention":5587,"totalTrials":149,"cells":5588},"Baminercept alfa",{"EARLY_PHASE1":5589,"PHASE1":5591,"PHASE2":5593,"PHASE3":5602,"PHASE4":5604,"NA":5606},{"trials":5590,"activeCount":98},[],{"trials":5592,"activeCount":98},[],{"trials":5594,"activeCount":98},[5595],{"nctId":5596,"briefTitle":5597,"status":522,"phases":5598,"primaryCompletion":4587,"completion":4587,"start":2519,"enrollment":5599,"conditions":5600,"interventions":5601},"NCT00664573","104RA204 Assessment of the Safety and Efficacy of BG9924 in Rheumatoid Arthritis (RA) Participants",[87],339,[32],[5587],{"trials":5603,"activeCount":98},[],{"trials":5605,"activeCount":98},[],{"trials":5607,"activeCount":98},[],{"intervention":5609,"totalTrials":149,"cells":5610},"berubicin hydrochloride",{"EARLY_PHASE1":5611,"PHASE1":5613,"PHASE2":5615,"PHASE3":5626,"PHASE4":5628,"NA":5630},{"trials":5612,"activeCount":98},[],{"trials":5614,"activeCount":98},[],{"trials":5616,"activeCount":98},[5617],{"nctId":5618,"briefTitle":5619,"status":522,"phases":5620,"primaryCompletion":2924,"completion":5621,"start":5622,"enrollment":2272,"conditions":5623,"interventions":5625},"NCT00538343","RTA 744 in Breast Cancer Patients With Progression of Previously Irradiated Brain Metastases",[87],"2009-01-01","2007-10-31",[5624],"Brain Metastases",[5609],{"trials":5627,"activeCount":98},[],{"trials":5629,"activeCount":98},[],{"trials":5631,"activeCount":98},[],{"intervention":1538,"totalTrials":149,"cells":5633},{"EARLY_PHASE1":5634,"PHASE1":5636,"PHASE2":5638,"PHASE3":5644,"PHASE4":5646,"NA":5648},{"trials":5635,"activeCount":98},[],{"trials":5637,"activeCount":98},[],{"trials":5639,"activeCount":98},[5640],{"nctId":1532,"briefTitle":1533,"status":104,"phases":5641,"primaryCompletion":1461,"completion":1461,"start":1535,"enrollment":654,"conditions":5642,"interventions":5643},[87],[699],[959,1538,1539,1540],{"trials":5645,"activeCount":98},[],{"trials":5647,"activeCount":98},[],{"trials":5649,"activeCount":98},[],{"intervention":5651,"totalTrials":149,"cells":5652},"Ad.hIFN-β",{"EARLY_PHASE1":5653,"PHASE1":5655,"PHASE2":5657,"PHASE3":5667,"PHASE4":5669,"NA":5671},{"trials":5654,"activeCount":98},[],{"trials":5656,"activeCount":98},[],{"trials":5658,"activeCount":98},[5659],{"nctId":5660,"briefTitle":5661,"status":104,"phases":5662,"completion":3744,"start":5663,"enrollment":1443,"conditions":5664,"interventions":5666},"NCT00107861","Interferon-Beta Gene Transfer (Ad.hIFN-β) as Treatment for Refractory Colorectal Carcinoma With Liver Metastases",[86,87],"2005-05",[5665,5400],"Colorectal Carcinoma",[5651],{"trials":5668,"activeCount":98},[],{"trials":5670,"activeCount":98},[],{"trials":5672,"activeCount":98},[],{"intervention":5674,"totalTrials":149,"cells":5675},"Vehicle Ophthalmic Solution",{"EARLY_PHASE1":5676,"PHASE1":5678,"PHASE2":5680,"PHASE3":5695,"PHASE4":5697,"NA":5699},{"trials":5677,"activeCount":98},[],{"trials":5679,"activeCount":98},[],{"trials":5681,"activeCount":98},[5682],{"nctId":5683,"briefTitle":5684,"status":104,"phases":5685,"primaryCompletion":682,"completion":4500,"start":2984,"enrollment":5686,"conditions":5687,"interventions":5692},"NCT02128113","RTA 408 Ophthalmic Suspension for the Prevention of Corneal Endothelial Cell Loss Following Cataract Surgery - GUARD",[87],307,[5688,5689,5690,5691],"Corneal Endothelial Cell Loss","Ocular Pain","Ocular Inflammation","Cataract Surgery",[5674,5693,5694],"Omaveloxolone Ophthalmic Suspension 0.5%","Omaveloxolone Ophthalmic Suspension 1%",{"trials":5696,"activeCount":98},[],{"trials":5698,"activeCount":98},[],{"trials":5700,"activeCount":98},[],{"intervention":5693,"totalTrials":149,"cells":5702},{"EARLY_PHASE1":5703,"PHASE1":5705,"PHASE2":5707,"PHASE3":5713,"PHASE4":5715,"NA":5717},{"trials":5704,"activeCount":98},[],{"trials":5706,"activeCount":98},[],{"trials":5708,"activeCount":98},[5709],{"nctId":5683,"briefTitle":5684,"status":104,"phases":5710,"primaryCompletion":682,"completion":4500,"start":2984,"enrollment":5686,"conditions":5711,"interventions":5712},[87],[5688,5689,5690,5691],[5674,5693,5694],{"trials":5714,"activeCount":98},[],{"trials":5716,"activeCount":98},[],{"trials":5718,"activeCount":98},[],{"intervention":5694,"totalTrials":149,"cells":5720},{"EARLY_PHASE1":5721,"PHASE1":5723,"PHASE2":5725,"PHASE3":5731,"PHASE4":5733,"NA":5735},{"trials":5722,"activeCount":98},[],{"trials":5724,"activeCount":98},[],{"trials":5726,"activeCount":98},[5727],{"nctId":5683,"briefTitle":5684,"status":104,"phases":5728,"primaryCompletion":682,"completion":4500,"start":2984,"enrollment":5686,"conditions":5729,"interventions":5730},[87],[5688,5689,5690,5691],[5674,5693,5694],{"trials":5732,"activeCount":98},[],{"trials":5734,"activeCount":98},[],{"trials":5736,"activeCount":98},[],{"intervention":5738,"totalTrials":149,"cells":5739},"BIIB105",{"EARLY_PHASE1":5740,"PHASE1":5742,"PHASE2":5744,"PHASE3":5754,"PHASE4":5756,"NA":5758},{"trials":5741,"activeCount":98},[],{"trials":5743,"activeCount":98},[],{"trials":5745,"activeCount":98},[5746],{"nctId":5747,"briefTitle":5748,"status":522,"phases":5749,"primaryCompletion":5750,"completion":5750,"start":4397,"enrollment":5751,"conditions":5752,"interventions":5753},"NCT04494256","A Study to Assess the Safety, Tolerability, and Effect on Disease Progression of BIIB105 in Participants With Amyotrophic Lateral Sclerosis (ALS) and Participants With the ALS Ataxin-2 (ATXN2) Genetic Mutation",[86,87],"2024-08-13",99,[137],[5738],{"trials":5755,"activeCount":98},[],{"trials":5757,"activeCount":98},[],{"trials":5759,"activeCount":98},[],{"intervention":4430,"totalTrials":149,"cells":5761},{"EARLY_PHASE1":5762,"PHASE1":5764,"PHASE2":5766,"PHASE3":5772,"PHASE4":5774,"NA":5776},{"trials":5763,"activeCount":98},[],{"trials":5765,"activeCount":98},[],{"trials":5767,"activeCount":98},[5768],{"nctId":4422,"briefTitle":4423,"status":104,"phases":5769,"primaryCompletion":4425,"completion":4425,"start":4426,"enrollment":4427,"conditions":5770,"interventions":5771},[87],[500],[4379,4430],{"trials":5773,"activeCount":98},[],{"trials":5775,"activeCount":98},[],{"trials":5777,"activeCount":98},[],{"intervention":5198,"totalTrials":149,"cells":5779},{"EARLY_PHASE1":5780,"PHASE1":5782,"PHASE2":5784,"PHASE3":5790,"PHASE4":5792,"NA":5794},{"trials":5781,"activeCount":98},[],{"trials":5783,"activeCount":98},[],{"trials":5785,"activeCount":98},[5786],{"nctId":5192,"briefTitle":5193,"status":522,"phases":5787,"primaryCompletion":673,"completion":2438,"start":2363,"enrollment":22,"conditions":5788,"interventions":5789},[87],[5196],[5198,5183],{"trials":5791,"activeCount":98},[],{"trials":5793,"activeCount":98},[],{"trials":5795,"activeCount":98},[],{"intervention":5797,"totalTrials":149,"cells":5798},"BIIB131",{"EARLY_PHASE1":5799,"PHASE1":5801,"PHASE2":5803,"PHASE3":5814,"PHASE4":5816,"NA":5818},{"trials":5800,"activeCount":98},[],{"trials":5802,"activeCount":98},[],{"trials":5804,"activeCount":98},[5805],{"nctId":5806,"briefTitle":5807,"status":705,"phases":5808,"primaryCompletion":5809,"completion":5809,"start":5810,"enrollment":98,"conditions":5811,"interventions":5813},"NCT05764122","A Study to Evaluate the Efficacy and Safety of BIIB131 for Participants With Ischemic Stroke Between 4.5 and 24 Hours After Last Known Well",[87],"2025-07-07","2024-03-29",[5812],"Ischemic Stroke",[5797],{"trials":5815,"activeCount":98},[],{"trials":5817,"activeCount":98},[],{"trials":5819,"activeCount":98},[],{"intervention":5821,"totalTrials":149,"cells":5822},"BIIB057",{"EARLY_PHASE1":5823,"PHASE1":5825,"PHASE2":5827,"PHASE3":5835,"PHASE4":5837,"NA":5839},{"trials":5824,"activeCount":98},[],{"trials":5826,"activeCount":98},[],{"trials":5828,"activeCount":98},[5829],{"nctId":5830,"briefTitle":5831,"status":705,"phases":5832,"primaryCompletion":1868,"completion":1715,"start":1579,"enrollment":98,"conditions":5833,"interventions":5834},"NCT01652937","BIIB057 in Subjects With Rheumatoid Arthritis and Inadequate Response to Disease-Modifying Antirheumatic Drugs",[87],[32],[5821],{"trials":5836,"activeCount":98},[],{"trials":5838,"activeCount":98},[],{"trials":5840,"activeCount":98},[],{"intervention":5842,"totalTrials":149,"cells":5843},"RTA 402 Dose1",{"EARLY_PHASE1":5844,"PHASE1":5846,"PHASE2":5848,"PHASE3":5858,"PHASE4":5860,"NA":5862},{"trials":5845,"activeCount":98},[],{"trials":5847,"activeCount":98},[],{"trials":5849,"activeCount":98},[5850],{"nctId":5851,"briefTitle":5852,"status":705,"phases":5853,"enrollment":98,"conditions":5854,"interventions":5856},"NCT00535314","Study of Two Dose Levels of RTA 402 in Patients With Advanced Malignant Melanoma",[87],[5855],"Malignant Melanoma",[5842,5857],"RTA 402 Dose2",{"trials":5859,"activeCount":98},[],{"trials":5861,"activeCount":98},[],{"trials":5863,"activeCount":98},[],{"intervention":5857,"totalTrials":149,"cells":5865},{"EARLY_PHASE1":5866,"PHASE1":5868,"PHASE2":5870,"PHASE3":5876,"PHASE4":5878,"NA":5880},{"trials":5867,"activeCount":98},[],{"trials":5869,"activeCount":98},[],{"trials":5871,"activeCount":98},[5872],{"nctId":5851,"briefTitle":5852,"status":705,"phases":5873,"enrollment":98,"conditions":5874,"interventions":5875},[87],[5855],[5842,5857],{"trials":5877,"activeCount":98},[],{"trials":5879,"activeCount":98},[],{"trials":5881,"activeCount":98},[],{"intervention":5207,"totalTrials":149,"cells":5883},{"EARLY_PHASE1":5884,"PHASE1":5886,"PHASE2":5888,"PHASE3":5894,"PHASE4":5896,"NA":5898},{"trials":5885,"activeCount":98},[],{"trials":5887,"activeCount":98},[],{"trials":5889,"activeCount":98},[5890],{"nctId":5200,"briefTitle":5201,"status":522,"phases":5891,"primaryCompletion":4799,"completion":3605,"start":5203,"enrollment":5204,"conditions":5892,"interventions":5893},[87],[5196],[5207,5183],{"trials":5895,"activeCount":98},[],{"trials":5897,"activeCount":98},[],{"trials":5899,"activeCount":98},[],{"intervention":428,"totalTrials":149,"cells":5901},{"EARLY_PHASE1":5902,"PHASE1":5904,"PHASE2":5906,"PHASE3":5912,"PHASE4":5914,"NA":5916},{"trials":5903,"activeCount":98},[],{"trials":5905,"activeCount":98},[],{"trials":5907,"activeCount":98},[5908],{"nctId":416,"briefTitle":417,"status":104,"phases":5909,"primaryCompletion":419,"completion":420,"start":421,"enrollment":422,"conditions":5910,"interventions":5911},[86,87],[424,425,426],[41,428,429,41,41],{"trials":5913,"activeCount":98},[],{"trials":5915,"activeCount":98},[],{"trials":5917,"activeCount":98},[],{"intervention":429,"totalTrials":149,"cells":5919},{"EARLY_PHASE1":5920,"PHASE1":5922,"PHASE2":5924,"PHASE3":5930,"PHASE4":5932,"NA":5934},{"trials":5921,"activeCount":98},[],{"trials":5923,"activeCount":98},[],{"trials":5925,"activeCount":98},[5926],{"nctId":416,"briefTitle":417,"status":104,"phases":5927,"primaryCompletion":419,"completion":420,"start":421,"enrollment":422,"conditions":5928,"interventions":5929},[86,87],[424,425,426],[41,428,429,41,41],{"trials":5931,"activeCount":98},[],{"trials":5933,"activeCount":98},[],{"trials":5935,"activeCount":98},[],{"intervention":5937,"totalTrials":149,"cells":5938},"Bardoxolone Methyl 20 mg",{"EARLY_PHASE1":5939,"PHASE1":5941,"PHASE2":5943,"PHASE3":5954,"PHASE4":5956,"NA":5958},{"trials":5940,"activeCount":98},[],{"trials":5942,"activeCount":98},[],{"trials":5944,"activeCount":98},[5945],{"nctId":5946,"briefTitle":5947,"status":705,"phases":5948,"primaryCompletion":1026,"completion":1026,"start":5949,"enrollment":98,"conditions":5950,"interventions":5953},"NCT01576887","A Double-Blind, Randomized, Placebo-Controlled Safety Study Evaluating the Effects of Residual Renal Function (RFF) in Patients With End-Stage Renal Disease and Type 2 Diabetes Mellitus on Peritoneal Dialysis",[87],"2012-07-31",[5951,5952],"End-Stage Renal Disease","Type 2 Diabetes Mellitus",[5937],{"trials":5955,"activeCount":98},[],{"trials":5957,"activeCount":98},[],{"trials":5959,"activeCount":98},[],{"intervention":5961,"totalTrials":149,"cells":5962},"active drug (BIIB014) at 10, 30, 100, or 300 mg once daily.",{"EARLY_PHASE1":5963,"PHASE1":5965,"PHASE2":5967,"PHASE3":5975,"PHASE4":5977,"NA":5979},{"trials":5964,"activeCount":98},[],{"trials":5966,"activeCount":98},[],{"trials":5968,"activeCount":98},[5969],{"nctId":5970,"briefTitle":5971,"status":705,"phases":5972,"enrollment":98,"conditions":5973,"interventions":5974},"NCT00451815","BIIB014 Phase 2a Monotherapy",[87],[4649],[5961],{"trials":5976,"activeCount":98},[],{"trials":5978,"activeCount":98},[],{"trials":5980,"activeCount":98},[],{"intervention":5982,"totalTrials":149,"cells":5983},"BG00002-E",{"EARLY_PHASE1":5984,"PHASE1":5986,"PHASE2":5988,"PHASE3":5998,"PHASE4":6000,"NA":6002},{"trials":5985,"activeCount":98},[],{"trials":5987,"activeCount":98},[],{"trials":5989,"activeCount":98},[5990],{"nctId":5991,"briefTitle":5992,"status":104,"phases":5993,"primaryCompletion":1462,"completion":2362,"start":5994,"enrollment":5995,"conditions":5996,"interventions":5997},"NCT00516893","Natalizumab High Titer Immunogenicity and Safety",[87],"2006-10",113,[15],[5982],{"trials":5999,"activeCount":98},[],{"trials":6001,"activeCount":98},[],{"trials":6003,"activeCount":98},[],{"intervention":6005,"totalTrials":149,"cells":6006},"BIIB033 100mg\u002FKg",{"EARLY_PHASE1":6007,"PHASE1":6009,"PHASE2":6011,"PHASE3":6021,"PHASE4":6023,"NA":6025},{"trials":6008,"activeCount":98},[],{"trials":6010,"activeCount":98},[],{"trials":6012,"activeCount":98},[6013],{"nctId":6014,"briefTitle":6015,"status":104,"phases":6016,"primaryCompletion":6017,"completion":6017,"start":6018,"enrollment":12,"conditions":6019,"interventions":6020},"NCT02657915","Long-Term Assessment of Remyelinating Therapy",[87],"2017-01-23","2016-03-10",[4335],[6005],{"trials":6022,"activeCount":98},[],{"trials":6024,"activeCount":98},[],{"trials":6026,"activeCount":98},[],{"intervention":6028,"totalTrials":149,"cells":6029},"Lumiliximab with FCR",{"EARLY_PHASE1":6030,"PHASE1":6032,"PHASE2":6034,"PHASE3":6042,"PHASE4":6044,"NA":6046},{"trials":6031,"activeCount":98},[],{"trials":6033,"activeCount":98},[],{"trials":6035,"activeCount":98},[6036],{"nctId":6037,"briefTitle":6038,"status":104,"phases":6039,"primaryCompletion":2271,"completion":1535,"start":1545,"enrollment":4677,"conditions":6040,"interventions":6041},"NCT00103558","Lumiliximab in Combination With FCR in Subjects With Relapsed Chronic Lymphocytic Leukemia (CLL)",[86,87],[5196],[6028],{"trials":6043,"activeCount":98},[],{"trials":6045,"activeCount":98},[],{"trials":6047,"activeCount":98},[],{"intervention":6049,"totalTrials":149,"cells":6050},"natalizumab IV",{"EARLY_PHASE1":6051,"PHASE1":6053,"PHASE2":6055,"PHASE3":6067,"PHASE4":6069,"NA":6071},{"trials":6052,"activeCount":98},[],{"trials":6054,"activeCount":98},[],{"trials":6056,"activeCount":98},[6057],{"nctId":6058,"briefTitle":6059,"status":104,"phases":6060,"primaryCompletion":645,"completion":1230,"start":1172,"enrollment":6061,"conditions":6062,"interventions":6063},"NCT01405820","Exploratory Study of the Safety, Tolerability and Efficacy of Multiple Regimens of Natalizumab in Adult Participants With Relapsing Multiple Sclerosis (MS)",[87],290,[21],[6049,6064,6065,6066],"natalizumab SC","IV Placebo","SC Placebo",{"trials":6068,"activeCount":98},[],{"trials":6070,"activeCount":98},[],{"trials":6072,"activeCount":98},[],{"intervention":6064,"totalTrials":149,"cells":6074},{"EARLY_PHASE1":6075,"PHASE1":6077,"PHASE2":6079,"PHASE3":6085,"PHASE4":6087,"NA":6089},{"trials":6076,"activeCount":98},[],{"trials":6078,"activeCount":98},[],{"trials":6080,"activeCount":98},[6081],{"nctId":6058,"briefTitle":6059,"status":104,"phases":6082,"primaryCompletion":645,"completion":1230,"start":1172,"enrollment":6061,"conditions":6083,"interventions":6084},[87],[21],[6049,6064,6065,6066],{"trials":6086,"activeCount":98},[],{"trials":6088,"activeCount":98},[],{"trials":6090,"activeCount":98},[],{"intervention":6065,"totalTrials":149,"cells":6092},{"EARLY_PHASE1":6093,"PHASE1":6095,"PHASE2":6097,"PHASE3":6103,"PHASE4":6105,"NA":6107},{"trials":6094,"activeCount":98},[],{"trials":6096,"activeCount":98},[],{"trials":6098,"activeCount":98},[6099],{"nctId":6058,"briefTitle":6059,"status":104,"phases":6100,"primaryCompletion":645,"completion":1230,"start":1172,"enrollment":6061,"conditions":6101,"interventions":6102},[87],[21],[6049,6064,6065,6066],{"trials":6104,"activeCount":98},[],{"trials":6106,"activeCount":98},[],{"trials":6108,"activeCount":98},[],{"intervention":6066,"totalTrials":149,"cells":6110},{"EARLY_PHASE1":6111,"PHASE1":6113,"PHASE2":6115,"PHASE3":6121,"PHASE4":6123,"NA":6125},{"trials":6112,"activeCount":98},[],{"trials":6114,"activeCount":98},[],{"trials":6116,"activeCount":98},[6117],{"nctId":6058,"briefTitle":6059,"status":104,"phases":6118,"primaryCompletion":645,"completion":1230,"start":1172,"enrollment":6061,"conditions":6119,"interventions":6120},[87],[21],[6049,6064,6065,6066],{"trials":6122,"activeCount":98},[],{"trials":6124,"activeCount":98},[],{"trials":6126,"activeCount":98},[],{"intervention":686,"totalTrials":149,"cells":6128},{"EARLY_PHASE1":6129,"PHASE1":6131,"PHASE2":6133,"PHASE3":6139,"PHASE4":6141,"NA":6143},{"trials":6130,"activeCount":98},[],{"trials":6132,"activeCount":98},[],{"trials":6134,"activeCount":98},[6135],{"nctId":678,"briefTitle":679,"status":104,"phases":6136,"primaryCompletion":681,"completion":681,"start":682,"enrollment":683,"conditions":6137,"interventions":6138},[87],[500],[624,686,687,688,689],{"trials":6140,"activeCount":98},[],{"trials":6142,"activeCount":98},[],{"trials":6144,"activeCount":98},[],{"intervention":687,"totalTrials":149,"cells":6146},{"EARLY_PHASE1":6147,"PHASE1":6149,"PHASE2":6151,"PHASE3":6157,"PHASE4":6159,"NA":6161},{"trials":6148,"activeCount":98},[],{"trials":6150,"activeCount":98},[],{"trials":6152,"activeCount":98},[6153],{"nctId":678,"briefTitle":679,"status":104,"phases":6154,"primaryCompletion":681,"completion":681,"start":682,"enrollment":683,"conditions":6155,"interventions":6156},[87],[500],[624,686,687,688,689],{"trials":6158,"activeCount":98},[],{"trials":6160,"activeCount":98},[],{"trials":6162,"activeCount":98},[],{"intervention":688,"totalTrials":149,"cells":6164},{"EARLY_PHASE1":6165,"PHASE1":6167,"PHASE2":6169,"PHASE3":6175,"PHASE4":6177,"NA":6179},{"trials":6166,"activeCount":98},[],{"trials":6168,"activeCount":98},[],{"trials":6170,"activeCount":98},[6171],{"nctId":678,"briefTitle":679,"status":104,"phases":6172,"primaryCompletion":681,"completion":681,"start":682,"enrollment":683,"conditions":6173,"interventions":6174},[87],[500],[624,686,687,688,689],{"trials":6176,"activeCount":98},[],{"trials":6178,"activeCount":98},[],{"trials":6180,"activeCount":98},[],{"intervention":689,"totalTrials":149,"cells":6182},{"EARLY_PHASE1":6183,"PHASE1":6185,"PHASE2":6187,"PHASE3":6193,"PHASE4":6195,"NA":6197},{"trials":6184,"activeCount":98},[],{"trials":6186,"activeCount":98},[],{"trials":6188,"activeCount":98},[6189],{"nctId":678,"briefTitle":679,"status":104,"phases":6190,"primaryCompletion":681,"completion":681,"start":682,"enrollment":683,"conditions":6191,"interventions":6192},[87],[500],[624,686,687,688,689],{"trials":6194,"activeCount":98},[],{"trials":6196,"activeCount":98},[],{"trials":6198,"activeCount":98},[],{"intervention":3473,"totalTrials":149,"cells":6200},{"EARLY_PHASE1":6201,"PHASE1":6203,"PHASE2":6205,"PHASE3":6211,"PHASE4":6213,"NA":6215},{"trials":6202,"activeCount":98},[],{"trials":6204,"activeCount":98},[],{"trials":6206,"activeCount":98},[6207],{"nctId":3465,"briefTitle":3466,"status":104,"phases":6208,"primaryCompletion":3468,"completion":3468,"start":3469,"enrollment":3470,"conditions":6209,"interventions":6210},[87],[21],[3440,3473],{"trials":6212,"activeCount":98},[],{"trials":6214,"activeCount":98},[],{"trials":6216,"activeCount":98},[],{"intervention":2424,"totalTrials":149,"cells":6218},{"EARLY_PHASE1":6219,"PHASE1":6221,"PHASE2":6223,"PHASE3":6229,"PHASE4":6231,"NA":6233},{"trials":6220,"activeCount":98},[],{"trials":6222,"activeCount":98},[],{"trials":6224,"activeCount":98},[6225],{"nctId":2415,"briefTitle":2416,"status":522,"phases":6226,"primaryCompletion":2418,"completion":2419,"start":2420,"enrollment":2421,"conditions":6227,"interventions":6228},[87],[32],[2424,2425,2426,2427,2428],{"trials":6230,"activeCount":98},[],{"trials":6232,"activeCount":98},[],{"trials":6234,"activeCount":98},[],{"intervention":2426,"totalTrials":149,"cells":6236},{"EARLY_PHASE1":6237,"PHASE1":6239,"PHASE2":6241,"PHASE3":6247,"PHASE4":6249,"NA":6251},{"trials":6238,"activeCount":98},[],{"trials":6240,"activeCount":98},[],{"trials":6242,"activeCount":98},[6243],{"nctId":2415,"briefTitle":2416,"status":522,"phases":6244,"primaryCompletion":2418,"completion":2419,"start":2420,"enrollment":2421,"conditions":6245,"interventions":6246},[87],[32],[2424,2425,2426,2427,2428],{"trials":6248,"activeCount":98},[],{"trials":6250,"activeCount":98},[],{"trials":6252,"activeCount":98},[],{"intervention":6254,"totalTrials":149,"cells":6255},"mefloquine",{"EARLY_PHASE1":6256,"PHASE1":6258,"PHASE2":6260,"PHASE3":6270,"PHASE4":6272,"NA":6274},{"trials":6257,"activeCount":98},[],{"trials":6259,"activeCount":98},[],{"trials":6261,"activeCount":98},[6262],{"nctId":6263,"briefTitle":6264,"status":522,"phases":6265,"primaryCompletion":1580,"completion":1580,"start":6266,"enrollment":6267,"conditions":6268,"interventions":6269},"NCT00746941","Study to Explore the Effect of Mefloquine in Participants With Progressive Multifocal Leukoencephalopathy (PML)",[86,87],"2009-01",37,[2074],[6254],{"trials":6271,"activeCount":98},[],{"trials":6273,"activeCount":98},[],{"trials":6275,"activeCount":98},[],{"intervention":6277,"totalTrials":149,"cells":6278},"Baminercept",{"EARLY_PHASE1":6279,"PHASE1":6281,"PHASE2":6283,"PHASE3":6291,"PHASE4":6293,"NA":6295},{"trials":6280,"activeCount":98},[],{"trials":6282,"activeCount":98},[],{"trials":6284,"activeCount":98},[6285],{"nctId":6286,"briefTitle":6287,"status":705,"phases":6288,"start":2438,"enrollment":98,"conditions":6289,"interventions":6290},"NCT01181089","Dose Escalation Study to Evaluate the Penetration and Pharmacodynamic Effects of Baminercept in the Cerebrospinal Fluid (CSF)and Safety in Subjects With Secondary Progressive Multiple Sclerosis (SPMS)",[86,87],[1465],[6277],{"trials":6292,"activeCount":98},[],{"trials":6294,"activeCount":98},[],{"trials":6296,"activeCount":98},[],{"intervention":2014,"totalTrials":149,"cells":6298},{"EARLY_PHASE1":6299,"PHASE1":6301,"PHASE2":6303,"PHASE3":6309,"PHASE4":6311,"NA":6313},{"trials":6300,"activeCount":98},[],{"trials":6302,"activeCount":98},[],{"trials":6304,"activeCount":98},[6305],{"nctId":2006,"briefTitle":2007,"status":705,"phases":6306,"primaryCompletion":2009,"completion":2009,"start":2010,"enrollment":98,"conditions":6307,"interventions":6308},[87],[1209],[2013,2014,551],{"trials":6310,"activeCount":98},[],{"trials":6312,"activeCount":98},[],{"trials":6314,"activeCount":98},[],{"intervention":372,"totalTrials":243,"cells":6316},{"EARLY_PHASE1":6317,"PHASE1":6319,"PHASE2":6337,"PHASE3":6339,"PHASE4":6341,"NA":6343},{"trials":6318,"activeCount":98},[],{"trials":6320,"activeCount":98},[6321,6325,6329,6333],{"nctId":4394,"briefTitle":4395,"status":104,"phases":6322,"primaryCompletion":3519,"completion":3519,"start":4397,"enrollment":4398,"conditions":6323,"interventions":6324},[86],[30],[4379,3531,372],{"nctId":3113,"briefTitle":3114,"status":104,"phases":6326,"primaryCompletion":3116,"completion":3116,"start":884,"enrollment":978,"conditions":6327,"interventions":6328},[86],[3118],[3087,372],{"nctId":4252,"briefTitle":4253,"status":104,"phases":6330,"primaryCompletion":4255,"completion":4255,"start":4256,"enrollment":33,"conditions":6331,"interventions":6332},[86],[18],[4204,372],{"nctId":357,"briefTitle":358,"status":104,"phases":6334,"primaryCompletion":360,"completion":361,"start":362,"enrollment":363,"conditions":6335,"interventions":6336},[86],[327],[41,366,367,368,369,370,371,372,373],{"trials":6338,"activeCount":98},[],{"trials":6340,"activeCount":98},[],{"trials":6342,"activeCount":98},[],{"trials":6344,"activeCount":98},[],{"intervention":6346,"totalTrials":577,"cells":6347},"CNF2024",{"EARLY_PHASE1":6348,"PHASE1":6350,"PHASE2":6375,"PHASE3":6377,"PHASE4":6379,"NA":6381},{"trials":6349,"activeCount":98},[],{"trials":6351,"activeCount":98},[6352,6361,6368],{"nctId":6353,"briefTitle":6354,"status":104,"phases":6355,"primaryCompletion":6356,"completion":2418,"start":2478,"enrollment":316,"conditions":6357,"interventions":6360},"NCT00345189","Study of Oral CNF2024 (BIIB021) in Advanced Solid Tumors",[86],"2008-07",[6358,6359],"Tumors","Lymphoma",[6346],{"nctId":6362,"briefTitle":6363,"status":522,"phases":6364,"primaryCompletion":6356,"completion":2352,"start":2478,"enrollment":304,"conditions":6365,"interventions":6367},"NCT00344786","Phase 1, Dose-Escalation Study of Oral CNF2024(BIIB021) in CLL",[86],[6366],"B-Cell Chronic Lymphocytic Leukemia",[6346],{"nctId":6369,"briefTitle":6370,"status":104,"phases":6371,"primaryCompletion":1890,"completion":1890,"start":2362,"enrollment":1027,"conditions":6372,"interventions":6373},"NCT00412412","CNF2024 (BIIB021) HER2- (QD) HER2+ (BIW w\u002FHerceptin) PK\u002FPD Study",[86],[4810],[6346,6374],"CNF2024 + trastuzumab",{"trials":6376,"activeCount":98},[],{"trials":6378,"activeCount":98},[],{"trials":6380,"activeCount":98},[],{"trials":6382,"activeCount":98},[],{"intervention":370,"totalTrials":470,"cells":6384},{"EARLY_PHASE1":6385,"PHASE1":6387,"PHASE2":6399,"PHASE3":6401,"PHASE4":6403,"NA":6405},{"trials":6386,"activeCount":98},[],{"trials":6388,"activeCount":98},[6389,6395],{"nctId":6390,"briefTitle":6391,"status":104,"phases":6392,"primaryCompletion":5949,"completion":5949,"start":4517,"enrollment":336,"conditions":6393,"interventions":6394},"NCT01598363","An Open-Label Study of the Effect of Bardoxolone Methyl on the Single Dose Pharmacokinetics of Digoxin and Rosuvastatin in Healthy Volunteers",[86],[30],[370,369],{"nctId":357,"briefTitle":358,"status":104,"phases":6396,"primaryCompletion":360,"completion":361,"start":362,"enrollment":363,"conditions":6397,"interventions":6398},[86],[327],[41,366,367,368,369,370,371,372,373],{"trials":6400,"activeCount":98},[],{"trials":6402,"activeCount":98},[],{"trials":6404,"activeCount":98},[],{"trials":6406,"activeCount":98},[],{"intervention":369,"totalTrials":470,"cells":6408},{"EARLY_PHASE1":6409,"PHASE1":6411,"PHASE2":6421,"PHASE3":6423,"PHASE4":6425,"NA":6427},{"trials":6410,"activeCount":98},[],{"trials":6412,"activeCount":98},[6413,6417],{"nctId":6390,"briefTitle":6391,"status":104,"phases":6414,"primaryCompletion":5949,"completion":5949,"start":4517,"enrollment":336,"conditions":6415,"interventions":6416},[86],[30],[370,369],{"nctId":357,"briefTitle":358,"status":104,"phases":6418,"primaryCompletion":360,"completion":361,"start":362,"enrollment":363,"conditions":6419,"interventions":6420},[86],[327],[41,366,367,368,369,370,371,372,373],{"trials":6422,"activeCount":98},[],{"trials":6424,"activeCount":98},[],{"trials":6426,"activeCount":98},[],{"trials":6428,"activeCount":98},[],{"intervention":6430,"totalTrials":470,"cells":6431},"BIIB078",{"EARLY_PHASE1":6432,"PHASE1":6434,"PHASE2":6452,"PHASE3":6454,"PHASE4":6456,"NA":6458},{"trials":6433,"activeCount":98},[],{"trials":6435,"activeCount":98},[6436,6444],{"nctId":6437,"briefTitle":6438,"status":522,"phases":6439,"primaryCompletion":6440,"completion":6440,"start":6441,"enrollment":564,"conditions":6442,"interventions":6443},"NCT04288856","Study to Assess the Safety, Tolerability, Pharmacokinetics, and Effect on Disease Progression of BIIB078 Administered to Previously Treated Adults C9ORF72-Associated Amyotrophic Lateral Sclerosis (ALS)",[86],"2022-05-03","2020-04-28",[137],[6430],{"nctId":6445,"briefTitle":6446,"status":104,"phases":6447,"primaryCompletion":6448,"completion":6448,"start":6449,"enrollment":1581,"conditions":6450,"interventions":6451},"NCT03626012","A Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB078 in Adults With C9ORF72-Associated Amyotrophic Lateral Sclerosis",[86],"2021-11-17","2018-09-10",[137],[6430],{"trials":6453,"activeCount":98},[],{"trials":6455,"activeCount":98},[],{"trials":6457,"activeCount":98},[],{"trials":6459,"activeCount":98},[],{"intervention":6461,"totalTrials":470,"cells":6462},"RTA 744",{"EARLY_PHASE1":6463,"PHASE1":6465,"PHASE2":6484,"PHASE3":6486,"PHASE4":6488,"NA":6490},{"trials":6464,"activeCount":98},[],{"trials":6466,"activeCount":98},[6467,6476],{"nctId":6468,"briefTitle":6469,"status":522,"phases":6470,"primaryCompletion":2924,"start":6471,"enrollment":6472,"conditions":6473,"interventions":6475},"NCT00527410","A Safety Study of RTA 744 in Recurrent, Progressive or Refractory Neoplastic Meningitis",[86],"2006-10-31",9,[6474],"Leptomeningeal Carcinomatosis",[6461],{"nctId":6477,"briefTitle":6478,"status":104,"phases":6479,"primaryCompletion":2924,"start":6480,"enrollment":2421,"conditions":6481,"interventions":6483},"NCT00526812","A Safety Study of RTA 744 in Patients With Recurrent High-Grade Gliomas",[86],"2005-11-30",[6482],"Glioma",[6461,6461],{"trials":6485,"activeCount":98},[],{"trials":6487,"activeCount":98},[],{"trials":6489,"activeCount":98},[],{"trials":6491,"activeCount":98},[],{"intervention":6493,"totalTrials":470,"cells":6494},"GSK1014802",{"EARLY_PHASE1":6495,"PHASE1":6497,"PHASE2":6517,"PHASE3":6519,"PHASE4":6521,"NA":6523},{"trials":6496,"activeCount":98},[],{"trials":6498,"activeCount":98},[6499,6510],{"nctId":6500,"briefTitle":6501,"status":104,"phases":6502,"primaryCompletion":6503,"completion":6503,"start":6504,"enrollment":6505,"conditions":6506,"interventions":6509},"NCT00908154","Safety, Tolerability and Pharmacokinetics of Repeat Doses of GSK1014802.",[86],"2008-12-31","2008-05-31",51,[6507,6508],"Bipolar Depression","Bipolar Disorder",[6493],{"nctId":6511,"briefTitle":6512,"status":104,"phases":6513,"primaryCompletion":3685,"completion":3685,"start":6514,"enrollment":808,"conditions":6515,"interventions":6516},"NCT00955396","Study to Investigate the Effect of GSK1014802 on Ambulatory Blood Pressure",[86],"2009-07-31",[24],[6493],{"trials":6518,"activeCount":98},[],{"trials":6520,"activeCount":98},[],{"trials":6522,"activeCount":98},[],{"trials":6524,"activeCount":98},[],{"intervention":3531,"totalTrials":470,"cells":6526},{"EARLY_PHASE1":6527,"PHASE1":6529,"PHASE2":6539,"PHASE3":6541,"PHASE4":6543,"NA":6545},{"trials":6528,"activeCount":98},[],{"trials":6530,"activeCount":98},[6531,6535],{"nctId":4394,"briefTitle":4395,"status":104,"phases":6532,"primaryCompletion":3519,"completion":3519,"start":4397,"enrollment":4398,"conditions":6533,"interventions":6534},[86],[30],[4379,3531,372],{"nctId":3524,"briefTitle":3525,"status":104,"phases":6536,"primaryCompletion":3527,"completion":3527,"start":3528,"enrollment":1000,"conditions":6537,"interventions":6538},[86],[24],[3509,3531],{"trials":6540,"activeCount":98},[],{"trials":6542,"activeCount":98},[],{"trials":6544,"activeCount":98},[],{"trials":6546,"activeCount":98},[],{"intervention":393,"totalTrials":470,"cells":6548},{"EARLY_PHASE1":6549,"PHASE1":6551,"PHASE2":6561,"PHASE3":6563,"PHASE4":6565,"NA":6567},{"trials":6550,"activeCount":98},[],{"trials":6552,"activeCount":98},[6553,6557],{"nctId":4402,"briefTitle":4403,"status":104,"phases":6554,"primaryCompletion":4405,"completion":4405,"start":4406,"enrollment":1184,"conditions":6555,"interventions":6556},[86],[24],[4379,393,4409,4410],{"nctId":384,"briefTitle":385,"status":104,"phases":6558,"primaryCompletion":387,"completion":387,"start":388,"enrollment":389,"conditions":6559,"interventions":6560},[86],[391],[41,393],{"trials":6562,"activeCount":98},[],{"trials":6564,"activeCount":98},[],{"trials":6566,"activeCount":98},[],{"trials":6568,"activeCount":98},[],{"intervention":3100,"totalTrials":470,"cells":6570},{"EARLY_PHASE1":6571,"PHASE1":6573,"PHASE2":6587,"PHASE3":6589,"PHASE4":6591,"NA":6593},{"trials":6572,"activeCount":98},[],{"trials":6574,"activeCount":98},[6575,6579],{"nctId":3094,"briefTitle":3095,"status":705,"phases":6576,"primaryCompletion":1089,"completion":1089,"start":3058,"enrollment":98,"conditions":6577,"interventions":6578},[86],[30,3098],[3100,3087,3101],{"nctId":6580,"briefTitle":6581,"status":104,"phases":6582,"primaryCompletion":6583,"completion":6583,"start":6584,"enrollment":1902,"conditions":6585,"interventions":6586},"NCT03454126","Evaluating the Safety, Tolerability, and Pharmacokinetics of BIIB095 in Healthy Participants",[86],"2019-04-30","2018-03-29",[24],[3100],{"trials":6588,"activeCount":98},[],{"trials":6590,"activeCount":98},[],{"trials":6592,"activeCount":98},[],{"trials":6594,"activeCount":98},[],{"intervention":3101,"totalTrials":470,"cells":6596},{"EARLY_PHASE1":6597,"PHASE1":6599,"PHASE2":6615,"PHASE3":6617,"PHASE4":6619,"NA":6621},{"trials":6598,"activeCount":98},[],{"trials":6600,"activeCount":98},[6601,6605],{"nctId":3094,"briefTitle":3095,"status":705,"phases":6602,"primaryCompletion":1089,"completion":1089,"start":3058,"enrollment":98,"conditions":6603,"interventions":6604},[86],[30,3098],[3100,3087,3101],{"nctId":6606,"briefTitle":6607,"status":522,"phases":6608,"primaryCompletion":6609,"completion":6609,"start":6514,"enrollment":978,"conditions":6610,"interventions":6612},"NCT00964288","Effect of GSK1014802 on Electrical Hyperalgesia and Threshold Tracking in Healthy Subjects",[86],"2009-11-30",[6611,3118],"Pain, Neuropathic",[6613,3101,6614],"GSK1014802 low dose","GSK1014802 high dose",{"trials":6616,"activeCount":98},[],{"trials":6618,"activeCount":98},[],{"trials":6620,"activeCount":98},[],{"trials":6622,"activeCount":98},[],{"intervention":6624,"totalTrials":470,"cells":6625},"BIIB118",{"EARLY_PHASE1":6626,"PHASE1":6628,"PHASE2":6648,"PHASE3":6650,"PHASE4":6652,"NA":6654},{"trials":6627,"activeCount":98},[],{"trials":6629,"activeCount":98},[6630,6640],{"nctId":6631,"briefTitle":6632,"status":104,"phases":6633,"primaryCompletion":6634,"completion":6634,"start":6635,"enrollment":1475,"conditions":6636,"interventions":6638},"NCT02691702","Multiple Dose Study Of BIIB118 (PF-05251749) In Healthy Volunteers",[86],"2017-01-12","2016-03-28",[327,6637],"Healthy Elderly Subjects",[6624,6639],"Melatonin",{"nctId":6641,"briefTitle":6642,"status":104,"phases":6643,"primaryCompletion":6644,"completion":6644,"start":6645,"enrollment":336,"conditions":6646,"interventions":6647},"NCT02443740","Safety, Tolerability and Pharmacokinetics of BIIB118 (PF-05251749)",[86],"2015-10-31","2015-05-31",[18],[6624,6624,6624],{"trials":6649,"activeCount":98},[],{"trials":6651,"activeCount":98},[],{"trials":6653,"activeCount":98},[],{"trials":6655,"activeCount":98},[],{"intervention":6657,"totalTrials":470,"cells":6658},"BIIB022",{"EARLY_PHASE1":6659,"PHASE1":6661,"PHASE2":6678,"PHASE3":6680,"PHASE4":6682,"NA":6684},{"trials":6660,"activeCount":98},[],{"trials":6662,"activeCount":98},[6663,6670],{"nctId":6664,"briefTitle":6665,"status":104,"phases":6666,"primaryCompletion":1982,"completion":4799,"start":2377,"enrollment":22,"conditions":6667,"interventions":6669},"NCT00555724","Phase 1 Study of BIIB022 (Anti-IGF-1R Monoclonal Antibody) in Relapsed\u002FRefractory Solid Tumors",[86],[6668],"Solid Tumors",[6657],{"nctId":6671,"briefTitle":6672,"status":104,"phases":6673,"primaryCompletion":1890,"completion":1890,"start":2395,"enrollment":22,"conditions":6674,"interventions":6676},"NCT00956436","Sorafenib With BIIB022 in Hepatocellular Carcinoma (HCC)",[86],[6675],"Hepatocellular Carcinoma",[6657,6677],"Sorafenib",{"trials":6679,"activeCount":98},[],{"trials":6681,"activeCount":98},[],{"trials":6683,"activeCount":98},[],{"trials":6685,"activeCount":98},[],{"intervention":3540,"totalTrials":470,"cells":6687},{"EARLY_PHASE1":6688,"PHASE1":6690,"PHASE2":6704,"PHASE3":6706,"PHASE4":6708,"NA":6710},{"trials":6689,"activeCount":98},[],{"trials":6691,"activeCount":98},[6692,6700],{"nctId":6693,"briefTitle":6694,"status":104,"phases":6695,"primaryCompletion":6696,"completion":6696,"start":6697,"enrollment":94,"conditions":6698,"interventions":6699},"NCT05119790","A Study of Mass Balance, Pharmacokinetics, Metabolite Profile, and Metabolite Identification of BIIB122\u002FDNL151 in Healthy Male Subjects",[86],"2021-11-05","2021-08-27",[30],[3540],{"nctId":3533,"briefTitle":3534,"status":104,"phases":6701,"primaryCompletion":3536,"completion":3536,"start":3537,"enrollment":109,"conditions":6702,"interventions":6703},[86],[30],[3509,3540],{"trials":6705,"activeCount":98},[],{"trials":6707,"activeCount":98},[],{"trials":6709,"activeCount":98},[],{"trials":6711,"activeCount":98},[],{"intervention":6713,"totalTrials":149,"cells":6714},"BMS-986168",{"EARLY_PHASE1":6715,"PHASE1":6717,"PHASE2":6730,"PHASE3":6732,"PHASE4":6734,"NA":6736},{"trials":6716,"activeCount":98},[],{"trials":6718,"activeCount":98},[6719],{"nctId":6720,"briefTitle":6721,"status":104,"phases":6722,"primaryCompletion":6723,"completion":6723,"start":6724,"enrollment":6725,"conditions":6726,"interventions":6728},"NCT02294851","A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study of Intravenously Administered BMS-986168 in Healthy Subjects",[86],"2016-04-30","2014-12-31",65,[6727],"Tauopathies",[6713,6729],"BMS-986168 Placebo",{"trials":6731,"activeCount":98},[],{"trials":6733,"activeCount":98},[],{"trials":6735,"activeCount":98},[],{"trials":6737,"activeCount":98},[],{"intervention":6729,"totalTrials":149,"cells":6739},{"EARLY_PHASE1":6740,"PHASE1":6742,"PHASE2":6748,"PHASE3":6750,"PHASE4":6752,"NA":6754},{"trials":6741,"activeCount":98},[],{"trials":6743,"activeCount":98},[6744],{"nctId":6720,"briefTitle":6721,"status":104,"phases":6745,"primaryCompletion":6723,"completion":6723,"start":6724,"enrollment":6725,"conditions":6746,"interventions":6747},[86],[6727],[6713,6729],{"trials":6749,"activeCount":98},[],{"trials":6751,"activeCount":98},[],{"trials":6753,"activeCount":98},[],{"trials":6755,"activeCount":98},[],{"intervention":640,"totalTrials":149,"cells":6757},{"EARLY_PHASE1":6758,"PHASE1":6760,"PHASE2":6766,"PHASE3":6768,"PHASE4":6770,"NA":6772},{"trials":6759,"activeCount":98},[],{"trials":6761,"activeCount":98},[6762],{"nctId":632,"briefTitle":633,"status":104,"phases":6763,"primaryCompletion":635,"completion":635,"start":636,"enrollment":637,"conditions":6764,"interventions":6765},[86],[18],[513,640],{"trials":6767,"activeCount":98},[],{"trials":6769,"activeCount":98},[],{"trials":6771,"activeCount":98},[],{"trials":6773,"activeCount":98},[],{"intervention":6775,"totalTrials":149,"cells":6776},"BG00012 Dose 1",{"EARLY_PHASE1":6777,"PHASE1":6779,"PHASE2":6789,"PHASE3":6791,"PHASE4":6793,"NA":6795},{"trials":6778,"activeCount":98},[],{"trials":6780,"activeCount":98},[6781],{"nctId":6782,"briefTitle":6783,"status":104,"phases":6784,"primaryCompletion":2021,"completion":2021,"start":6785,"enrollment":683,"conditions":6786,"interventions":6787},"NCT01453426","Phase 1 Study to Evaluate the PK, Safety, and Tolerability of BG00012 in Chinese, Japanese, and Caucasian Healthy Volunteers",[86],"2012-01",[18],[6775,6788],"BG00012 Dose 2",{"trials":6790,"activeCount":98},[],{"trials":6792,"activeCount":98},[],{"trials":6794,"activeCount":98},[],{"trials":6796,"activeCount":98},[],{"intervention":6788,"totalTrials":149,"cells":6798},{"EARLY_PHASE1":6799,"PHASE1":6801,"PHASE2":6807,"PHASE3":6809,"PHASE4":6811,"NA":6813},{"trials":6800,"activeCount":98},[],{"trials":6802,"activeCount":98},[6803],{"nctId":6782,"briefTitle":6783,"status":104,"phases":6804,"primaryCompletion":2021,"completion":2021,"start":6785,"enrollment":683,"conditions":6805,"interventions":6806},[86],[18],[6775,6788],{"trials":6808,"activeCount":98},[],{"trials":6810,"activeCount":98},[],{"trials":6812,"activeCount":98},[],{"trials":6814,"activeCount":98},[],{"intervention":6816,"totalTrials":149,"cells":6817},"Bardoxolone Methyl 20mg",{"EARLY_PHASE1":6818,"PHASE1":6820,"PHASE2":6833,"PHASE3":6835,"PHASE4":6837,"NA":6839},{"trials":6819,"activeCount":98},[],{"trials":6821,"activeCount":98},[6822],{"nctId":6823,"briefTitle":6824,"status":104,"phases":6825,"primaryCompletion":2897,"completion":2897,"start":4518,"enrollment":6826,"conditions":6827,"interventions":6828},"NCT01689116","Multiple-Dose Study of Effect of Bardoxolone Methyl on QT\u002FQTC Interval Volunteers",[86],179,[30],[6816,6829,6830,6831,6832],"Bardoxolone Methyl 80mg","Bardoxolone Methyl Placebo","Moxifloxacin 400mg","Moxifloxacin Placebo",{"trials":6834,"activeCount":98},[],{"trials":6836,"activeCount":98},[],{"trials":6838,"activeCount":98},[],{"trials":6840,"activeCount":98},[],{"intervention":6829,"totalTrials":149,"cells":6842},{"EARLY_PHASE1":6843,"PHASE1":6845,"PHASE2":6851,"PHASE3":6853,"PHASE4":6855,"NA":6857},{"trials":6844,"activeCount":98},[],{"trials":6846,"activeCount":98},[6847],{"nctId":6823,"briefTitle":6824,"status":104,"phases":6848,"primaryCompletion":2897,"completion":2897,"start":4518,"enrollment":6826,"conditions":6849,"interventions":6850},[86],[30],[6816,6829,6830,6831,6832],{"trials":6852,"activeCount":98},[],{"trials":6854,"activeCount":98},[],{"trials":6856,"activeCount":98},[],{"trials":6858,"activeCount":98},[],{"intervention":6830,"totalTrials":149,"cells":6860},{"EARLY_PHASE1":6861,"PHASE1":6863,"PHASE2":6869,"PHASE3":6871,"PHASE4":6873,"NA":6875},{"trials":6862,"activeCount":98},[],{"trials":6864,"activeCount":98},[6865],{"nctId":6823,"briefTitle":6824,"status":104,"phases":6866,"primaryCompletion":2897,"completion":2897,"start":4518,"enrollment":6826,"conditions":6867,"interventions":6868},[86],[30],[6816,6829,6830,6831,6832],{"trials":6870,"activeCount":98},[],{"trials":6872,"activeCount":98},[],{"trials":6874,"activeCount":98},[],{"trials":6876,"activeCount":98},[],{"intervention":6831,"totalTrials":149,"cells":6878},{"EARLY_PHASE1":6879,"PHASE1":6881,"PHASE2":6887,"PHASE3":6889,"PHASE4":6891,"NA":6893},{"trials":6880,"activeCount":98},[],{"trials":6882,"activeCount":98},[6883],{"nctId":6823,"briefTitle":6824,"status":104,"phases":6884,"primaryCompletion":2897,"completion":2897,"start":4518,"enrollment":6826,"conditions":6885,"interventions":6886},[86],[30],[6816,6829,6830,6831,6832],{"trials":6888,"activeCount":98},[],{"trials":6890,"activeCount":98},[],{"trials":6892,"activeCount":98},[],{"trials":6894,"activeCount":98},[],{"intervention":6832,"totalTrials":149,"cells":6896},{"EARLY_PHASE1":6897,"PHASE1":6899,"PHASE2":6905,"PHASE3":6907,"PHASE4":6909,"NA":6911},{"trials":6898,"activeCount":98},[],{"trials":6900,"activeCount":98},[6901],{"nctId":6823,"briefTitle":6824,"status":104,"phases":6902,"primaryCompletion":2897,"completion":2897,"start":4518,"enrollment":6826,"conditions":6903,"interventions":6904},[86],[30],[6816,6829,6830,6831,6832],{"trials":6906,"activeCount":98},[],{"trials":6908,"activeCount":98},[],{"trials":6910,"activeCount":98},[],{"trials":6912,"activeCount":98},[],{"intervention":1357,"totalTrials":149,"cells":6914},{"EARLY_PHASE1":6915,"PHASE1":6917,"PHASE2":6923,"PHASE3":6925,"PHASE4":6927,"NA":6929},{"trials":6916,"activeCount":98},[],{"trials":6918,"activeCount":98},[6919],{"nctId":1350,"briefTitle":1351,"status":104,"phases":6920,"primaryCompletion":1353,"completion":1353,"start":1354,"enrollment":182,"conditions":6921,"interventions":6922},[86],[24],[1357,46],{"trials":6924,"activeCount":98},[],{"trials":6926,"activeCount":98},[],{"trials":6928,"activeCount":98},[],{"trials":6930,"activeCount":98},[],{"intervention":6932,"totalTrials":149,"cells":6933},"BIIB021 and Food",{"EARLY_PHASE1":6934,"PHASE1":6936,"PHASE2":6947,"PHASE3":6949,"PHASE4":6951,"NA":6953},{"trials":6935,"activeCount":98},[],{"trials":6937,"activeCount":98},[6938],{"nctId":6939,"briefTitle":6940,"status":104,"phases":6941,"primaryCompletion":6942,"completion":6943,"start":2376,"enrollment":325,"conditions":6944,"interventions":6945},"NCT01017198","Effect of Food and Antacid on BIIB021 With Advanced Solid Tumors",[86],"2010-08","2011-01",[2927],[6932,6946],"BIIB0121 and Antacid",{"trials":6948,"activeCount":98},[],{"trials":6950,"activeCount":98},[],{"trials":6952,"activeCount":98},[],{"trials":6954,"activeCount":98},[],{"intervention":6946,"totalTrials":149,"cells":6956},{"EARLY_PHASE1":6957,"PHASE1":6959,"PHASE2":6965,"PHASE3":6967,"PHASE4":6969,"NA":6971},{"trials":6958,"activeCount":98},[],{"trials":6960,"activeCount":98},[6961],{"nctId":6939,"briefTitle":6940,"status":104,"phases":6962,"primaryCompletion":6942,"completion":6943,"start":2376,"enrollment":325,"conditions":6963,"interventions":6964},[86],[2927],[6932,6946],{"trials":6966,"activeCount":98},[],{"trials":6968,"activeCount":98},[],{"trials":6970,"activeCount":98},[],{"trials":6972,"activeCount":98},[],{"intervention":6974,"totalTrials":149,"cells":6975},"20 mg bardoxolone methyl",{"EARLY_PHASE1":6976,"PHASE1":6978,"PHASE2":6989,"PHASE3":6991,"PHASE4":6993,"NA":6995},{"trials":6977,"activeCount":98},[],{"trials":6979,"activeCount":98},[6980],{"nctId":6981,"briefTitle":6982,"status":522,"phases":6983,"primaryCompletion":6984,"completion":6985,"start":6986,"enrollment":1000,"conditions":6987,"interventions":6988},"NCT01500798","A Pharmacodynamic Study of Measured Glomerular Filtration Rate in Patients With Chronic Kidney Disease and Type 2 Diabetes",[86],"2012-11-01","2013-10-01","2012-01-31",[2974,2975],[6974],{"trials":6990,"activeCount":98},[],{"trials":6992,"activeCount":98},[],{"trials":6994,"activeCount":98},[],{"trials":6996,"activeCount":98},[],{"intervention":6998,"totalTrials":149,"cells":6999},"CNF1010",{"EARLY_PHASE1":7000,"PHASE1":7002,"PHASE2":7010,"PHASE3":7012,"PHASE4":7014,"NA":7016},{"trials":7001,"activeCount":98},[],{"trials":7003,"activeCount":98},[7004],{"nctId":7005,"briefTitle":7006,"status":522,"phases":7007,"completion":2547,"start":5663,"enrollment":1858,"conditions":7008,"interventions":7009},"NCT00319930","Phase 1, Dose-Escalation, Pharmacodynamic Study of IV CNF1010 in ZAP-70 Positive CLL",[86],[5196],[6998],{"trials":7011,"activeCount":98},[],{"trials":7013,"activeCount":98},[],{"trials":7015,"activeCount":98},[],{"trials":7017,"activeCount":98},[],{"intervention":7019,"totalTrials":149,"cells":7020},"DNL151",{"EARLY_PHASE1":7021,"PHASE1":7023,"PHASE2":7033,"PHASE3":7035,"PHASE4":7037,"NA":7039},{"trials":7022,"activeCount":98},[],{"trials":7024,"activeCount":98},[7025],{"nctId":7026,"briefTitle":7027,"status":104,"phases":7028,"primaryCompletion":7029,"completion":7029,"start":7030,"enrollment":876,"conditions":7031,"interventions":7032},"NCT04056689","Study to Evaluate DNL151 in Subjects With Parkinson's Disease",[86],"2020-12-02","2019-07-23",[4649],[7019],{"trials":7034,"activeCount":98},[],{"trials":7036,"activeCount":98},[],{"trials":7038,"activeCount":98},[],{"trials":7040,"activeCount":98},[],{"intervention":7042,"totalTrials":149,"cells":7043},"BIIB037",{"EARLY_PHASE1":7044,"PHASE1":7046,"PHASE2":7054,"PHASE3":7056,"PHASE4":7058,"NA":7060},{"trials":7045,"activeCount":98},[],{"trials":7047,"activeCount":98},[7048],{"nctId":7049,"briefTitle":7050,"status":104,"phases":7051,"primaryCompletion":646,"completion":646,"start":4287,"enrollment":3317,"conditions":7052,"interventions":7053},"NCT01397539","Single Ascending Dose Study of BIIB037 in Participants With Alzheimer's Disease",[86],[3354],[7042],{"trials":7055,"activeCount":98},[],{"trials":7057,"activeCount":98},[],{"trials":7059,"activeCount":98},[],{"trials":7061,"activeCount":98},[],{"intervention":329,"totalTrials":149,"cells":7063},{"EARLY_PHASE1":7064,"PHASE1":7066,"PHASE2":7072,"PHASE3":7074,"PHASE4":7076,"NA":7078},{"trials":7065,"activeCount":98},[],{"trials":7067,"activeCount":98},[7068],{"nctId":320,"briefTitle":321,"status":104,"phases":7069,"primaryCompletion":323,"completion":323,"start":324,"enrollment":325,"conditions":7070,"interventions":7071},[86],[327],[41,329],{"trials":7073,"activeCount":98},[],{"trials":7075,"activeCount":98},[],{"trials":7077,"activeCount":98},[],{"trials":7079,"activeCount":98},[],{"intervention":7081,"totalTrials":149,"cells":7082},"BIIB019 subcutaneous",{"EARLY_PHASE1":7083,"PHASE1":7085,"PHASE2":7093,"PHASE3":7095,"PHASE4":7097,"NA":7099},{"trials":7084,"activeCount":98},[],{"trials":7086,"activeCount":98},[7087],{"nctId":7088,"briefTitle":7089,"status":104,"phases":7090,"primaryCompletion":1715,"completion":1715,"start":1217,"enrollment":637,"conditions":7091,"interventions":7092},"NCT01929746","Daclizumab Japanese PK Study",[86],[18],[7081],{"trials":7094,"activeCount":98},[],{"trials":7096,"activeCount":98},[],{"trials":7098,"activeCount":98},[],{"trials":7100,"activeCount":98},[],{"intervention":4409,"totalTrials":149,"cells":7102},{"EARLY_PHASE1":7103,"PHASE1":7105,"PHASE2":7111,"PHASE3":7113,"PHASE4":7115,"NA":7117},{"trials":7104,"activeCount":98},[],{"trials":7106,"activeCount":98},[7107],{"nctId":4402,"briefTitle":4403,"status":104,"phases":7108,"primaryCompletion":4405,"completion":4405,"start":4406,"enrollment":1184,"conditions":7109,"interventions":7110},[86],[24],[4379,393,4409,4410],{"trials":7112,"activeCount":98},[],{"trials":7114,"activeCount":98},[],{"trials":7116,"activeCount":98},[],{"trials":7118,"activeCount":98},[],{"intervention":4410,"totalTrials":149,"cells":7120},{"EARLY_PHASE1":7121,"PHASE1":7123,"PHASE2":7129,"PHASE3":7131,"PHASE4":7133,"NA":7135},{"trials":7122,"activeCount":98},[],{"trials":7124,"activeCount":98},[7125],{"nctId":4402,"briefTitle":4403,"status":104,"phases":7126,"primaryCompletion":4405,"completion":4405,"start":4406,"enrollment":1184,"conditions":7127,"interventions":7128},[86],[24],[4379,393,4409,4410],{"trials":7130,"activeCount":98},[],{"trials":7132,"activeCount":98},[],{"trials":7134,"activeCount":98},[],{"trials":7136,"activeCount":98},[],{"intervention":7138,"totalTrials":149,"cells":7139},"dimethyl fumarate - Reference form",{"EARLY_PHASE1":7140,"PHASE1":7142,"PHASE2":7151,"PHASE3":7153,"PHASE4":7155,"NA":7157},{"trials":7141,"activeCount":98},[],{"trials":7143,"activeCount":98},[7144],{"nctId":7145,"briefTitle":7146,"status":104,"phases":7147,"primaryCompletion":955,"completion":955,"start":886,"enrollment":1902,"conditions":7148,"interventions":7149},"NCT02171208","A Healthy Volunteer Study to Establish the Bioequivalence of BG00012 Supplied by 2 Different Commercial Manufacturers",[86],[18],[7138,7150],"dimethyl fumarate - Test form",{"trials":7152,"activeCount":98},[],{"trials":7154,"activeCount":98},[],{"trials":7156,"activeCount":98},[],{"trials":7158,"activeCount":98},[],{"intervention":7150,"totalTrials":149,"cells":7160},{"EARLY_PHASE1":7161,"PHASE1":7163,"PHASE2":7169,"PHASE3":7171,"PHASE4":7173,"NA":7175},{"trials":7162,"activeCount":98},[],{"trials":7164,"activeCount":98},[7165],{"nctId":7145,"briefTitle":7146,"status":104,"phases":7166,"primaryCompletion":955,"completion":955,"start":886,"enrollment":1902,"conditions":7167,"interventions":7168},[86],[18],[7138,7150],{"trials":7170,"activeCount":98},[],{"trials":7172,"activeCount":98},[],{"trials":7174,"activeCount":98},[],{"trials":7176,"activeCount":98},[],{"intervention":6639,"totalTrials":149,"cells":7178},{"EARLY_PHASE1":7179,"PHASE1":7181,"PHASE2":7187,"PHASE3":7189,"PHASE4":7191,"NA":7193},{"trials":7180,"activeCount":98},[],{"trials":7182,"activeCount":98},[7183],{"nctId":6631,"briefTitle":6632,"status":104,"phases":7184,"primaryCompletion":6634,"completion":6634,"start":6635,"enrollment":1475,"conditions":7185,"interventions":7186},[86],[327,6637],[6624,6639],{"trials":7188,"activeCount":98},[],{"trials":7190,"activeCount":98},[],{"trials":7192,"activeCount":98},[],{"trials":7194,"activeCount":98},[],{"intervention":3111,"totalTrials":149,"cells":7196},{"EARLY_PHASE1":7197,"PHASE1":7199,"PHASE2":7205,"PHASE3":7207,"PHASE4":7209,"NA":7211},{"trials":7198,"activeCount":98},[],{"trials":7200,"activeCount":98},[7201],{"nctId":3103,"briefTitle":3104,"status":104,"phases":7202,"primaryCompletion":3106,"completion":3106,"start":3107,"enrollment":389,"conditions":7203,"interventions":7204},[86],[3109],[3087,3111],{"trials":7206,"activeCount":98},[],{"trials":7208,"activeCount":98},[],{"trials":7210,"activeCount":98},[],{"trials":7212,"activeCount":98},[],{"intervention":7214,"totalTrials":149,"cells":7215},"Omaveloxolone 50 mg",{"EARLY_PHASE1":7216,"PHASE1":7218,"PHASE2":7228,"PHASE3":7230,"PHASE4":7232,"NA":7234},{"trials":7217,"activeCount":98},[],{"trials":7219,"activeCount":98},[7220],{"nctId":7221,"briefTitle":7222,"status":104,"phases":7223,"primaryCompletion":7224,"completion":7224,"start":7225,"enrollment":1754,"conditions":7226,"interventions":7227},"NCT03902002","A Pharmacokinetic Study of Omaveloxolone in Subjects With Hepatic Impairment and Normal Hepatic Function",[86],"2020-01-27","2019-07-19",[2952],[7214],{"trials":7229,"activeCount":98},[],{"trials":7231,"activeCount":98},[],{"trials":7233,"activeCount":98},[],{"trials":7235,"activeCount":98},[],{"intervention":7237,"totalTrials":149,"cells":7238},"Bardoxolone methyl capsules 10 mg",{"EARLY_PHASE1":7239,"PHASE1":7241,"PHASE2":7252,"PHASE3":7254,"PHASE4":7256,"NA":7258},{"trials":7240,"activeCount":98},[],{"trials":7242,"activeCount":98},[7243],{"nctId":7244,"briefTitle":7245,"status":104,"phases":7246,"primaryCompletion":7247,"completion":7247,"start":7248,"enrollment":978,"conditions":7249,"interventions":7250},"NCT03264079","Effect of Itraconazole on the Pharmacokinetics of Bardoxolone Methyl in Healthy Adults",[86],"2017-11-13","2017-10-16",[30],[7237,7251],"Itraconazole capsules 100 mg",{"trials":7253,"activeCount":98},[],{"trials":7255,"activeCount":98},[],{"trials":7257,"activeCount":98},[],{"trials":7259,"activeCount":98},[],{"intervention":7251,"totalTrials":149,"cells":7261},{"EARLY_PHASE1":7262,"PHASE1":7264,"PHASE2":7270,"PHASE3":7272,"PHASE4":7274,"NA":7276},{"trials":7263,"activeCount":98},[],{"trials":7265,"activeCount":98},[7266],{"nctId":7244,"briefTitle":7245,"status":104,"phases":7267,"primaryCompletion":7247,"completion":7247,"start":7248,"enrollment":978,"conditions":7268,"interventions":7269},[86],[30],[7237,7251],{"trials":7271,"activeCount":98},[],{"trials":7273,"activeCount":98},[],{"trials":7275,"activeCount":98},[],{"trials":7277,"activeCount":98},[],{"intervention":7279,"totalTrials":149,"cells":7280},"BIIB107",{"EARLY_PHASE1":7281,"PHASE1":7283,"PHASE2":7292,"PHASE3":7294,"PHASE4":7296,"NA":7298},{"trials":7282,"activeCount":98},[],{"trials":7284,"activeCount":98},[7285],{"nctId":7286,"briefTitle":7287,"status":104,"phases":7288,"primaryCompletion":7289,"completion":7289,"start":3078,"enrollment":838,"conditions":7290,"interventions":7291},"NCT04593121","Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BIIB107 in Healthy Adult Participants",[86],"2024-03-05",[30],[7279],{"trials":7293,"activeCount":98},[],{"trials":7295,"activeCount":98},[],{"trials":7297,"activeCount":98},[],{"trials":7299,"activeCount":98},[],{"intervention":7301,"totalTrials":149,"cells":7302},"BIIB104 Reference Formulation",{"EARLY_PHASE1":7303,"PHASE1":7305,"PHASE2":7316,"PHASE3":7318,"PHASE4":7320,"NA":7322},{"trials":7304,"activeCount":98},[],{"trials":7306,"activeCount":98},[7307],{"nctId":7308,"briefTitle":7309,"status":104,"phases":7310,"primaryCompletion":7311,"completion":7311,"start":7312,"enrollment":876,"conditions":7313,"interventions":7314},"NCT05152485","A Study to Evaluate the Relative Bioavailability of Two Formulations of BIIB104 and Assess the Effect of Food on the Pharmacokinetics of BIIB104 Following Administration of a Single, Fixed, Oral Dose of BIIB104 in Healthy Participants",[86],"2022-01-31","2021-12-15",[30],[7301,7315],"BIIB104 Test Formulation",{"trials":7317,"activeCount":98},[],{"trials":7319,"activeCount":98},[],{"trials":7321,"activeCount":98},[],{"trials":7323,"activeCount":98},[],{"intervention":7315,"totalTrials":149,"cells":7325},{"EARLY_PHASE1":7326,"PHASE1":7328,"PHASE2":7334,"PHASE3":7336,"PHASE4":7338,"NA":7340},{"trials":7327,"activeCount":98},[],{"trials":7329,"activeCount":98},[7330],{"nctId":7308,"briefTitle":7309,"status":104,"phases":7331,"primaryCompletion":7311,"completion":7311,"start":7312,"enrollment":876,"conditions":7332,"interventions":7333},[86],[30],[7301,7315],{"trials":7335,"activeCount":98},[],{"trials":7337,"activeCount":98},[],{"trials":7339,"activeCount":98},[],{"trials":7341,"activeCount":98},[],{"intervention":4243,"totalTrials":149,"cells":7343},{"EARLY_PHASE1":7344,"PHASE1":7346,"PHASE2":7352,"PHASE3":7354,"PHASE4":7356,"NA":7358},{"trials":7345,"activeCount":98},[],{"trials":7347,"activeCount":98},[7348],{"nctId":4237,"briefTitle":4238,"status":104,"phases":7349,"primaryCompletion":4240,"completion":4240,"start":2394,"enrollment":159,"conditions":7350,"interventions":7351},[86],[18],[4204,4243],{"trials":7353,"activeCount":98},[],{"trials":7355,"activeCount":98},[],{"trials":7357,"activeCount":98},[],{"trials":7359,"activeCount":98},[],{"intervention":7361,"totalTrials":149,"cells":7362},"BIIB023 - low dose IV Dose",{"EARLY_PHASE1":7363,"PHASE1":7365,"PHASE2":7375,"PHASE3":7377,"PHASE4":7379,"NA":7381},{"trials":7364,"activeCount":98},[],{"trials":7366,"activeCount":98},[7367],{"nctId":7368,"briefTitle":7369,"status":104,"phases":7370,"primaryCompletion":2437,"completion":2437,"start":7371,"enrollment":1754,"conditions":7372,"interventions":7373},"NCT01407406","Phase 1 Study to Evaluate the PK, Safety, Tolerability of BIIB023 in Chinese, Japanese, and Caucasian Healthy Volunteers",[86],"2011-09",[30],[7361,7374],"BIIB023 - high dose IV Dose",{"trials":7376,"activeCount":98},[],{"trials":7378,"activeCount":98},[],{"trials":7380,"activeCount":98},[],{"trials":7382,"activeCount":98},[],{"intervention":7374,"totalTrials":149,"cells":7384},{"EARLY_PHASE1":7385,"PHASE1":7387,"PHASE2":7393,"PHASE3":7395,"PHASE4":7397,"NA":7399},{"trials":7386,"activeCount":98},[],{"trials":7388,"activeCount":98},[7389],{"nctId":7368,"briefTitle":7369,"status":104,"phases":7390,"primaryCompletion":2437,"completion":2437,"start":7371,"enrollment":1754,"conditions":7391,"interventions":7392},[86],[30],[7361,7374],{"trials":7394,"activeCount":98},[],{"trials":7396,"activeCount":98},[],{"trials":7398,"activeCount":98},[],{"trials":7400,"activeCount":98},[],{"intervention":7402,"totalTrials":149,"cells":7403},"BIIB014 50mg",{"EARLY_PHASE1":7404,"PHASE1":7406,"PHASE2":7415,"PHASE3":7417,"PHASE4":7419,"NA":7421},{"trials":7405,"activeCount":98},[],{"trials":7407,"activeCount":98},[7408],{"nctId":7409,"briefTitle":7410,"status":104,"phases":7411,"primaryCompletion":1982,"completion":1982,"start":2351,"enrollment":947,"conditions":7412,"interventions":7413},"NCT01035515","BIIB014 Cardiovascular Monitoring Study",[86],[18],[7402,7414],"BIIB014 100mg",{"trials":7416,"activeCount":98},[],{"trials":7418,"activeCount":98},[],{"trials":7420,"activeCount":98},[],{"trials":7422,"activeCount":98},[],{"intervention":7414,"totalTrials":149,"cells":7424},{"EARLY_PHASE1":7425,"PHASE1":7427,"PHASE2":7433,"PHASE3":7435,"PHASE4":7437,"NA":7439},{"trials":7426,"activeCount":98},[],{"trials":7428,"activeCount":98},[7429],{"nctId":7409,"briefTitle":7410,"status":104,"phases":7430,"primaryCompletion":1982,"completion":1982,"start":2351,"enrollment":947,"conditions":7431,"interventions":7432},[86],[18],[7402,7414],{"trials":7434,"activeCount":98},[],{"trials":7436,"activeCount":98},[],{"trials":7438,"activeCount":98},[],{"trials":7440,"activeCount":98},[],{"intervention":112,"totalTrials":149,"cells":7442},{"EARLY_PHASE1":7443,"PHASE1":7445,"PHASE2":7451,"PHASE3":7453,"PHASE4":7455,"NA":7457},{"trials":7444,"activeCount":98},[],{"trials":7446,"activeCount":98},[7447],{"nctId":102,"briefTitle":103,"status":104,"phases":7448,"primaryCompletion":106,"completion":107,"start":108,"enrollment":109,"conditions":7449,"interventions":7450},[86],[30],[93,112],{"trials":7452,"activeCount":98},[],{"trials":7454,"activeCount":98},[],{"trials":7456,"activeCount":98},[],{"trials":7458,"activeCount":98},[],{"intervention":7460,"totalTrials":149,"cells":7461},"GSK drug",{"EARLY_PHASE1":7462,"PHASE1":7464,"PHASE2":7473,"PHASE3":7475,"PHASE4":7477,"NA":7479},{"trials":7463,"activeCount":98},[],{"trials":7465,"activeCount":98},[7466],{"nctId":7467,"briefTitle":7468,"status":104,"phases":7469,"primaryCompletion":6504,"completion":6504,"start":7470,"enrollment":2100,"conditions":7471,"interventions":7472},"NCT00488566","GSK Drug Single Dose Escalation And Their Effect On Resting Motor Threshold In Healthy Volunteers",[86],"2007-05-31",[6508],[7460],{"trials":7474,"activeCount":98},[],{"trials":7476,"activeCount":98},[],{"trials":7478,"activeCount":98},[],{"trials":7480,"activeCount":98},[],{"intervention":6613,"totalTrials":149,"cells":7482},{"EARLY_PHASE1":7483,"PHASE1":7485,"PHASE2":7491,"PHASE3":7493,"PHASE4":7495,"NA":7497},{"trials":7484,"activeCount":98},[],{"trials":7486,"activeCount":98},[7487],{"nctId":6606,"briefTitle":6607,"status":522,"phases":7488,"primaryCompletion":6609,"completion":6609,"start":6514,"enrollment":978,"conditions":7489,"interventions":7490},[86],[6611,3118],[6613,3101,6614],{"trials":7492,"activeCount":98},[],{"trials":7494,"activeCount":98},[],{"trials":7496,"activeCount":98},[],{"trials":7498,"activeCount":98},[],{"intervention":6614,"totalTrials":149,"cells":7500},{"EARLY_PHASE1":7501,"PHASE1":7503,"PHASE2":7509,"PHASE3":7511,"PHASE4":7513,"NA":7515},{"trials":7502,"activeCount":98},[],{"trials":7504,"activeCount":98},[7505],{"nctId":6606,"briefTitle":6607,"status":522,"phases":7506,"primaryCompletion":6609,"completion":6609,"start":6514,"enrollment":978,"conditions":7507,"interventions":7508},[86],[6611,3118],[6613,3101,6614],{"trials":7510,"activeCount":98},[],{"trials":7512,"activeCount":98},[],{"trials":7514,"activeCount":98},[],{"trials":7516,"activeCount":98},[],{"intervention":7518,"totalTrials":149,"cells":7519},"IDEC-152",{"EARLY_PHASE1":7520,"PHASE1":7522,"PHASE2":7531,"PHASE3":7533,"PHASE4":7535,"NA":7537},{"trials":7521,"activeCount":98},[],{"trials":7523,"activeCount":98},[7524],{"nctId":7525,"briefTitle":7526,"status":104,"phases":7527,"primaryCompletion":7528,"completion":1535,"start":5166,"enrollment":316,"conditions":7529,"interventions":7530},"NCT00046488","Safety and Efficacy of IDEC-152 in the Treatment of Chronic Lymphocytic Leukemia (CLL)",[86],"2004-04",[5196],[7518],{"trials":7532,"activeCount":98},[],{"trials":7534,"activeCount":98},[],{"trials":7536,"activeCount":98},[],{"trials":7538,"activeCount":98},[],{"intervention":7540,"totalTrials":149,"cells":7541},"Glyburide for",{"EARLY_PHASE1":7542,"PHASE1":7544,"PHASE2":7556,"PHASE3":7558,"PHASE4":7560,"NA":7562},{"trials":7543,"activeCount":98},[],{"trials":7545,"activeCount":98},[7546],{"nctId":7547,"briefTitle":7548,"status":104,"phases":7549,"primaryCompletion":7550,"completion":7550,"start":7551,"enrollment":1027,"conditions":7552,"interventions":7555},"NCT01132703","Safety Study of RP-1127 (Glyburide for Injection) in Healthy Volunteers",[86],"2010-05-07","2010-01-07",[7553,7554],"Traumatic Brain Injury","Stroke",[7540],{"trials":7557,"activeCount":98},[],{"trials":7559,"activeCount":98},[],{"trials":7561,"activeCount":98},[],{"trials":7563,"activeCount":98},[],{"intervention":3129,"totalTrials":149,"cells":7565},{"EARLY_PHASE1":7566,"PHASE1":7568,"PHASE2":7574,"PHASE3":7576,"PHASE4":7578,"NA":7580},{"trials":7567,"activeCount":98},[],{"trials":7569,"activeCount":98},[7570],{"nctId":3121,"briefTitle":3122,"status":104,"phases":7571,"primaryCompletion":3124,"completion":3124,"start":3125,"enrollment":876,"conditions":7572,"interventions":7573},[86],[3127],[3087,3129],{"trials":7575,"activeCount":98},[],{"trials":7577,"activeCount":98},[],{"trials":7579,"activeCount":98},[],{"trials":7581,"activeCount":98},[],{"intervention":7583,"totalTrials":149,"cells":7584},"BIIB022 With Paclitaxel and Carboplatin",{"EARLY_PHASE1":7585,"PHASE1":7587,"PHASE2":7596,"PHASE3":7598,"PHASE4":7600,"NA":7602},{"trials":7586,"activeCount":98},[],{"trials":7588,"activeCount":98},[7589],{"nctId":7590,"briefTitle":7591,"status":104,"phases":7592,"primaryCompletion":7371,"completion":7371,"start":2270,"enrollment":1000,"conditions":7593,"interventions":7595},"NCT00970580","A Study of BIIB022 in Combination With Paclitaxel and Carboplatin in Subjects With Non-Small Cell Lung Cancer",[86],[7594],"Non-Small Cell Lung Cancer",[7583],{"trials":7597,"activeCount":98},[],{"trials":7599,"activeCount":98},[],{"trials":7601,"activeCount":98},[],{"trials":7603,"activeCount":98},[],{"intervention":366,"totalTrials":149,"cells":7605},{"EARLY_PHASE1":7606,"PHASE1":7608,"PHASE2":7614,"PHASE3":7616,"PHASE4":7618,"NA":7620},{"trials":7607,"activeCount":98},[],{"trials":7609,"activeCount":98},[7610],{"nctId":357,"briefTitle":358,"status":104,"phases":7611,"primaryCompletion":360,"completion":361,"start":362,"enrollment":363,"conditions":7612,"interventions":7613},[86],[327],[41,366,367,368,369,370,371,372,373],{"trials":7615,"activeCount":98},[],{"trials":7617,"activeCount":98},[],{"trials":7619,"activeCount":98},[],{"trials":7621,"activeCount":98},[],{"intervention":367,"totalTrials":149,"cells":7623},{"EARLY_PHASE1":7624,"PHASE1":7626,"PHASE2":7632,"PHASE3":7634,"PHASE4":7636,"NA":7638},{"trials":7625,"activeCount":98},[],{"trials":7627,"activeCount":98},[7628],{"nctId":357,"briefTitle":358,"status":104,"phases":7629,"primaryCompletion":360,"completion":361,"start":362,"enrollment":363,"conditions":7630,"interventions":7631},[86],[327],[41,366,367,368,369,370,371,372,373],{"trials":7633,"activeCount":98},[],{"trials":7635,"activeCount":98},[],{"trials":7637,"activeCount":98},[],{"trials":7639,"activeCount":98},[],{"intervention":368,"totalTrials":149,"cells":7641},{"EARLY_PHASE1":7642,"PHASE1":7644,"PHASE2":7650,"PHASE3":7652,"PHASE4":7654,"NA":7656},{"trials":7643,"activeCount":98},[],{"trials":7645,"activeCount":98},[7646],{"nctId":357,"briefTitle":358,"status":104,"phases":7647,"primaryCompletion":360,"completion":361,"start":362,"enrollment":363,"conditions":7648,"interventions":7649},[86],[327],[41,366,367,368,369,370,371,372,373],{"trials":7651,"activeCount":98},[],{"trials":7653,"activeCount":98},[],{"trials":7655,"activeCount":98},[],{"trials":7657,"activeCount":98},[],{"intervention":371,"totalTrials":149,"cells":7659},{"EARLY_PHASE1":7660,"PHASE1":7662,"PHASE2":7668,"PHASE3":7670,"PHASE4":7672,"NA":7674},{"trials":7661,"activeCount":98},[],{"trials":7663,"activeCount":98},[7664],{"nctId":357,"briefTitle":358,"status":104,"phases":7665,"primaryCompletion":360,"completion":361,"start":362,"enrollment":363,"conditions":7666,"interventions":7667},[86],[327],[41,366,367,368,369,370,371,372,373],{"trials":7669,"activeCount":98},[],{"trials":7671,"activeCount":98},[],{"trials":7673,"activeCount":98},[],{"trials":7675,"activeCount":98},[],{"intervention":373,"totalTrials":149,"cells":7677},{"EARLY_PHASE1":7678,"PHASE1":7680,"PHASE2":7686,"PHASE3":7688,"PHASE4":7690,"NA":7692},{"trials":7679,"activeCount":98},[],{"trials":7681,"activeCount":98},[7682],{"nctId":357,"briefTitle":358,"status":104,"phases":7683,"primaryCompletion":360,"completion":361,"start":362,"enrollment":363,"conditions":7684,"interventions":7685},[86],[327],[41,366,367,368,369,370,371,372,373],{"trials":7687,"activeCount":98},[],{"trials":7689,"activeCount":98},[],{"trials":7691,"activeCount":98},[],{"trials":7693,"activeCount":98},[],{"intervention":7695,"totalTrials":149,"cells":7696},"SAGE-217 high dose",{"EARLY_PHASE1":7697,"PHASE1":7699,"PHASE2":7711,"PHASE3":7713,"PHASE4":7715,"NA":7717},{"trials":7698,"activeCount":98},[],{"trials":7700,"activeCount":98},[7701],{"nctId":7702,"briefTitle":7703,"status":104,"phases":7704,"primaryCompletion":7705,"completion":7706,"start":7707,"enrollment":1090,"conditions":7708,"interventions":7709},"NCT03284931","A Study to Assess the Pharmacodynamic Effects of SAGE-217 in Healthy Adults Using an Insomnia Model",[86],"2017-12-04","2017-12-18","2017-09-14",[18],[7695,7710],"SAGE-217 low dose",{"trials":7712,"activeCount":98},[],{"trials":7714,"activeCount":98},[],{"trials":7716,"activeCount":98},[],{"trials":7718,"activeCount":98},[],{"intervention":7710,"totalTrials":149,"cells":7720},{"EARLY_PHASE1":7721,"PHASE1":7723,"PHASE2":7729,"PHASE3":7731,"PHASE4":7733,"NA":7735},{"trials":7722,"activeCount":98},[],{"trials":7724,"activeCount":98},[7725],{"nctId":7702,"briefTitle":7703,"status":104,"phases":7726,"primaryCompletion":7705,"completion":7706,"start":7707,"enrollment":1090,"conditions":7727,"interventions":7728},[86],[18],[7695,7710],{"trials":7730,"activeCount":98},[],{"trials":7732,"activeCount":98},[],{"trials":7734,"activeCount":98},[],{"trials":7736,"activeCount":98},[],{"intervention":7738,"totalTrials":149,"cells":7739},"BG9928",{"EARLY_PHASE1":7740,"PHASE1":7742,"PHASE2":7751,"PHASE3":7753,"PHASE4":7755,"NA":7757},{"trials":7741,"activeCount":98},[],{"trials":7743,"activeCount":98},[7744],{"nctId":7745,"briefTitle":7746,"status":104,"phases":7747,"primaryCompletion":2395,"completion":2395,"start":2418,"enrollment":7748,"conditions":7749,"interventions":7750},"NCT00858156","BG9928 in Subjects With Hepatic Impairment",[86],23,[2952],[7738],{"trials":7752,"activeCount":98},[],{"trials":7754,"activeCount":98},[],{"trials":7756,"activeCount":98},[],{"trials":7758,"activeCount":98},[],{"intervention":7760,"totalTrials":149,"cells":7761},"Test product",{"EARLY_PHASE1":7762,"PHASE1":7764,"PHASE2":7773,"PHASE3":7775,"PHASE4":7777,"NA":7779},{"trials":7763,"activeCount":98},[],{"trials":7765,"activeCount":98},[7766],{"nctId":7767,"briefTitle":7768,"status":104,"phases":7769,"primaryCompletion":4240,"completion":4240,"start":2394,"enrollment":1902,"conditions":7770,"interventions":7771},"NCT01632449","Study in Healthy Volunteers to Establish the Bioequivalence of Two Different Manufacturers.",[86],[30],[7760,7772],"Reference product",{"trials":7774,"activeCount":98},[],{"trials":7776,"activeCount":98},[],{"trials":7778,"activeCount":98},[],{"trials":7780,"activeCount":98},[],{"intervention":7772,"totalTrials":149,"cells":7782},{"EARLY_PHASE1":7783,"PHASE1":7785,"PHASE2":7791,"PHASE3":7793,"PHASE4":7795,"NA":7797},{"trials":7784,"activeCount":98},[],{"trials":7786,"activeCount":98},[7787],{"nctId":7767,"briefTitle":7768,"status":104,"phases":7788,"primaryCompletion":4240,"completion":4240,"start":2394,"enrollment":1902,"conditions":7789,"interventions":7790},[86],[30],[7760,7772],{"trials":7792,"activeCount":98},[],{"trials":7794,"activeCount":98},[],{"trials":7796,"activeCount":98},[],{"trials":7798,"activeCount":98},[],{"intervention":7800,"totalTrials":149,"cells":7801},"hCBE-11",{"EARLY_PHASE1":7802,"PHASE1":7804,"PHASE2":7812,"PHASE3":7814,"PHASE4":7816,"NA":7818},{"trials":7803,"activeCount":98},[],{"trials":7805,"activeCount":98},[7806],{"nctId":7807,"briefTitle":7808,"status":522,"phases":7809,"primaryCompletion":2448,"completion":2448,"start":1605,"enrollment":33,"conditions":7810,"interventions":7811},"NCT00105170","Safety and Tolerability of hCBE-11 in Subjects With Advanced Solid Tumors",[86],[6358],[7800],{"trials":7813,"activeCount":98},[],{"trials":7815,"activeCount":98},[],{"trials":7817,"activeCount":98},[],{"trials":7819,"activeCount":98},[],{"intervention":7821,"totalTrials":149,"cells":7822},"BIIB100",{"EARLY_PHASE1":7823,"PHASE1":7825,"PHASE2":7836,"PHASE3":7838,"PHASE4":7840,"NA":7842},{"trials":7824,"activeCount":98},[],{"trials":7826,"activeCount":98},[7827],{"nctId":7828,"briefTitle":7829,"status":104,"phases":7830,"primaryCompletion":7831,"completion":7831,"start":7832,"enrollment":7833,"conditions":7834,"interventions":7835},"NCT03945279","A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB100 Administered Orally to Adults With Amyotrophic Lateral Sclerosis",[86],"2021-06-21","2019-05-30",49,[137],[7821],{"trials":7837,"activeCount":98},[],{"trials":7839,"activeCount":98},[],{"trials":7841,"activeCount":98},[],{"trials":7843,"activeCount":98},[],{"intervention":7845,"totalTrials":149,"cells":7846},"BIIB113",{"EARLY_PHASE1":7847,"PHASE1":7849,"PHASE2":7860,"PHASE3":7862,"PHASE4":7864,"NA":7866},{"trials":7848,"activeCount":98},[],{"trials":7850,"activeCount":98},[7851],{"nctId":7852,"briefTitle":7853,"status":104,"phases":7854,"primaryCompletion":7855,"completion":7855,"start":7856,"enrollment":4347,"conditions":7857,"interventions":7858},"NCT05195008","A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics, With Target Occupancy Study of BIIB113 in Healthy Participants",[86],"2023-07-10","2022-01-24",[24],[7845,7859],"11^C]BIO-1819578",{"trials":7861,"activeCount":98},[],{"trials":7863,"activeCount":98},[],{"trials":7865,"activeCount":98},[],{"trials":7867,"activeCount":98},[],{"intervention":7859,"totalTrials":149,"cells":7869},{"EARLY_PHASE1":7870,"PHASE1":7872,"PHASE2":7878,"PHASE3":7880,"PHASE4":7882,"NA":7884},{"trials":7871,"activeCount":98},[],{"trials":7873,"activeCount":98},[7874],{"nctId":7852,"briefTitle":7853,"status":104,"phases":7875,"primaryCompletion":7855,"completion":7855,"start":7856,"enrollment":4347,"conditions":7876,"interventions":7877},[86],[24],[7845,7859],{"trials":7879,"activeCount":98},[],{"trials":7881,"activeCount":98},[],{"trials":7883,"activeCount":98},[],{"trials":7885,"activeCount":98},[],{"intervention":6677,"totalTrials":149,"cells":7887},{"EARLY_PHASE1":7888,"PHASE1":7890,"PHASE2":7896,"PHASE3":7898,"PHASE4":7900,"NA":7902},{"trials":7889,"activeCount":98},[],{"trials":7891,"activeCount":98},[7892],{"nctId":6671,"briefTitle":6672,"status":104,"phases":7893,"primaryCompletion":1890,"completion":1890,"start":2395,"enrollment":22,"conditions":7894,"interventions":7895},[86],[6675],[6657,6677],{"trials":7897,"activeCount":98},[],{"trials":7899,"activeCount":98},[],{"trials":7901,"activeCount":98},[],{"trials":7903,"activeCount":98},[],{"intervention":7905,"totalTrials":149,"cells":7906},"BIIB074 Treatment A",{"EARLY_PHASE1":7907,"PHASE1":7909,"PHASE2":7923,"PHASE3":7925,"PHASE4":7927,"NA":7929},{"trials":7908,"activeCount":98},[],{"trials":7910,"activeCount":98},[7911],{"nctId":7912,"briefTitle":7913,"status":104,"phases":7914,"primaryCompletion":1228,"completion":1228,"start":7915,"enrollment":1016,"conditions":7916,"interventions":7919},"NCT02951221","New Formulation and Food Effect Study of BIIB074",[86],"2016-12",[7917,7918],"Trigeminal Neuralgia (TN)","Other Neuropathic Pain",[7905,7920,7921,7922],"BIIB074 Treatment B","BIIB074 Treatment C","BIIB074 Treatment D",{"trials":7924,"activeCount":98},[],{"trials":7926,"activeCount":98},[],{"trials":7928,"activeCount":98},[],{"trials":7930,"activeCount":98},[],{"intervention":7920,"totalTrials":149,"cells":7932},{"EARLY_PHASE1":7933,"PHASE1":7935,"PHASE2":7941,"PHASE3":7943,"PHASE4":7945,"NA":7947},{"trials":7934,"activeCount":98},[],{"trials":7936,"activeCount":98},[7937],{"nctId":7912,"briefTitle":7913,"status":104,"phases":7938,"primaryCompletion":1228,"completion":1228,"start":7915,"enrollment":1016,"conditions":7939,"interventions":7940},[86],[7917,7918],[7905,7920,7921,7922],{"trials":7942,"activeCount":98},[],{"trials":7944,"activeCount":98},[],{"trials":7946,"activeCount":98},[],{"trials":7948,"activeCount":98},[],{"intervention":7921,"totalTrials":149,"cells":7950},{"EARLY_PHASE1":7951,"PHASE1":7953,"PHASE2":7959,"PHASE3":7961,"PHASE4":7963,"NA":7965},{"trials":7952,"activeCount":98},[],{"trials":7954,"activeCount":98},[7955],{"nctId":7912,"briefTitle":7913,"status":104,"phases":7956,"primaryCompletion":1228,"completion":1228,"start":7915,"enrollment":1016,"conditions":7957,"interventions":7958},[86],[7917,7918],[7905,7920,7921,7922],{"trials":7960,"activeCount":98},[],{"trials":7962,"activeCount":98},[],{"trials":7964,"activeCount":98},[],{"trials":7966,"activeCount":98},[],{"intervention":7922,"totalTrials":149,"cells":7968},{"EARLY_PHASE1":7969,"PHASE1":7971,"PHASE2":7977,"PHASE3":7979,"PHASE4":7981,"NA":7983},{"trials":7970,"activeCount":98},[],{"trials":7972,"activeCount":98},[7973],{"nctId":7912,"briefTitle":7913,"status":104,"phases":7974,"primaryCompletion":1228,"completion":1228,"start":7915,"enrollment":1016,"conditions":7975,"interventions":7976},[86],[7917,7918],[7905,7920,7921,7922],{"trials":7978,"activeCount":98},[],{"trials":7980,"activeCount":98},[],{"trials":7982,"activeCount":98},[],{"trials":7984,"activeCount":98},[],{"intervention":1877,"totalTrials":149,"cells":7986},{"EARLY_PHASE1":7987,"PHASE1":7989,"PHASE2":7995,"PHASE3":7997,"PHASE4":7999,"NA":8001},{"trials":7988,"activeCount":98},[],{"trials":7990,"activeCount":98},[7991],{"nctId":1872,"briefTitle":1873,"status":104,"phases":7992,"primaryCompletion":1473,"completion":1473,"start":1230,"enrollment":389,"conditions":7993,"interventions":7994},[86],[15],[1857,1877],{"trials":7996,"activeCount":98},[],{"trials":7998,"activeCount":98},[],{"trials":8000,"activeCount":98},[],{"trials":8002,"activeCount":98},[],{"intervention":8004,"totalTrials":149,"cells":8005},"BIIB068",{"EARLY_PHASE1":8006,"PHASE1":8008,"PHASE2":8017,"PHASE3":8019,"PHASE4":8021,"NA":8023},{"trials":8007,"activeCount":98},[],{"trials":8009,"activeCount":98},[8010],{"nctId":8011,"briefTitle":8012,"status":104,"phases":8013,"primaryCompletion":7915,"completion":7915,"start":1921,"enrollment":876,"conditions":8014,"interventions":8016},"NCT02829541","A Phase 1, Single-Ascending-Dose, Safety, Tolerability, Pharmacokinetic(PK), and Pharmacodynamic(PD) Study of BIIB068 in Healthy Participants",[86],[8015],"Systemic Lupos Erythematosus, SLE",[8004],{"trials":8018,"activeCount":98},[],{"trials":8020,"activeCount":98},[],{"trials":8022,"activeCount":98},[],{"trials":8024,"activeCount":98},[],{"intervention":8026,"totalTrials":149,"cells":8027},"BIIB076",{"EARLY_PHASE1":8028,"PHASE1":8030,"PHASE2":8040,"PHASE3":8042,"PHASE4":8044,"NA":8046},{"trials":8029,"activeCount":98},[],{"trials":8031,"activeCount":98},[8032],{"nctId":8033,"briefTitle":8034,"status":104,"phases":8035,"primaryCompletion":8036,"completion":8036,"start":8037,"enrollment":1116,"conditions":8038,"interventions":8039},"NCT03056729","Single-Ascending-Dose Study of BIIB076 in Healthy Volunteers and Participants With Alzheimer's Disease",[86],"2020-03-03","2017-02-17",[3354,24],[8026],{"trials":8041,"activeCount":98},[],{"trials":8043,"activeCount":98},[],{"trials":8045,"activeCount":98},[],{"trials":8047,"activeCount":98},[],{"intervention":8049,"totalTrials":149,"cells":8050},"RTA 901 Capsules, 10 or 40 mg",{"EARLY_PHASE1":8051,"PHASE1":8053,"PHASE2":8063,"PHASE3":8065,"PHASE4":8067,"NA":8069},{"trials":8052,"activeCount":98},[],{"trials":8054,"activeCount":98},[8055],{"nctId":8056,"briefTitle":8057,"status":104,"phases":8058,"primaryCompletion":8059,"completion":8059,"start":8060,"enrollment":1407,"conditions":8061,"interventions":8062},"NCT02666963","A Study of the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of RTA 901 in Healthy Adults",[86],"2017-07-23","2017-01-01",[18],[8049],{"trials":8064,"activeCount":98},[],{"trials":8066,"activeCount":98},[],{"trials":8068,"activeCount":98},[],{"trials":8070,"activeCount":98},[],{"intervention":8072,"totalTrials":149,"cells":8073},"Galiximab",{"EARLY_PHASE1":8074,"PHASE1":8076,"PHASE2":8085,"PHASE3":8087,"PHASE4":8089,"NA":8091},{"trials":8075,"activeCount":98},[],{"trials":8077,"activeCount":98},[8078],{"nctId":8079,"briefTitle":8080,"status":522,"phases":8081,"primaryCompletion":1580,"completion":3605,"start":8082,"enrollment":325,"conditions":8083,"interventions":8084},"NCT00651443","Mechanism of Action of Galiximab in Subjects With Previously Untreated Follicular Non-Hodgkin's Lymphoma",[86],"2008-08",[3747],[8072],{"trials":8086,"activeCount":98},[],{"trials":8088,"activeCount":98},[],{"trials":8090,"activeCount":98},[],{"trials":8092,"activeCount":98},[],{"intervention":4282,"totalTrials":149,"cells":8094},{"EARLY_PHASE1":8095,"PHASE1":8097,"PHASE2":8103,"PHASE3":8105,"PHASE4":8107,"NA":8109},{"trials":8096,"activeCount":98},[],{"trials":8098,"activeCount":98},[8099],{"nctId":4276,"briefTitle":4277,"status":104,"phases":8100,"primaryCompletion":1868,"completion":1868,"start":4279,"enrollment":3224,"conditions":8101,"interventions":8102},[86],[4249],[4204,4282,4282],{"trials":8104,"activeCount":98},[],{"trials":8106,"activeCount":98},[],{"trials":8108,"activeCount":98},[],{"trials":8110,"activeCount":98},[],{"intervention":8112,"totalTrials":149,"cells":8113},"BIIB800",{"EARLY_PHASE1":8114,"PHASE1":8116,"PHASE2":8128,"PHASE3":8130,"PHASE4":8132,"NA":8134},{"trials":8115,"activeCount":98},[],{"trials":8117,"activeCount":98},[8118],{"nctId":8119,"briefTitle":8120,"status":104,"phases":8121,"primaryCompletion":8122,"completion":8123,"start":8124,"enrollment":452,"conditions":8125,"interventions":8126},"NCT06262477","A Study to Evaluate the Pharmacokinetics, Safety and Immunogenicity of BIIB800 Subcutaneously (SC) Compared to Actemra® in Healthy Male Participants",[86],"2024-09-25","2024-10-04","2024-01-02",[24],[8112,8127],"Actemra",{"trials":8129,"activeCount":98},[],{"trials":8131,"activeCount":98},[],{"trials":8133,"activeCount":98},[],{"trials":8135,"activeCount":98},[],{"intervention":8127,"totalTrials":149,"cells":8137},{"EARLY_PHASE1":8138,"PHASE1":8140,"PHASE2":8146,"PHASE3":8148,"PHASE4":8150,"NA":8152},{"trials":8139,"activeCount":98},[],{"trials":8141,"activeCount":98},[8142],{"nctId":8119,"briefTitle":8120,"status":104,"phases":8143,"primaryCompletion":8122,"completion":8123,"start":8124,"enrollment":452,"conditions":8144,"interventions":8145},[86],[24],[8112,8127],{"trials":8147,"activeCount":98},[],{"trials":8149,"activeCount":98},[],{"trials":8151,"activeCount":98},[],{"trials":8153,"activeCount":98},[],{"intervention":2946,"totalTrials":149,"cells":8155},{"EARLY_PHASE1":8156,"PHASE1":8158,"PHASE2":8164,"PHASE3":8166,"PHASE4":8168,"NA":8170},{"trials":8157,"activeCount":98},[],{"trials":8159,"activeCount":98},[8160],{"nctId":2937,"briefTitle":2938,"status":522,"phases":8161,"primaryCompletion":2940,"completion":2940,"start":2941,"enrollment":11,"conditions":8162,"interventions":8163},[86],[2943,2944],[2887,2887,2887,2887,2887,2887,2887,2946,2887],{"trials":8165,"activeCount":98},[],{"trials":8167,"activeCount":98},[],{"trials":8169,"activeCount":98},[],{"trials":8171,"activeCount":98},[],{"intervention":4563,"totalTrials":149,"cells":8173},{"EARLY_PHASE1":8174,"PHASE1":8176,"PHASE2":8182,"PHASE3":8184,"PHASE4":8186,"NA":8188},{"trials":8175,"activeCount":98},[],{"trials":8177,"activeCount":98},[8178],{"nctId":4558,"briefTitle":4559,"status":104,"phases":8179,"primaryCompletion":1453,"completion":1453,"start":653,"enrollment":8,"conditions":8180,"interventions":8181},[86],[18],[2013,4563],{"trials":8183,"activeCount":98},[],{"trials":8185,"activeCount":98},[],{"trials":8187,"activeCount":98},[],{"trials":8189,"activeCount":98},[],{"intervention":8191,"totalTrials":149,"cells":8192},"Study Drug",{"EARLY_PHASE1":8193,"PHASE1":8195,"PHASE2":8204,"PHASE3":8206,"PHASE4":8208,"NA":8210},{"trials":8194,"activeCount":98},[],{"trials":8196,"activeCount":98},[8197],{"nctId":8198,"briefTitle":8199,"status":104,"phases":8200,"primaryCompletion":1473,"completion":1473,"start":955,"enrollment":1431,"conditions":8201,"interventions":8202},"NCT02201849","A Study of ALKS 8700, a Monomethyl Fumarate (MMF) Molecule, in Healthy Adults",[86],[15],[8191,8203],"Active Control",{"trials":8205,"activeCount":98},[],{"trials":8207,"activeCount":98},[],{"trials":8209,"activeCount":98},[],{"trials":8211,"activeCount":98},[],{"intervention":8203,"totalTrials":149,"cells":8213},{"EARLY_PHASE1":8214,"PHASE1":8216,"PHASE2":8222,"PHASE3":8224,"PHASE4":8226,"NA":8228},{"trials":8215,"activeCount":98},[],{"trials":8217,"activeCount":98},[8218],{"nctId":8198,"briefTitle":8199,"status":104,"phases":8219,"primaryCompletion":1473,"completion":1473,"start":955,"enrollment":1431,"conditions":8220,"interventions":8221},[86],[15],[8191,8203],{"trials":8223,"activeCount":98},[],{"trials":8225,"activeCount":98},[],{"trials":8227,"activeCount":98},[],{"trials":8229,"activeCount":98},[],{"intervention":8231,"totalTrials":149,"cells":8232},"BIIB063",{"EARLY_PHASE1":8233,"PHASE1":8235,"PHASE2":8244,"PHASE3":8246,"PHASE4":8248,"NA":8250},{"trials":8234,"activeCount":98},[],{"trials":8236,"activeCount":98},[8237],{"nctId":8238,"briefTitle":8239,"status":522,"phases":8240,"primaryCompletion":8241,"completion":8241,"start":665,"enrollment":3224,"conditions":8242,"interventions":8243},"NCT02555085","Single Ascending Doses of BIIB063 in Healthy Volunteers",[86],"2016-06-01",[18],[8231],{"trials":8245,"activeCount":98},[],{"trials":8247,"activeCount":98},[],{"trials":8249,"activeCount":98},[],{"trials":8251,"activeCount":98},[],{"intervention":8253,"totalTrials":149,"cells":8254},"Interferon-beta",{"EARLY_PHASE1":8255,"PHASE1":8257,"PHASE2":8271,"PHASE3":8273,"PHASE4":8275,"NA":8277},{"trials":8256,"activeCount":98},[],{"trials":8258,"activeCount":98},[8259],{"nctId":8260,"briefTitle":8261,"status":104,"phases":8262,"completion":8263,"start":8264,"enrollment":159,"conditions":8265,"interventions":8270},"NCT00031083","Dose Escalation Study to Determine the Safety of IFN-Beta Gene Transfer in the Treatment of Grade III & Grade IV Gliomas",[86],"2003-10-10","2002-04-02",[8266,8267,8268,8269],"Glioblastoma Multiforme","Anaplastic Astrocytoma","Oligoastrocytoma, Mixed","Gliosarcoma",[8253],{"trials":8272,"activeCount":98},[],{"trials":8274,"activeCount":98},[],{"trials":8276,"activeCount":98},[],{"trials":8278,"activeCount":98},[],{"intervention":8280,"totalTrials":149,"cells":8281},"[14C]-Omaveloxolone",{"EARLY_PHASE1":8282,"PHASE1":8284,"PHASE2":8295,"PHASE3":8297,"PHASE4":8299,"NA":8301},{"trials":8283,"activeCount":98},[],{"trials":8285,"activeCount":98},[8286],{"nctId":8287,"briefTitle":8288,"status":104,"phases":8289,"primaryCompletion":8290,"completion":8290,"start":8291,"enrollment":109,"conditions":8292,"interventions":8294},"NCT03931590","A Human AME Study for Omaveloxolone",[86],"2019-05-31","2019-04-11",[8293],"Healthy Male Subjects",[8280],{"trials":8296,"activeCount":98},[],{"trials":8298,"activeCount":98},[],{"trials":8300,"activeCount":98},[],{"trials":8302,"activeCount":98},[],{"intervention":8304,"totalTrials":149,"cells":8305},"[14C]-BIIB091",{"EARLY_PHASE1":8306,"PHASE1":8308,"PHASE2":8318,"PHASE3":8320,"PHASE4":8322,"NA":8324},{"trials":8307,"activeCount":98},[],{"trials":8309,"activeCount":98},[8310],{"nctId":8311,"briefTitle":8312,"status":104,"phases":8313,"primaryCompletion":8314,"completion":8314,"start":8315,"enrollment":109,"conditions":8316,"interventions":8317},"NCT06311786","A Study to Look at How a Single Oral Dose of Carbon-14-Labelled [14C] BIIB091 Moves Through and is Processed by the Body in Healthy Male Participants",[86],"2024-05-11","2024-04-08",[24],[8304],{"trials":8319,"activeCount":98},[],{"trials":8321,"activeCount":98},[],{"trials":8323,"activeCount":98},[],{"trials":8325,"activeCount":98},[],{"intervention":8327,"totalTrials":149,"cells":8328},"RTA 1701",{"EARLY_PHASE1":8329,"PHASE1":8331,"PHASE2":8341,"PHASE3":8343,"PHASE4":8345,"NA":8347},{"trials":8330,"activeCount":98},[],{"trials":8332,"activeCount":98},[8333],{"nctId":8334,"briefTitle":8335,"status":104,"phases":8336,"primaryCompletion":8337,"completion":8337,"start":8338,"enrollment":606,"conditions":8339,"interventions":8340},"NCT03579030","Safety and PK\u002FPD of RTA 1701 in Healthy Adults",[86],"2019-06-28","2018-06-20",[18],[8327],{"trials":8342,"activeCount":98},[],{"trials":8344,"activeCount":98},[],{"trials":8346,"activeCount":98},[],{"trials":8348,"activeCount":98},[],{"intervention":8350,"totalTrials":149,"cells":8351},"RTA 408 Lotion 0.5%, 1%, 3%",{"EARLY_PHASE1":8352,"PHASE1":8354,"PHASE2":8364,"PHASE3":8366,"PHASE4":8368,"NA":8370},{"trials":8353,"activeCount":98},[],{"trials":8355,"activeCount":98},[8356],{"nctId":8357,"briefTitle":8358,"status":104,"phases":8359,"primaryCompletion":8360,"completion":8360,"start":399,"enrollment":1248,"conditions":8361,"interventions":8362},"NCT02029716","RTA 408 Lotion in Healthy Volunteers",[86],"2014-04-01",[18],[8350,8363],"Lotion vehicle\u002Fplacebo",{"trials":8365,"activeCount":98},[],{"trials":8367,"activeCount":98},[],{"trials":8369,"activeCount":98},[],{"trials":8371,"activeCount":98},[],{"intervention":8363,"totalTrials":149,"cells":8373},{"EARLY_PHASE1":8374,"PHASE1":8376,"PHASE2":8382,"PHASE3":8384,"PHASE4":8386,"NA":8388},{"trials":8375,"activeCount":98},[],{"trials":8377,"activeCount":98},[8378],{"nctId":8357,"briefTitle":8358,"status":104,"phases":8379,"primaryCompletion":8360,"completion":8360,"start":399,"enrollment":1248,"conditions":8380,"interventions":8381},[86],[18],[8350,8363],{"trials":8383,"activeCount":98},[],{"trials":8385,"activeCount":98},[],{"trials":8387,"activeCount":98},[],{"trials":8389,"activeCount":98},[],{"intervention":8391,"totalTrials":149,"cells":8392},"BIIB028",{"EARLY_PHASE1":8393,"PHASE1":8395,"PHASE2":8404,"PHASE3":8406,"PHASE4":8408,"NA":8410},{"trials":8394,"activeCount":98},[],{"trials":8396,"activeCount":98},[8397],{"nctId":8398,"briefTitle":8399,"status":104,"phases":8400,"primaryCompletion":1963,"completion":1963,"start":8401,"enrollment":19,"conditions":8402,"interventions":8403},"NCT00725933","Administration of BIIB028 to Subjects With Solid Tumors",[86],"2008-06",[2927],[8391],{"trials":8405,"activeCount":98},[],{"trials":8407,"activeCount":98},[],{"trials":8409,"activeCount":98},[],{"trials":8411,"activeCount":98},[],{"intervention":8413,"totalTrials":149,"cells":8414},"Experimental",{"EARLY_PHASE1":8415,"PHASE1":8417,"PHASE2":8425,"PHASE3":8427,"PHASE4":8429,"NA":8431},{"trials":8416,"activeCount":98},[],{"trials":8418,"activeCount":98},[8419],{"nctId":8420,"briefTitle":8421,"status":104,"phases":8422,"primaryCompletion":7371,"completion":7371,"start":1172,"enrollment":1902,"conditions":8423,"interventions":8424},"NCT01420458","Study in Healthy Volunteers to Establish the BioEquivalence of Two Formulations of BG00012",[86],[30],[8413],{"trials":8426,"activeCount":98},[],{"trials":8428,"activeCount":98},[],{"trials":8430,"activeCount":98},[],{"trials":8432,"activeCount":98},[],{"intervention":8434,"totalTrials":149,"cells":8435},"BIIB015",{"EARLY_PHASE1":8436,"PHASE1":8438,"PHASE2":8447,"PHASE3":8449,"PHASE4":8451,"NA":8453},{"trials":8437,"activeCount":98},[],{"trials":8439,"activeCount":98},[8440],{"nctId":8441,"briefTitle":8442,"status":104,"phases":8443,"primaryCompletion":4287,"completion":4287,"start":8401,"enrollment":8444,"conditions":8445,"interventions":8446},"NCT00674947","A Phase I Study of BIIB015 in Relapsed\u002FRefractory Solid Tumors",[86],55,[6668],[8434],{"trials":8448,"activeCount":98},[],{"trials":8450,"activeCount":98},[],{"trials":8452,"activeCount":98},[],{"trials":8454,"activeCount":98},[],{"intervention":8456,"totalTrials":149,"cells":8457},"BIIB133",{"EARLY_PHASE1":8458,"PHASE1":8460,"PHASE2":8470,"PHASE3":8472,"PHASE4":8474,"NA":8476},{"trials":8459,"activeCount":98},[],{"trials":8461,"activeCount":98},[8462],{"nctId":8463,"briefTitle":8464,"status":104,"phases":8465,"primaryCompletion":8466,"completion":8466,"start":8467,"enrollment":11,"conditions":8468,"interventions":8469},"NCT04571424","A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB133 (Dapirolizumab Pegol) in Healthy Japanese and Caucasian Participants",[86],"2021-04-08","2020-10-14",[30],[8456],{"trials":8471,"activeCount":98},[],{"trials":8473,"activeCount":98},[],{"trials":8475,"activeCount":98},[],{"trials":8477,"activeCount":98},[],{"intervention":657,"totalTrials":149,"cells":8479},{"EARLY_PHASE1":8480,"PHASE1":8482,"PHASE2":8488,"PHASE3":8490,"PHASE4":8492,"NA":8494},{"trials":8481,"activeCount":98},[],{"trials":8483,"activeCount":98},[8484],{"nctId":650,"briefTitle":651,"status":104,"phases":8485,"primaryCompletion":653,"completion":653,"start":646,"enrollment":654,"conditions":8486,"interventions":8487},[86],[18],[657,624],{"trials":8489,"activeCount":98},[],{"trials":8491,"activeCount":98},[],{"trials":8493,"activeCount":98},[],{"trials":8495,"activeCount":98},[],{"intervention":8497,"totalTrials":149,"cells":8498},"Serum containing Avonex",{"EARLY_PHASE1":8499,"PHASE1":8501,"PHASE2":8512,"PHASE3":8514,"PHASE4":8516,"NA":8518},{"trials":8500,"activeCount":98},[],{"trials":8502,"activeCount":98},[8503],{"nctId":8504,"briefTitle":8505,"status":104,"phases":8506,"completion":2457,"start":8507,"enrollment":8508,"conditions":8509,"interventions":8510},"NCT00913250","A Bioequivalence Study of Serum Free Avonex and Serum Containing Avonex in Healthy Volunteers",[86],"2003-08",96,[15],[8497,8511],"Serum Free Avonex",{"trials":8513,"activeCount":98},[],{"trials":8515,"activeCount":98},[],{"trials":8517,"activeCount":98},[],{"trials":8519,"activeCount":98},[],{"intervention":8511,"totalTrials":149,"cells":8521},{"EARLY_PHASE1":8522,"PHASE1":8524,"PHASE2":8530,"PHASE3":8532,"PHASE4":8534,"NA":8536},{"trials":8523,"activeCount":98},[],{"trials":8525,"activeCount":98},[8526],{"nctId":8504,"briefTitle":8505,"status":104,"phases":8527,"completion":2457,"start":8507,"enrollment":8508,"conditions":8528,"interventions":8529},[86],[15],[8497,8511],{"trials":8531,"activeCount":98},[],{"trials":8533,"activeCount":98},[],{"trials":8535,"activeCount":98},[],{"trials":8537,"activeCount":98},[],{"intervention":6374,"totalTrials":149,"cells":8539},{"EARLY_PHASE1":8540,"PHASE1":8542,"PHASE2":8548,"PHASE3":8550,"PHASE4":8552,"NA":8554},{"trials":8541,"activeCount":98},[],{"trials":8543,"activeCount":98},[8544],{"nctId":6369,"briefTitle":6370,"status":104,"phases":8545,"primaryCompletion":1890,"completion":1890,"start":2362,"enrollment":1027,"conditions":8546,"interventions":8547},[86],[4810],[6346,6374],{"trials":8549,"activeCount":98},[],{"trials":8551,"activeCount":98},[],{"trials":8553,"activeCount":98},[],{"trials":8555,"activeCount":98},[],{"intervention":8557,"totalTrials":149,"cells":8558},"BG00010 IV",{"EARLY_PHASE1":8559,"PHASE1":8561,"PHASE2":8571,"PHASE3":8573,"PHASE4":8575,"NA":8577},{"trials":8560,"activeCount":98},[],{"trials":8562,"activeCount":98},[8563],{"nctId":8564,"briefTitle":8565,"status":104,"phases":8566,"primaryCompletion":4547,"completion":4547,"start":8567,"enrollment":2421,"conditions":8568,"interventions":8569},"NCT01842126","Phase 1 Subcutaneous Single and Multiple Ascending Dose Study of BG00010 (Neublastin)",[86],"2013-04",[4744,18],[8557,8570],"BG00010 SC",{"trials":8572,"activeCount":98},[],{"trials":8574,"activeCount":98},[],{"trials":8576,"activeCount":98},[],{"trials":8578,"activeCount":98},[],{"intervention":8570,"totalTrials":149,"cells":8580},{"EARLY_PHASE1":8581,"PHASE1":8583,"PHASE2":8589,"PHASE3":8591,"PHASE4":8593,"NA":8595},{"trials":8582,"activeCount":98},[],{"trials":8584,"activeCount":98},[8585],{"nctId":8564,"briefTitle":8565,"status":104,"phases":8586,"primaryCompletion":4547,"completion":4547,"start":8567,"enrollment":2421,"conditions":8587,"interventions":8588},[86],[4744,18],[8557,8570],{"trials":8590,"activeCount":98},[],{"trials":8592,"activeCount":98},[],{"trials":8594,"activeCount":98},[],{"trials":8596,"activeCount":98},[],{"intervention":8598,"totalTrials":149,"cells":8599},"BIIB132",{"EARLY_PHASE1":8600,"PHASE1":8602,"PHASE2":8612,"PHASE3":8614,"PHASE4":8616,"NA":8618},{"trials":8601,"activeCount":98},[],{"trials":8603,"activeCount":98},[8604],{"nctId":8605,"briefTitle":8606,"status":522,"phases":8607,"primaryCompletion":4426,"completion":4426,"start":8608,"enrollment":109,"conditions":8609,"interventions":8611},"NCT05160558","A Pharmacokinetics and Safety Study of BIIB132 in Adults With Spinocerebellar Ataxia 3",[86],"2022-02-02",[8610],"Spinocerebellar Ataxia Type 3",[8598],{"trials":8613,"activeCount":98},[],{"trials":8615,"activeCount":98},[],{"trials":8617,"activeCount":98},[],{"trials":8619,"activeCount":98},[],{"intervention":8621,"totalTrials":149,"cells":8622},"natalizumab treatment",{"EARLY_PHASE1":8623,"PHASE1":8631,"PHASE2":8633,"PHASE3":8635,"PHASE4":8637,"NA":8639},{"trials":8624,"activeCount":98},[8625],{"nctId":8626,"briefTitle":8627,"status":104,"phases":8628,"primaryCompletion":1462,"completion":1462,"start":2323,"enrollment":159,"conditions":8629,"interventions":8630},"NCT00424788","A Multicenter Study to Assess the Effect of Plasma Exchange in Accelerating the Clearance of Natalizumab in Subjects With Multiple Sclerosis (MS)",[85],[500],[8621],{"trials":8632,"activeCount":98},[],{"trials":8634,"activeCount":98},[],{"trials":8636,"activeCount":98},[],{"trials":8638,"activeCount":98},[],{"trials":8640,"activeCount":98},[],{"intervention":3502,"totalTrials":33,"cells":8642},{"EARLY_PHASE1":8643,"PHASE1":8645,"PHASE2":8653,"PHASE3":8672,"PHASE4":8690,"NA":8724},{"trials":8644,"activeCount":98},[],{"trials":8646,"activeCount":98},[8647],{"nctId":8648,"briefTitle":8649,"status":104,"phases":8650,"primaryCompletion":2021,"completion":2021,"start":6785,"enrollment":1547,"conditions":8651,"interventions":8652},"NCT01500408","Demonstrate the Bioequivalence of Interferon Beta-1a (INFB) Manufactured by Two Different Processes in Healthy Volunteers",[86],[15],[3502,3502],{"trials":8654,"activeCount":98},[8655,8664],{"nctId":8656,"briefTitle":8657,"status":104,"phases":8658,"primaryCompletion":2478,"completion":2478,"start":8659,"enrollment":1493,"conditions":8660,"interventions":8662},"NCT00099489","Safety and Efficacy of Avonex in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)",[87],"2004-02",[8661],"Chronic Inflammatory Demyelinating Polyradiculoneuropathy",[8663],"Interferon Beta-1a",{"nctId":8665,"briefTitle":8666,"status":104,"phases":8667,"primaryCompletion":8668,"completion":1605,"start":2661,"enrollment":8669,"conditions":8670,"interventions":8671},"NCT00912860","Immunogenicity and Safety Study of Serum-Free Avonex",[87],"2004-12",155,[15],[3502],{"trials":8673,"activeCount":98},[8674,8678,8686],{"nctId":2018,"briefTitle":2019,"status":522,"phases":8675,"primaryCompletion":2021,"completion":2021,"start":1535,"enrollment":838,"conditions":8676,"interventions":8677},[88],[699],[2024,1905,1540],{"nctId":8679,"briefTitle":8680,"status":104,"phases":8681,"primaryCompletion":8682,"completion":8682,"start":8683,"enrollment":2109,"conditions":8684,"interventions":8685},"NCT00915577","Patient Satisfaction Study of Single-Use Autoinjector for the Delivery of Pre-Filled Avonex Syringe",[88],"2006-04","2005-08",[15],[3502],{"nctId":3495,"briefTitle":3496,"status":104,"phases":8687,"primaryCompletion":1715,"completion":955,"start":1173,"enrollment":3498,"conditions":8688,"interventions":8689},[88],[21],[3440,3501,3502,3503],{"trials":8691,"activeCount":98},[8692,8696,8702,8709,8717],{"nctId":1897,"briefTitle":1898,"status":104,"phases":8693,"primaryCompletion":1900,"completion":1900,"start":1901,"enrollment":1902,"conditions":8694,"interventions":8695},[89],[699],[1857,1905,1906],{"nctId":8697,"briefTitle":8698,"status":522,"phases":8699,"primaryCompletion":2363,"completion":2363,"start":2029,"enrollment":1828,"conditions":8700,"interventions":8701},"NCT00574041","How Side Effects of Avonex Are Affected by Gradually Increasing to Full Dose vs Starting at Full Dose",[89],[699],[3502],{"nctId":8703,"briefTitle":8704,"status":104,"phases":8705,"primaryCompletion":1546,"completion":1554,"start":8706,"enrollment":898,"conditions":8707,"interventions":8708},"NCT00915460","Open-Label Safety Extension Study of Avonex",[89],"1999-09",[15],[3502],{"nctId":8710,"briefTitle":8711,"status":104,"phases":8712,"completion":8659,"start":8713,"enrollment":8714,"conditions":8715,"interventions":8716},"NCT00534261","Does Quality of Life Improve in Multiple Sclerosis Patients Treated With Interferon Beta-1a?",[89],"1999-11",284,[699],[3502],{"nctId":8718,"briefTitle":8719,"status":104,"phases":8720,"completion":1604,"start":5173,"enrollment":8721,"conditions":8722,"interventions":8723},"NCT00913666","Pharmacodynamic Study to Better Understand the Therapeutic Response and Immunomodulatory Effects of Avonex in Multiple Sclerosis (MS) Patients and Healthy Volunteers",[89],121,[15],[3502],{"trials":8725,"activeCount":98},[8726,8733],{"nctId":8727,"briefTitle":8728,"status":104,"phases":8729,"primaryCompletion":1453,"completion":8730,"start":4279,"enrollment":2387,"conditions":8731,"interventions":8732},"NCT01272128","Avonex-evaluation of Quality of Life and Convenience in Belgian Participants - The AVAIL Study",[],"2015-09",[15],[3502],{"nctId":8734,"briefTitle":8735,"status":104,"phases":8736,"completion":8737,"start":8738,"enrollment":498,"conditions":8739,"interventions":8740},"NCT00599274","Study to Determine if Avonex and Rebif Work Comparably Well in Subjects With Relapsing Multiple Sclerosis",[],"2003-05","2002-08",[15],[3502,3502],{"intervention":8742,"totalTrials":243,"cells":8743},"Fampridine",{"EARLY_PHASE1":8744,"PHASE1":8746,"PHASE2":8748,"PHASE3":8750,"PHASE4":8760,"NA":8769},{"trials":8745,"activeCount":98},[],{"trials":8747,"activeCount":98},[],{"trials":8749,"activeCount":98},[],{"trials":8751,"activeCount":98},[8752],{"nctId":8753,"briefTitle":8754,"status":104,"phases":8755,"primaryCompletion":884,"completion":884,"start":1453,"enrollment":8756,"conditions":8757,"interventions":8758},"NCT02219932","Efficacy and Safety Study of Prolonged-Release Fampridine in Participants With Multiple Sclerosis",[88],646,[15],[8759],"fampridine",{"trials":8761,"activeCount":98},[8762],{"nctId":8763,"briefTitle":8764,"status":104,"phases":8765,"primaryCompletion":1454,"completion":646,"start":2437,"enrollment":8766,"conditions":8767,"interventions":8768},"NCT01480076","Open-Label Study to Assess the Effect of Long-Term Prolonged-Release Fampridine (BIIB041) on Quality of Life as Reported by Participants With Multiple Sclerosis",[89],901,[15],[8742],{"trials":8770,"activeCount":98},[8771,8780],{"nctId":8772,"briefTitle":8773,"status":104,"phases":8774,"primaryCompletion":8775,"completion":8775,"start":8776,"enrollment":8777,"conditions":8778,"interventions":8779},"NCT01480063","An Observational Study to Collect Information on Safety and to Document the Drug Utilization of Fampyra (BIIB041) When Used In Routine Medical Practice",[],"2019-02-08","2012-04-16",4734,[15],[8742],{"nctId":8781,"briefTitle":8782,"status":522,"phases":8783,"primaryCompletion":884,"completion":884,"start":4554,"enrollment":149,"conditions":8784,"interventions":8786},"NCT01532154","Fampridine Pregnancy Exposure Registry",[],[15,8785],"Pregnancy",[8742],{"intervention":8788,"totalTrials":243,"cells":8789},"BG9418",{"EARLY_PHASE1":8790,"PHASE1":8792,"PHASE2":8794,"PHASE3":8803,"PHASE4":8817,"NA":8819},{"trials":8791,"activeCount":98},[],{"trials":8793,"activeCount":98},[],{"trials":8795,"activeCount":98},[8796],{"nctId":8797,"briefTitle":8798,"status":104,"phases":8799,"primaryCompletion":1535,"completion":1535,"start":1182,"enrollment":3385,"conditions":8800,"interventions":8802},"NCT00616434","A Phase 2 Study of Interferon Beta-1a (Avonex®) in Ulcerative Colitis",[87],[8801],"Active Ulcerative Colitis",[8788],{"trials":8804,"activeCount":98},[8805,8811],{"nctId":8806,"briefTitle":8807,"status":522,"phases":8808,"primaryCompletion":3460,"completion":3460,"start":4587,"enrollment":577,"conditions":8809,"interventions":8810},"NCT00784836","Immunogenicity and Safety of Subcutaneously-administered Avonex (Interferon Beta-1a) in Multiple Sclerosis (MS) Patients",[88],[15],[8788],{"nctId":8812,"briefTitle":8813,"status":104,"phases":8814,"primaryCompletion":4799,"completion":1474,"start":6266,"enrollment":9,"conditions":8815,"interventions":8816},"NCT00828204","Evaluate the Safe and Effective Use of the Avonex® Single-Use Autoinjector in Multiple Sclerosis Subjects",[88],[15],[8788],{"trials":8818,"activeCount":98},[],{"trials":8820,"activeCount":98},[8821],{"nctId":8822,"briefTitle":8823,"status":104,"phases":8824,"primaryCompletion":7371,"completion":7371,"start":8659,"enrollment":8825,"conditions":8826,"interventions":8828},"NCT00168714","Pregnancy Exposure Registry for Avonex (Interferon Beta-1a)",[],329,[8827,15,8785],"Prenatal Exposure Delayed Effects",[8788],{"intervention":2427,"totalTrials":577,"cells":8830},{"EARLY_PHASE1":8831,"PHASE1":8833,"PHASE2":8835,"PHASE3":8841,"PHASE4":8843,"NA":8845},{"trials":8832,"activeCount":98},[],{"trials":8834,"activeCount":98},[],{"trials":8836,"activeCount":98},[8837],{"nctId":2415,"briefTitle":2416,"status":522,"phases":8838,"primaryCompletion":2418,"completion":2419,"start":2420,"enrollment":2421,"conditions":8839,"interventions":8840},[87],[32],[2424,2425,2426,2427,2428],{"trials":8842,"activeCount":98},[],{"trials":8844,"activeCount":98},[],{"trials":8846,"activeCount":98},[8847,8861],{"nctId":8848,"briefTitle":8849,"status":104,"phases":8850,"primaryCompletion":8851,"completion":8851,"start":8852,"enrollment":8853,"conditions":8854,"interventions":8859},"NCT03662919","One-year Persistence to Treatment of Participants Receiving Flixabi or Imraldi: a French Cohort Study",[],"2022-06-30","2018-07-02",2274,[8855,8856,8857,1529,8858],"Arthritis, Rheumatoid","Spondylitis, Ankylosing","Arthritis, Psoriatic","Colitis, Ulcerative",[8860,2427],"Infliximab",{"nctId":8862,"briefTitle":8863,"status":104,"phases":8864,"primaryCompletion":8865,"completion":8865,"start":8866,"enrollment":8867,"conditions":8868,"interventions":8874},"NCT04089514","A Real-world Study of Imraldi® Use",[],"2021-11-30","2019-06-30",1000,[8869,8870,8871,8872,8873],"Arthritis, Rheumatoid (RA)","Axial Spondyloarthritis (axSpA)","Arthritis, Psoriatic (PsA)","Crohn's Disease (CD)","Colitis, Ulcerative (UC)",[2427],{"intervention":8876,"totalTrials":470,"cells":8877},"Benepali",{"EARLY_PHASE1":8878,"PHASE1":8880,"PHASE2":8882,"PHASE3":8884,"PHASE4":8886,"NA":8888},{"trials":8879,"activeCount":98},[],{"trials":8881,"activeCount":98},[],{"trials":8883,"activeCount":98},[],{"trials":8885,"activeCount":98},[],{"trials":8887,"activeCount":98},[],{"trials":8889,"activeCount":98},[8890,8900],{"nctId":8891,"briefTitle":8892,"status":104,"phases":8893,"primaryCompletion":8894,"completion":8894,"start":8895,"enrollment":8896,"conditions":8897,"interventions":8899},"NCT03327454","Benepali® PEN Patient Satisfaction Survey",[],"2018-06-21","2017-08-10",500,[32,8898],"Spondyloarthropathies",[8876],{"nctId":8901,"briefTitle":8902,"status":104,"phases":8903,"primaryCompletion":8904,"completion":8904,"start":2071,"enrollment":1625,"conditions":8905,"interventions":8907},"NCT03100734","Observational Study to Evaluate the Real-Life Effectiveness of Benepali Following Transition From Enbrel",[],"2018-11-30",[32,8906],"Axial Spondyloarthritis",[8876,8908],"Enbrel",{"intervention":8910,"totalTrials":149,"cells":8911},"Tysabri®",{"EARLY_PHASE1":8912,"PHASE1":8914,"PHASE2":8916,"PHASE3":8918,"PHASE4":8920,"NA":8922},{"trials":8913,"activeCount":98},[],{"trials":8915,"activeCount":98},[],{"trials":8917,"activeCount":98},[],{"trials":8919,"activeCount":98},[],{"trials":8921,"activeCount":98},[],{"trials":8923,"activeCount":98},[8924],{"nctId":8925,"briefTitle":8926,"status":104,"phases":8927,"primaryCompletion":3604,"completion":3604,"start":1535,"enrollment":8928,"conditions":8929,"interventions":8930},"NCT01070823","JC-Virus (JCV) Antibody Program",[],1096,[15],[8910],{"intervention":8932,"totalTrials":149,"cells":8933},"Interferon Beta Therapy",{"EARLY_PHASE1":8934,"PHASE1":8936,"PHASE2":8938,"PHASE3":8940,"PHASE4":8942,"NA":8944},{"trials":8935,"activeCount":98},[],{"trials":8937,"activeCount":98},[],{"trials":8939,"activeCount":98},[],{"trials":8941,"activeCount":98},[],{"trials":8943,"activeCount":98},[],{"trials":8945,"activeCount":98},[8946],{"nctId":8947,"briefTitle":8948,"status":104,"phases":8949,"primaryCompletion":8950,"completion":8950,"start":8951,"enrollment":8952,"conditions":8953,"interventions":8954},"NCT04655222","Study to Investigate Pregnancy Outcomes in Female Participants Exposed to Subcutaneous (SC) Peginterferon Beta-1a and Intramuscular (IM) Interferon Beta-1a Reported in a German Participant Support Program",[],"2021-10-15","2021-04-30",470,[15,27],[8932],{"intervention":8860,"totalTrials":149,"cells":8956},{"EARLY_PHASE1":8957,"PHASE1":8959,"PHASE2":8961,"PHASE3":8963,"PHASE4":8965,"NA":8967},{"trials":8958,"activeCount":98},[],{"trials":8960,"activeCount":98},[],{"trials":8962,"activeCount":98},[],{"trials":8964,"activeCount":98},[],{"trials":8966,"activeCount":98},[],{"trials":8968,"activeCount":98},[8969],{"nctId":8848,"briefTitle":8849,"status":104,"phases":8970,"primaryCompletion":8851,"completion":8851,"start":8852,"enrollment":8853,"conditions":8971,"interventions":8972},[],[8855,8856,8857,1529,8858],[8860,2427],{"intervention":8974,"totalTrials":149,"cells":8975},"SC Peginterferon beta-1a",{"EARLY_PHASE1":8976,"PHASE1":8978,"PHASE2":8980,"PHASE3":8982,"PHASE4":8984,"NA":8986},{"trials":8977,"activeCount":98},[],{"trials":8979,"activeCount":98},[],{"trials":8981,"activeCount":98},[],{"trials":8983,"activeCount":98},[],{"trials":8985,"activeCount":98},[],{"trials":8987,"activeCount":98},[8988],{"nctId":8989,"briefTitle":8990,"status":104,"phases":8991,"primaryCompletion":3350,"completion":3350,"start":8992,"enrollment":8993,"conditions":8994,"interventions":8995},"NCT03347370","A Post-Authorization Safety Study of Interferon Beta Therapy in Participants With Multiple Sclerosis",[],"2017-11-27",626,[27],[8974,8996,8997],"SC interferon beta-1a","SC interferon beta-1b",{"intervention":8996,"totalTrials":149,"cells":8999},{"EARLY_PHASE1":9000,"PHASE1":9002,"PHASE2":9004,"PHASE3":9006,"PHASE4":9008,"NA":9010},{"trials":9001,"activeCount":98},[],{"trials":9003,"activeCount":98},[],{"trials":9005,"activeCount":98},[],{"trials":9007,"activeCount":98},[],{"trials":9009,"activeCount":98},[],{"trials":9011,"activeCount":98},[9012],{"nctId":8989,"briefTitle":8990,"status":104,"phases":9013,"primaryCompletion":3350,"completion":3350,"start":8992,"enrollment":8993,"conditions":9014,"interventions":9015},[],[27],[8974,8996,8997],{"intervention":8997,"totalTrials":149,"cells":9017},{"EARLY_PHASE1":9018,"PHASE1":9020,"PHASE2":9022,"PHASE3":9024,"PHASE4":9026,"NA":9028},{"trials":9019,"activeCount":98},[],{"trials":9021,"activeCount":98},[],{"trials":9023,"activeCount":98},[],{"trials":9025,"activeCount":98},[],{"trials":9027,"activeCount":98},[],{"trials":9029,"activeCount":98},[9030],{"nctId":8989,"briefTitle":8990,"status":104,"phases":9031,"primaryCompletion":3350,"completion":3350,"start":8992,"enrollment":8993,"conditions":9032,"interventions":9033},[],[27],[8974,8996,8997],{"intervention":9035,"totalTrials":149,"cells":9036},"BG0002",{"EARLY_PHASE1":9037,"PHASE1":9039,"PHASE2":9041,"PHASE3":9043,"PHASE4":9045,"NA":9047},{"trials":9038,"activeCount":98},[],{"trials":9040,"activeCount":98},[],{"trials":9042,"activeCount":98},[],{"trials":9044,"activeCount":98},[],{"trials":9046,"activeCount":98},[],{"trials":9048,"activeCount":98},[9049],{"nctId":9050,"briefTitle":9051,"status":104,"phases":9052,"primaryCompletion":2860,"completion":2860,"start":9053,"enrollment":389,"conditions":9054,"interventions":9055},"NCT00818038","A Proof of Concept Study to Evaluate the Effectiveness of Tysabri in Relapsing Remitting Multiple Sclerosis (RRMS) Patient Bladder Function",[],"2009-03",[21],[9035],{"intervention":8908,"totalTrials":149,"cells":9057},{"EARLY_PHASE1":9058,"PHASE1":9060,"PHASE2":9062,"PHASE3":9064,"PHASE4":9066,"NA":9068},{"trials":9059,"activeCount":98},[],{"trials":9061,"activeCount":98},[],{"trials":9063,"activeCount":98},[],{"trials":9065,"activeCount":98},[],{"trials":9067,"activeCount":98},[],{"trials":9069,"activeCount":98},[9070],{"nctId":8901,"briefTitle":8902,"status":104,"phases":9071,"primaryCompletion":8904,"completion":8904,"start":2071,"enrollment":1625,"conditions":9072,"interventions":9073},[],[32,8906],[8876,8908]]